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ABSTRACT 
 
 
Morphine is the most widely prescribed opiate for alleviation of persistent pain; however, 
it is becoming increasingly clear that morphine is less potent in women compared to 
men. Morphine primarily binds mu opioid receptors, which are densely localized in the 
midbrain periaqueductal gray (PAG). Anatomical and physiological studies conducted in 
the 1960s identified the PAG, and its projections to the rostral ventromedial medulla 
(RVM) and spinal cord dorsal horn, as an essential neural circuit mediating opioid-
based analgesia. Remarkably, the majority of studies since then were conducted in 
males with the implicit assumption that this circuit was the same in females; this is not 
the case. It is now well established that morphine produces greater analgesia in males 
compared to females in a wide range of vertebrates, however, the mechanism(s) driving 
this sex difference is not clear. Our recent studies indicate that two factors appear to be 
contributing to the sexually dimorphic effects of morphine. First, there are sex 
differences in the anatomy and physiology of the descending inhibitory pathway on 
which morphine acts to produce analgesia. Specifically, the projections from the PAG to 
the RVM are sexually dimorphic and activated to a greater degree by both inflammatory 
pain and systemic morphine in males. In the absence of pain, the PAG-RVM circuit is 
activated to a greater degree in males compared to females, while this activation 
steadily declines during the development of tolerance in males only. We also have 
evidence of a sexually dimorphic expression of mu opioid receptor within the PAG that 
appears to contribute to sex differences in morphine potency. Microinjection of 
morphine directly into the PAG produces significantly greater analgesia in males, 
indicating that the PAG is sufficient for eliciting this sexually dimorphic behavior. 
Furthermore, mu opioid receptor-expressing PAG neurons are necessary for eliciting a 
sexually dimorphic response to morphine as lesioning mu opioid receptor-expressing 
neurons attenuates analgesia in males only. Together, these data indicate that the 
PAG-RVM pathway and mu opioid receptor expression in the PAG is sexually dimorphic 
and provides a primary mechanism for sex differences in morphine potency. 
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CHAPTER ONE 
 
INTRODUCTORY OVERVIEW 
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1.1  HISTORY OF A DESCENDING PAIN MODULATORY PATHWAY IN MALES 
 
In 1969, a novel field of research emerged when it was first reported that electrical 
stimulation of a midbrain structure, the periaqueductal gray (PAG), produced profound 
analgesia in the male rat (Reynolds, 1969). Remarkably, the stimulation-elicited 
analgesia from the PAG was sufficient to allow for invasive abdominal surgical 
procedures to be performed (Mayer et al., 1971). Further research soon revealed that 
stimulation-elicited analgesia from the lateral and ventrolateral PAG produced “pure 
analgesia” with no other behavioral alterations (Guilbaud et al., 1972; Liebeskind et al., 
1973; Oliveras et al., 1974), while stimulation of loci mainly within the dorsal and lateral 
PAG also produced increased motor behavior (Jacquet & Lajtha, 1973; 1974) and 
vocalization (Fardin et al., 1984b; a). These findings launched an extensive effort to 
characterize the neural mechanisms driving this descending control of pain. In 1976, 
Akil et al. reported that administration of the opioid receptor antagonist naloxone 
partially attenuated PAG stimulation-produced analgesia (Akil et al., 1976), implicating 
the endogenous opioid system. Later, it was reported that administration of opioid 
receptor agonists into the PAG produced potent analgesia that was blocked by either 
central or systemic administration of naloxone (Satoh et al., 1983; Jensen & Yaksh, 
1986; Bodnar et al., 1988b).  
 
During the search for the descending neural pathways involved in analgesia, stimulation 
of both the PAG and a novel area, the nucleus raphe magnus of the rostral 
ventromedial medulla (RVM), were reported to preferentially inhibit nociceptive dorsal 
horn neurons thus producing antinociception (Liebeskind et al., 1973; Fields et al., 
1977; Carstens et al., 1979; Jensen & Yaksh, 1984; Sandkuhler & Gebhart, 1984; Light 
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et al., 1986; Sandkuhler et al., 1988; Zhang et al., 1991), an effect that was reversible 
with naloxone treatment in both rats (Jones & Gebhart, 1988) and humans (Hosobuchi 
et al., 1977). At the time, it was unknown how the PAG and the RVM provided inhibitory 
input to the nociceptive dorsal horn neurons. Even though the PAG had been shown to 
produce profound antinociception, there was little evidence of a direct projection from 
the PAG to the spinal cord dorsal horn (Mantyh & Peschanski, 1982). Alternatively, the 
pioneering studies of Basbaum and Fields (1979) demonstrated that the descending 
projections in the dorsolateral funiculus, a major spinal cord nerve fiber tract, were 
involved in PAG-mediated antinociception. In addition, the majority of axons that travel 
through the dorsolateral funiculus were reported to arise from the RVM (Basbaum & 
Fields, 1979; Abols & Basbaum, 1981; Lakos & Basbaum, 1988; Sim & Joseph, 1992). 
Indeed, lesions of the RVM or dorsolateral funiculus were found to abolish or 
significantly attenuate PAG-produced antinociception (Proudfit & Anderson, 1975; 
Basbaum et al., 1977; Chance et al., 1978; Mohrland & Gebhart, 1980; Proudfit, 1980; 
Gebhart et al., 1983; Prieto et al., 1983; Sandkuhler & Gebhart, 1984; Guo & Tang, 
1990). Later, electrophysiological studies reported an excitatory projection from the 
PAG to spinally projecting neurons in the RVM (Basbaum & Fields, 1979; Behbehani & 
Fields, 1979; Shah & Dostrovsky, 1980; Behbehani, 1981; Behbehani et al., 1981; 
Behbehani, 1982) and this projection was further characterized by multiple tract-tracing 
studies (Beitz et al., 1983; Lakos & Basbaum, 1988; Li et al., 1990).  
 
The anatomical and physiological organization of the PAG (Beitz, 1985; Beitz & 
Shepard, 1985) and, in particular, the PAG-RVM-spinal cord circuit is now well 
characterized in a variety of species, including the rat (Basbaum & Fields, 1978; 
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Behbehani & Fields, 1979; Beitz, 1982b; Beitz et al., 1983; Beitz, 1985; Beitz & 
Shepard, 1985; Jones & Light, 1992; Williams et al., 1995), cat (Basbaum et al., 1978; 
Shah & Dostrovsky, 1980; Abols & Basbaum, 1981; Sandkuhler et al., 1987a; 
Sandkuhler et al., 1987b; Holstege & Cowie, 1989; Vanderhorst et al., 1996; 
VanderHorst et al., 1998; Mouton & Holstege, 2000), squirrel monkey (Mantyh, 1983; 
Gerhart et al., 1984), and rabbit (Haselton et al., 1988) (see Figure 2.1). Subsequent 
anatomical studies characterized the efferents and afferents of the PAG (Beitz, 1982a; 
c) and further demonstrated the central role of the PAG in both stimulation-produced 
and opioid-induced antinociception (Basbaum et al., 1976; Basbaum et al., 1977; Barton 
et al., 1980; Morgan et al., 1992). It is now clear that the PAG, and its descending 
projections to the RVM and spinal cord, comprises an essential neural circuit for both 
endogenous and exogenous opioid-mediated antinociception (Basbaum et al., 1978; 
Basbaum & Fields, 1978; Basbaum & Fields, 1984).  
 
An extensive amount of research has focused on the mechanisms whereby opiates, the 
exogenous analgesics, produce antinociception via the PAG. Involvement of opiates in 
PAG-mediated antinociception was first demonstrated in 1978, when microinjection of 
the mu opioid receptor agonist morphine into the PAG produced naloxone-reversible 
antinociception (Yaksh & Rudy, 1978), and specifically, naloxone-reversible excitation of 
RVM neurons (Behbehani & Fields, 1979; Cheng et al., 1986; Morgan et al., 1992). 
Studies utilizing both autoradiography and immunohistochemistry reported that the PAG 
contained a high density of mu opioid receptors (Mansour et al., 1986; Mansour et al., 
1987; Kalyuzhny et al., 1996; Gutstein et al., 1998; Commons et al., 1999; Commons et 
al., 2000b; Wang & Wessendorf, 2002). Antinociception produced by opioid 
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microinjection into the PAG has now been repeated and confirmed in a variety of 
species (Pert & Yaksh, 1974; Jacquet & Lajtha, 1976; Mohrland & Gebhart, 1980; 
Kayser & Guilbaud, 1983; Gebhart et al., 1984; Ossipov et al., 1984; Camarata & 
Yaksh, 1985; Jensen & Yaksh, 1986; Carstens et al., 1988; Carstens et al., 1990). 
Similarly, lesions of the PAG or microinjection of mu opioid receptor antagonists into the 
PAG (Wilcox et al., 1979; Ma & Han, 1991; Zhang et al., 1998) attenuate the 
antinociceptive effects of systemic morphine across a wide range of analgesiometric 
tests (Lewis & Gebhart, 1977).  
 
By the 1990’s, electrophysiological studies reported that morphine, as well as other 
opioid agonists, inhibit and excite different populations of PAG neurons, including PAG 
neurons projecting to the RVM (PAG-RVM neurons). Indeed, two mechanisms for 
morphine’s antinociceptive actions at the level of the PAG have been proposed: (1) 
opioids disinhibit PAG-RVM neurons by presynaptically inhibiting tonically active 
GABAergic neurons (Behbehani et al., 1990a; Behbehani et al., 1990b; Chieng & 
Christie, 1994a; Stiller et al., 1995), thus resulting in the activation of PAG-RVM 
neurons; and (2) opiates directly inhibit a subset of PAG-RVM neurons localized 
primarily in the lateral and ventrolateral PAG (Chieng & Christie, 1994a; Osborne et al., 
1996b). Soon it was reported that mu opioid receptors were localized on approximately 
27-50% of PAG neurons retrogradely labeled from the RVM (Commons et al., 2000b; 
Wang & Wessendorf, 2002).  
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1.2  BUT WHAT ABOUT FEMALES? SEX DIFFERENCES IN MORPHINE 
ANALGESIA 
 
While it is well established that the PAG-RVM-spinal cord pathway is essential for the 
analgesic actions of both systemic and intra-PAG morphine, these early studies were 
conducted exclusively in male subjects. Only recently have studies begun including 
‘sex’ as an independent variable, and it is becoming increasingly clear that morphine 
does not produce the same degree of antinociception in males and females, especially 
following the induction of persistent pain. Sex differences in morphine potency were first 
reported in rodents in the late 1980’s, when it was shown that morphine produced a 
significantly greater degree of antinociception in males compared to females in studies 
employing acute pain assays (Kavaliers & Innes, 1987; Baamonde et al., 1989; Kepler 
et al., 1989; Kepler et al., 1991). Indeed, the vast majority of studies to date confirm this 
effect, including studies employing orofacial (Okamoto et al., 2005) and visceral (Ji et 
al., 2006; 2007) pain models, as well as persistent somatic pain models (Bartok & Craft, 
1997; Cicero et al., 1997; Boyer et al., 1998; Kest et al., 1999; Barrett et al., 2001; Cook 
& Nickerson, 2005; Wang et al., 2006). Sex differences in the antihyperalgesic effects of 
morphine are not trivial; in both persistent inflammatory pain (Wang et al., 2006) and 
visceral pain (Ji et al., 2006; 2007) studies, the ED50 for females was twice the ED50 of 
males. This is quite a remarkable difference, and to date, the mechanism(s) underlying 
the sexually dimorphic actions of morphine remain unknown. 
 
 
 
 7 
1.3  ROLE OF GONADAL HORMONES IN SEX DIFFERENCES IN MORPHINE  
ANALGESIA 
 
Sex differences in gonadal hormone concentrations contribute to sex differences in 
morphine analgesia (Kepler et al., 1989; Islam et al., 1993; Krzanowska & Bodnar, 
1999; 2000; Stoffel et al., 2003; Cataldo et al., 2005; Stoffel et al., 2005). In females, the 
primary gonadal hormones are estradiol and progesterone, while in males it is 
testosterone. Both centrally and peripherally, testosterone is aromatized to estradiol, 
thus male and females both secrete steroid hormones that bind both androgen 
receptors (AR) and estrogen receptors (ERα and ERβ).  
 
Numerous behavioral studies have suggested that both the organizational and 
activational actions of gonadal steroids can have an effect on morphine analgesia 
(Kepler et al., 1989; Islam et al., 1993; Krzanowska & Bodnar, 1999; 2000; Stoffel et al., 
2003; Cataldo et al., 2005; Stoffel et al., 2005). Compared to normal controls, male rats 
castrated at birth demonstrate reduced morphine potency in adulthood, while female 
rats masculinized at birth demonstrate greater morphine potency in adulthood (Cicero et 
al., 2002; Krzanowska et al., 2002). Similarly, morphine is less effective in 
gonadectomized adult males and more effective in ovariectomized adult females 
(Kepler et al., 1989; Ratka & Simpkins, 1991; Krzanowska & Bodnar, 1999; Terner et 
al., 2002; Stoffel et al., 2003; Stoffel et al., 2005; Terner et al., 2005). These effects can 
be reversed with hormone replacement treatment (Ratka & Simpkins, 1991; Kiefel & 
Bodnar, 1992; Ji et al., 2007). In females, circulating levels of estradiol across the 
estrous cycle reportedly influence morphine antinociception, with greater potency 
reported during diestrus, when circulating estradiol is lowest (Stoffel et al., 2003; Craft et 
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al., 2004; Okamoto et al., 2005; Stoffel et al., 2005; Terner et al., 2005). In fact, 
microinjection of morphine directly into the PAG produces significantly lower 
antinociception during the estrus stage in female rats, while there was no significant 
difference in morphine potency between females in diestrus compared to males (Bernal 
et al., 2007). 
 
1.4  CLINICAL EVIDENCE OF SEX DIFFERENCES IN MORPHINE ANALGESIA 
 
Recently, clinical studies in humans have also reported sex differences in morphine 
analgesia. Of the limited number of studies that examined sex (gender) as an 
independent variable, the majority reported that males experience greater analgesia 
compared to females (Cepeda et al., 2002; Cepeda & Carr, 2003; Miller & Ernst, 2004). 
In fact, one study reported that females required 30% more morphine to reach the same 
level of analgesia as males (Cepeda & Carr, 2003). Results to the contrary have also 
been reported; Sarton et al. reported greater morphine antinociception in females 
(Sarton et al., 2000), while two studies reported no sex difference (Gordon et al., 1995; 
Fillingim et al., 2005). Sex differences in morphine consumption have also been 
reported (Miaskowski et al., 2000); however, morphine consumption is not a reliable 
indicator of morphine analgesia, particularly given that all of the negative side effects 
associated with morphine consumption, including nausea, headache and dysphoria, are 
exacerbated in females compared to males (Cepeda et al., 2003; Fillingim et al., 2005). 
Importantly, sex differences in morphine analgesia are not due to sex differences in the 
pharmacokinetics of morphine [humans (Sarton et al., 2000) or rodents (Cicero et al., 
1997)]. Rather, sex differences in morphine analgesia are likely due to the inherent 
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differences in how the central nervous system of males and females responds to 
exogenous opioids.  
 
1.5 DISSERTATION AIMS 
 
Given that the PAG and its descending projections to the RVM and dorsal horn of the 
spinal cord provide a primary pathway for the actions of exogenous opiates on pain 
modulation, we hypothesized that (1) sex differences in the anatomy and physiology of 
the PAG-RVM pathway are responsible for differential morphine potency in a rat model 
of inflammatory pain; and (2) a sexually dimorphic expression of mu opioid receptor is a 
necessary and sufficient mechanism within the PAG for eliciting sexually dimorphic 
morphine analgesia. The dissertation research reported here tested these hypotheses 
via the following questions: (1) Are there sex differences in the anatomical organization 
of the PAG-RVM pathway? (2) Is there a sexually dimorphic response of the PAG-RVM 
output neurons to persistent pain? (3) Does administration of morphine, both during 
inflammatory pain and in the absence of pain, differentially engage the PAG-RVM 
pathway in male and female rats? and (4) Are mu opioid receptor-expressing neurons in 
the PAG necessary and sufficient in eliciting sex differences in morphine analgesia? 
The objective of this research is to provide evidence of a primary mechanism 
responsible for driving observed sex differences in morphine potency. It is intended that 
the findings of this research will ultimately improve the treatment of persistent pain in 
the clinical setting. 
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Figure 1.1. A schematic of the descending inhibitory pathway for pain modulation 
illustrating the projections from the midbrain periaqueductal gray to the brainstem rostral 
ventromedial medulla and the spinal cord dorsal horn. 
 11 
 
 
 
CHAPTER TWO 
 
Sex Differences in the Anatomical and Functional Organization of the 
Periaqueductal Gray - Rostral Ventromedial Medullary Pathway in the 
Rat: A Potential Circuit Mediating the Sexually Dimorphic Actions of 
Morphine 
 
Dayna R. Loyd and Anne Z. Murphy 
 
Department of Biology, Center for Behavioral Neuroscience 
Georgia State University, Atlanta, Georgia 30302-4010  
 
 
 
 
 
 
 
 
 
 
 
 
Published in the Journal of Comparative Neurology (2006) 496: 723-738
 12 
2.1  ABSTRACT 
 
Previous studies have demonstrated that morphine, administered systemically or 
directly into the PAG, produces a significantly greater degree of antinociception in males 
in comparison to females.   As the midbrain periaqueductal gray (PAG) and its 
descending projections to the rostral ventromedial medulla (RVM) constitute an 
essential neural circuit for opioid-based analgesia, the present studies were conducted 
to determine if sex differences in the anatomical organization of the PAG-RVM pathway, 
and its activation during persistent inflammatory pain, could account for sex-based 
differences in opioid analgesia. In the rat, retrograde tracing was combined with Fos 
immunocytochemistry to investigate sexual dimorphism in the organization of the PAG-
RVM circuit and its activation by persistent inflammatory pain induced by intraplantar 
injection of complete Freund’s adjuvant (CFA).  The ability of morphine to suppress the 
activation of the PAG-RVM circuit was also examined.  Sexually dimorphic retrograde 
labeling was observed within the dorsomedial and lateral/ventrolateral PAG at all 
rostrocaudal levels, with females having significantly more PAG-RVM output neurons in 
comparison to males.  While no sex differences were noted in the activation of the PAG-
RVM circuit by persistent inflammatory pain, significantly more double labeled cells 
were found in males in comparison to females.  Systemic administration of morphine 
significantly suppressed CFA-induced Fos in the PAG in males only. The results of 
these studies demonstrate that both the anatomical organization, and functional 
activation, of the PAG-RVM circuit is sexually dimorphic, and may provide the 
anatomical substrate for sex-based differences in morphine analgesia.  
 13 
2.2  INTRODUCTION 
 
It is becoming increasingly clear that morphine produces a differential degree of 
analgesia in males and females.  In studies using either acute (Kepler et al., 1989; Islam 
et al., 1993; Cicero et al., 1996a; 1997) or persistent pain models (Cook & Nickerson, 
2005; Wang & Murphy, 2005), morphine has been shown to produce a significantly 
greater degree of analgesia in males in comparison to females.  Similar findings have 
also been reported in humans (Cepeda & Carr, 2003; Miller & Ernst, 2004).  The 
midbrain periaqueductal gray (PAG), along with its descending projections to the rostral 
ventromedial medulla (RVM), is one of the primary anatomical substrates mediating 
opioid analgesia. Administration of mu opioid receptor agonists into the PAG produces 
potent analgesia that is blocked by central or systemic administration of the opioid 
antagonist naloxone (Satoh et al., 1983; Jensen & Yaksh, 1986; Bodnar et al., 1988b).  
Similarly, lesions of the PAG or intra-PAG administration of mu opioid receptor (MOR) 
antagonists (Wilcox et al., 1979; Ma & Han, 1991; Zhang et al., 1998) attenuate the 
antinociceptive effects of systemic morphine.  Together, these studies indicate that the 
PAG is an essential locus for opioid-mediated analgesia.  
 
There are no direct projections from the PAG to the dorsal horn of the spinal cord.  
Rather, the PAG projects heavily onto reticulospinal neurons of the RVM (Beitz, 1982b; 
Beitz et al., 1983; van Bockstaele et al., 1991; Cameron et al., 1995b), and this PAG-
RVM-spinal cord circuit is essential for the analgesic actions of systemic or intra-PAG 
morphine. Lesions of the RVM or dorsolateral funiculus (DLF) completely abolish PAG 
opiate-produced analgesia (Proudfit & Anderson, 1975; Basbaum et al., 1977; Chance 
et al., 1978; Mohrland & Gebhart, 1980; Proudfit, 1980; Guo & Tang, 1990).  In fact, 
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lesions of the DLF attenuate all analgesic manipulations tested, including systemic, 
intraventricular and intrathecally administered morphine, indicating that the PAG-RVM-
spinal cord pathway is the critical neural circuit for opioid-induced analgesia. 
 
The anatomical and physiological organization of the PAG-RVM-spinal cord circuit has 
been well characterized in a variety of species, including the rat (Basbaum & Fields, 
1978; Behbehani & Fields, 1979; Beitz, 1982b; Jones & Light, 1992; Williams et al., 
1995), cat (Basbaum et al., 1978; Shah & Dostrovsky, 1980; Abols & Basbaum, 1981; 
Sandkuhler et al., 1987a; Sandkuhler et al., 1987b; Holstege & Cowie, 1989), squirrel 
monkey (Mantyh, 1983; Gerhart et al., 1984), and rabbit (Haselton et al., 1988).  
However to date, all of these studies have been conducted exclusively in male animals.  
Therefore, it is not known if the PAG-RVM-spinal cord circuit is organized anatomically 
in a similar manner in females.  Sex differences in the organization of this circuit may 
provide an anatomical substrate for the observed sex differences in opioid analgesia. 
 
The present studies were conducted to determine if the PAG-RVM circuit is organized 
differentially in males and females.  Additional behavioral studies were performed to 
examine the activation of this circuit by persistent inflammatory pain.  The results of 
these studies demonstrate for the first time that the PAG-RVM circuit is sexually 
dimorphic in both its anatomical organization and in its functional activation during 
persistent inflammatory pain. Collectively, these data suggest that the PAG, and its 
descending projections to the RVM, may provide the anatomical substrate for the 
observed sex differences in morphine analgesia.  Portions of this paper have been 
previously published in abstract form (Loyd & Murphy, 2004b). 
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2.3  METHODS 
 
Subjects 
Fifteen adult intact male Sprague-Dawley rats and fifteen adult cycling female Sprague-
Dawley rats (Zivic-Miller) were used in these experiments.  Animals were weight-
matched (250-300g) and housed in same-sex pairs in separate rooms on a 12:12 hour 
light: dark cycle (lights on at 7:00A.M.).  Access to food and water was available ad 
libitum throughout the experiment except during surgery.  These studies were 
performed in strict compliance with the Institutional Animal Care and Use Committee at 
Georgia State University.  All efforts were made to minimize any possible suffering by 
the animal, and to reduce the number of animals used.   
 
Iontophoresis Injections 
Twelve male and twelve female rats were anesthetized with ketamine/xylazine (50 
mg/kg/10mg/kg; s.c.) and placed in a stereotaxic frame upon achieving a deep surgical 
plane of anesthesia.  The skull was adjusted so that bregma and lambda were at the 
same dorsoventral coordinate.  Glass micropipettes (10-20 µM) were filled with the 
retrograde tracer Fluorogold (FG; 2% soln. w/v in saline; Fluorochrome Inc.) and 
lowered into the RVM at the following coordinates (in mm): AP: -2.0 Lambda; ML: 0.0; 
DV: -8.5.  FG was iontophoresed (50/50 duty cycle, 7.5 µA current) for 20 min.  Pipettes 
remained in place for five minutes after injection to prevent backflow of tracer along the 
pipette tract and to facilitate neuronal uptake.  Special care was taken to ensure that all 
injection protocols were comparable for males and females.  Following surgery the 
animals were allowed to recover under a heat lamp in clean cages, and returned to their 
original housing facilities upon recovery from the anesthetic.  
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Inflammatory Hyperalgesia 
Ten days following surgery, persistent inflammatory pain was induced by injection of 
complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 µl), 
suspended in an oil/saline (1:1) emulsion, into the plantar surface of the right hindpaw. 
Animals were under brief Isoflo (isofluorane, USP) anesthesia during the plantar 
injections. We have previously used this procedure to induce persistent inflammatory 
pain and reported no sex differences in the degree of edema produced by intraplantar 
CFA, nor in the ensuing hyperalgesia, assayed using the paw thermal stimulator (Wang 
and Murphy, 2005).  
 
Morphine Analgesia 
Twenty-four hours following the induction of inflammation, all FG-injected animals were 
given a subcutaneous injection of either morphine sulfate (4.5mg/kg, s.c.; NIDA) or the 
drug vehicle as a control. Morphine sulfate was prepared fresh in a saline vehicle on the 
day of the experiment.   
 
Perfusion fixation 
One hour after morphine administration, animals were given a euthanizing dose of 
Nembutal (160mg/kg; i.p.).  Upon achieving a deep surgical plane, the animals were 
perfused transcardially (descending aorta clamped) with 100-200 ml of 0.9% sodium 
chloride containing 2% sodium nitrite as a vasodilator, followed immediately by 250 ml 
of 4% paraformaldehyde in 0.1M phosphate buffer containing 2.5% acrolein 
(Polyscience).  Following fixation, a final rinse with the sodium chloride/sodium nitrate 
solution was used to remove any residual acrolein from the animal.  Immediately 
following perfusion, the brains were removed and a mark made along the base of the 
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brain to demarcate left from right side. The tissue was stored at 4oC in 30% sucrose 
solution until sectioned.  The dura and pia mater were removed and the brains were cut 
into 25µm coronal sections with a Leica 2000R freezing microtome and stored free-
floating in cryoprotectant-antifreeze solution (Watson et al., 1986a) at –20oC until 
immunocytochemical processing was initiated. 
 
Immunocytochemistry 
A 1:6 series through the rostrocaudal axis of each brain was processed for FG and/or 
Fos immunoreactivity as previously described (Murphy & Hoffman, 2001).  Briefly, 
sections were removed from the cryoprotectant-antifreeze solution, rinsed extensively in 
potassium phosphate-buffered saline, and then reacted for 20 minutes in 1% sodium 
borohydride to remove excess aldehydes.  Sections were then incubated in primary 
antibody solution directed against either Fos or FG in KPBS containing 0.1% Triton X 
for 1 hour at room temperature followed by 48 hours at 4°C.  Cells containing Fos were 
identified using the polyclonal rabbit anti-Fos antibody (Oncogene, Cat. No. PC38; lot 
no. 4194) at a concentration of 1:50,000. This rabbit antiserum was prepared against 
the synthetic peptide (SGFNADYEASSSRC) corresponding to amino acids 4-17 of 
human c-Fos. In western blots, this antibody recognizes the ~55 kDa c-Fos and ~62 
kDa v-Fos proteins, and does not cross-react with the ~39 kDa Jun protein 
(manufacturer’s technical information). FG containing cells were recognized using the 
polyclonal rabbit anti-Fluorogold antibody (Chemicon, Cat. No. AB153; lot no. 
25060005) at a concentration of 1:10,000. This antibody was raised against the 
chemical compound hydroxystildamidine. No cytoplasmic FG staining was present in 
animals in which the tracer failed to be ejected from the electrode. In addition, the 
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retrograde labeling pattern in the PAG noted with this antibody is identical to published 
reports using alternative retrograde tracers (Rizvi et al., 1996; Beitz et al., 1983). 
 
After rinsing in KPBS, the tissue was incubated for 1 hour in biotinylated goat anti-rabbit 
IgG (Jackson Immunoresearch, 1:200), rinsed in KPBS, followed by a 1 hour incubation 
in avidin-biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs).  After rinsing in 
KPBS and sodium acetate (0.175 M; pH 6.5), Fos was always visualized as a black 
reaction product using nickel sulfate intensified 3,3’-diaminobenzidine solution 
containing 0.08% hydrogen peroxide in sodium acetate buffer.  FG was always 
visualized as a brown reaction product using 3,3’-diaminobenzidine containing 0.08% 
hydrogen peroxide in Tris buffer (pH 7.2).  The reaction product was terminated after 7-
25 minutes by rinsing in sodium acetate buffer.   
 
For dual labeling, sections were first processed for Fos immunocytochemistry as 
described above.  Following visualization of Fos, sections were rinsed several times in 
KPBS and then incubated for 1 hour at room temperature in primary antibody directed 
against FG followed by 48 hours at 4°C. Secondary and ABC reactions are as stated 
above.  FG was visualized as a brown reaction product using 3,3’-diaminobenzidine 
containing 0.08% hydrogen peroxide in Tris buffer (pH 7.2) for a brown cytoplasmic 
reaction product.  Sections were mounted out of saline onto gelatin-subbed slides, air-
dried overnight, dehydrated in a series of graded alcohols, cleared in Histoclear, and 
cover-slipped using Histomount. 
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Data Analysis and Presentation 
Previous anatomical studies have demonstrated that the PAG is not a homogenous 
structure, but rather has distinct afferents, efferents and neurochemical composition that 
are dependent on the rostrocaudal level (van Bockstaele et al., 1991; Bandler & 
Shipley, 1994a). Therefore, the number of FG+, Fos+, or Fos+FG neurons was 
determined for six rostrocaudal levels of PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -
8.80). Fos counts were made ipsilateral to the CFA-injected paw. In our preliminary 
studies (Loyd and Murphy, 2004), no differences were noted in the number of FG+ cells 
for the left versus right side of PAG; similarly, no laterality was observed in CFA-induced 
Fos expression in the PAG. Therefore, FG, Fos and Fos+FG labeled cells were only 
counted for the side ipsilateral to the CFA injected paw. 
 
Results for each rostrocaudal level of the PAG are expressed as the mean + standard 
error of the mean (SEM). Only animals with comparable injection sites limited to the 
RVM were used for analysis.  Neurons were counted in two PAG subdivisions: 
dorsomedial and lateral/ventrolateral; these subdivisions are clearly distinguishable 
based on the distribution of retrograde labeling from the RVM (van Bockstaele et al., 
1991; Bandler & Shipley, 1994a). Sections (25 µm thick) were immunocytochemically 
processed in a 1:6 series; therefore, each section analyzed is separated by 125µm. Cell 
counts were adjusted (Guillery, 2002) taking into consideration that PAG somal sizes 
range between 11-40µm (Lovick & Stezhka, 1999), with a mean somal length of 14.8µm 
(Beitz, 1985; Beitz & Shepard, 1985). 
 
Analysis of variance (ANOVA) was used to test for significant main effects of sex (male, 
female), PAG subdivision (dorsomedial, lateral/ventrolateral), PAG level (Bregma –6.72 
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through -8.80); treatment (morphine, saline) was included as a fourth factor where 
relevant. P<0.05 was considered significant for all analyses. To determine the PAG 
area, an image of the section was captured with a 4x objective on a Nikon Eclipse E800 
microscope using a Sensys digital camera (Biovisions Technology, Exton, PA).  With IP 
Spectrum software (Scanalytics, Fairfax, VA), the PAG area (in mm2) was determined. 
 
For data presentation, a representative animal from each experimental group was 
selected and the distribution of FG and Fos within the PAG were plotted using a Nikon 
Drawing Tube attached to a Nikon Optiphot microscope. Plots were imported to the 
computer and finalized using Adobe Illustrator 10.  Photomicrographs were generated 
using a Synsys digital camera attached to a Nikon Eclipse E800 microscope.  Images 
were captured with IP Spectrum software and finalized using Adobe Photoshop 7.0.  
Alterations to the images were strictly limited to enhancement of brightness/contrast. 
 
2.4  RESULTS 
  
Sexually Dimorphic Anatomical Organization of the PAG-RVM Circuit  
Figure 2.1 shows an example of a typical iontophoretic injection of the retrograde tracer 
Fluorogold (FG) into the RVM of a male (top; n=12) and female (bottom; n=12) rat.  All 
injections were located on the midline and dorsal to the pyramidal tract, just caudal to 
the level of the facial nucleus (Lambda –2.0).  Injections outside of the RVM were not 
included for analysis. Injection of FG into the RVM produced dense retrograde labeling 
throughout the rostral-caudal axis of the PAG in both males and females (Figure 2.2).   
Within the rostral half of PAG (Bregma –6.72 - –7.64), retrogradely labeled cells were 
concentrated within the dorsomedial and lateral regions of PAG.  A few scattered cells 
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were present within the ventrolateral PAG. More caudally (Bregma –8.0 - –8.30), 
retrogradely labeled cells were most prominent within the lateral and ventrolateral 
regions of PAG.  At the caudal pole of PAG (Bregma –8.80), retrograde labeling was 
primarily localized within the dorsal half of PAG, with a few scattered cells present in the 
ventrolateral region. 
 
Although there were no differences in the overall distribution pattern of retrogradely 
labeled cells for males and females, sex differences in the actual number of FG positive 
cells were evident at all rostrocaudal levels of PAG.  For example, at mid-levels of PAG 
(Bregma –7.64), the mean number of FG+ cells in the lateral/ventrolateral region was 
109 + 13 for males, in comparison to 142 + 15 for females. More caudally (Bregma –
8.30), the mean number of retrogradely labeled cells within the lateral/ventrolateral PAG 
was 32% higher in females (175 + 19) in comparison to males (133 + 14). An ANOVA 
on the number of FG labeled cells revealed significant main effects for sex 
(F(1,248)=26.10, p<0.01), PAG subdivisions (F(1, 248)=27.40, p<0.01) and a significant 
subdivisions by rostrocaudal level interaction (F(5,248)=12.10, p<0.01). A significant 
interaction between level and subdivisions was expected based on previous studies 
demonstrating shifts in the regional distribution of PAG-RVM output neurons that are 
dependent on the rostrocaudal level of PAG (Bandler and Shipley, 1994).  
 
The observed sex differences in the number of PAG-RVM output neurons was not due 
to sex differences in FG transport rates; the number of FG+ cells retrogradely labeled 
from the RVM within layer 5 of the motor/somatosensory cortex was comparable for 
males and females ((F(1,8) = .009, p>0.05); Figure 2.3). Sex differences in retrograde 
labeling are not due to differences in the area of the PAG for males and females; no 
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significant differences were noted in the mean area (mm2) for males in comparison to 
females (F(1, 48)=1.70, p>0.05).  
 
Sexually Dimorphic Activation of the PAG-RVM Circuit  
The results from the above studies demonstrate that the PAG-RVM circuit is sexually 
dimorphic in its anatomical organization, with females having significantly more PAG-
RVM output neurons than males. The next series of experiments was conducted to 
determine if the activation of the PAG-RVM circuit by persistent inflammatory pain was 
comparable for males and females.  Intraplantar injection of CFA induced extensive Fos 
expression throughout the rostral-caudal axis of PAG (Figure 2.4). Fos+ cells were 
distributed throughout all regions of the PAG with no sex differences noted in the 
distribution; similarly, an ANOVA revealed no significant main effect of sex in the 
number of Fos+ cells induced by intraplantar CFA (F(1,107)=0.02, p>0.05).   
 
While no significant differences were noted in the overall number of Fos+ cells for males 
versus females, the number of PAG-RVM output neurons that expressed CFA-induced 
Fos was significantly greater in males in comparison to females. Figure 2.5 shows the 
distribution of PAG cells retrogradely labeled from the RVM that co-expressed CFA-
induced Fos and an example of CFA-induced Fos and retrograde labeling from the 
RVM in the male is presented in Figure 2.6. At all rostrocaudal levels of PAG, and within 
all regions analyzed, dual labeled cells were more prevalent in males in comparison to 
females. An ANOVA on the number of dual labeled neurons revealed significant main 
effects for sex (F(1,108)=39.30, p<0.01), PAG subdivisions (F(1,108)=23.50, p<0.01) 
and level (F(5,108)=2.20, p<0.05). In addition, a significant levels by subdivision 
interaction was noted (F(5,108)=6.50, p<0.01); no other interactions reached 
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significance (p>0.05).While FG/Fos+ cells were distributed within the dorsomedial and 
lateral/ventrolateral regions of PAG, sex differences in the activation of the PAG-RVM 
circuit were most evident within the lateral/ventrolateral PAG, where in males, 
approximately 50% of all PAG-RVM output neurons expressed Fos, in comparison to 
approximately 20% in females (Figure 2.7). An indication of the degree of variability in 
the percentile data is shown in Figure 10. 
   
As females had significantly more FG+ cells in comparison to males (see Figure 2.2), 
we also determined the percentage of CFA-induced Fos+ cells that were present in 
PAG-RVM cells. As no differences were noted in the number or distribution of Fos in 
males versus females (see Figure 2.4), this would provide an indication of the 
percentage of PAG cells activated by persistent inflammatory pain that were localized in 
PAG-RVM output neurons.  As shown in Figure 2.8, CFA-induced Fos preferentially 
engaged a higher percentage of PAG-RVM output neurons in males in comparison to 
females. An indication of the degree of variability in the percentile data is shown in 
Figure 2.11. Similar to what was noted in Figure 2.5, this held true for all rostrocaudal 
levels of PAG and for each region examined. Together, these data indicate that while 
females have significantly more PAG-RVM output neurons, this circuit is preferentially 
engaged in males in comparison to females during persistent pain states. 
   
Morphine differentially suppresses persistent pain-induced activation of PAG-RVM  
neurons 
The above studies demonstrate that while persistent inflammatory pain activates a 
comparable number of PAG neurons in males and females, PAG-RVM output neurons 
were activated to a greater degree in males in comparison to females. The next series 
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of experiments examined the ability of morphine to suppress CFA-induced Fos in males 
versus females. Systemic morphine administration (4.5mg/kg, s.c.) attenuated CFA-
induced Fos at all rostrocaudal levels of PAG in males (Figure 2.9); by contrast, 
comparable numbers of CFA-induced Fos+ cells were noted for saline versus morphine 
treated females.  An ANOVA revealed significant main effects of sex (F(1,225)=5.70, 
p<0.05), treatment (F(1, 225)=20.84, p<0.01), PAG subdivision (F(1, 225)=16.65, 
p<0.01, and level (F(5, 225)=5.06, p<0.01). In addition, a significant sex by treatment 
interaction was noted (F(1, 225)=4.72, p<0.05). Across all levels, morphine 
administration resulted in a 26%-46% reduction in Fos expression in males; by contrast 
only a 0-19% reduction in the number of Fos+ cells was noted in females.  
 
We next examined if morphine was preferentially acting on PAG-RVM neurons to 
suppress CFA-induced Fos.  Figure 2.10 shows the percentage of PAG-RVM output 
neurons that expressed CFA-induced Fos following administration of either saline or 
morphine (4.5 mg/kg, s.c.) for males and females. An ANOVA on the number of 
FG+Fos labeled cells revealed significant main effects of sex (F(1,228)=60.57, p<0.01), 
treatment (F(1,228)=44.78, p<0.01), and PAG subdivision (F(1,228)=21.32, p<0.01), as 
well as a significant sex by treatment interaction (F(1,228)=8.15, p<0.01.  In addition, a 
significant treatment by PAG subdivision by level interaction was noted (F(5,228)=2.42, 
p<0.05), indicating that the effect of morphine on CFA-induced Fos in PAG-RVM output 
neurons was variable and both level- and region-dependent. For example, in males, 
morphine administration reduced the percentage of dual labeled cells in both the 
dorsomedial and lateral/ventrolateral PAG within the rostral pole of PAG (-6.72). More 
caudally, morphine administration either had no effect or actually increased the 
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percentage of dual labeled cells in the dorsomedial PAG in comparison to saline treated 
animals. Similar level- and region-dependent effects were noted for the 
lateral/ventrolateral PAG. In females, the percentage of PAG-RVM neurons that 
expressed CFA-induced Fos following morphine administration was comparable across 
levels. 
 
As morphine significantly reduced the number of CFA-induced Fos+ neurons in males 
but not females, comparing the percent change in the activation of the PAG-RVM circuit 
(%FG that contained Fos) for morphine versus saline treated males and females is 
potentially biased. Therefore, we also examined the percentage of Fos+ neurons that 
were present in PAG-RVM neurons (%Fos in FG neurons) following morphine or saline 
treatment. A decrease in the %Fos present in PAG-RVM output neurons would suggest 
that the observed morphine-induced decreases in Fos expression (see Figure 2.4) were 
due to an inhibitory action on PAG-RVM output neurons. By contrast, if morphine was 
primarily acting on intrinsic PAG neurons, then the percentage of Fos present in FG+ 
neurons should be comparable for morphine and saline treated animals or increased in 
morphine treated animals, presumably due to the removal of a tonic inhibitory influence. 
The results are presented in Figure 2.11. Similar to what was noted in Figure 2.10, the 
effects of morphine on CFA-induced Fos in PAG-RVM neurons was variable across 
levels and PAG regions. For example, within the lateral/ventrolateral region of PAG of 
males, morphine increased (Bregma –8.00), decreased (Bregma –8.30) or had no effect 
(Bregma –8.80) on the percentage of Fos localized in PAG-RVM neurons. In females, 
the percentage of Fos present in PAG-RVM neurons was comparable for saline versus 
morphine treated animals. Together, these results suggest the influence of multiple 
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mechanisms of morphine action on persistent pain induced Fos, or alternatively, natural 
variability across PAG regions and levels. 
 
2.5 DISCUSSION 
 
There are now well-established sex differences in the analgesic effects of morphine; 
however, the CNS mechanisms underlying the sexually dimorphic actions of morphine 
are unknown. As the PAG, and its descending projections to the RVM, constitute an 
essential circuit for opioid analgesia, the present studies were conducted to determine if 
the PAG-RVM pathway is sexually dimorphic in its anatomical organization and in its 
activation during persistent inflammatory pain.  The results of the present study 
demonstrate profound sex differences in both the anatomical and functional 
organization of the PAG-RVM pathway. The action of morphine on PAG neurons was 
also found to be sexually dimorphic. Together, these results suggest that the PAG-RVM 
pathway may provide an anatomical basis for observed sex differences in morphine 
analgesia. 
 
Sexually Dimorphic PAG-RVM Circuit: Functional Implications  
Retrograde tracer injection into the RVM produced dense retrograde labeling within the 
dorsomedial, lateral and ventrolateral regions of PAG; these results are consistent with 
previous anatomical studies characterizing PAG outputs to the medulla (van Bockstaele 
et al., 1991). Interestingly, while no sex differences were noted in the distribution of 
PAG-RVM output neurons, females had significantly more retrogradely labeled cells in 
comparison to males. The most prominent sex difference in retrograde labeling was 
observed within the lateral/ventrolateral region of the PAG, where at some rostrocaudal 
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levels, females had almost twice the number of retrogradely labeled neurons in 
comparison to males. These studies are the first to demonstrate a sexually dimorphic 
organization of a primary endogenous pain pathway. 
 
The lateral/ventrolateral region of PAG has been implicated in a variety of physiological 
functions, including the cardiovascular regulation (Bandler et al., 1991; Murphy et al., 
1995b), initiation of the ‘fight or flight’ response (Bandler & Carrive, 1988a; Carrive et 
al., 1988; Zhang et al., 1990a), vocalization (Larson & Kistler, 1984; Larson, 1985; 
Zhang et al., 1994; Jurgens, 2002; Dujardin & Jurgens, 2005) and reproductive behavior 
(McCarthy et al., 1991a; Ogawa et al., 1991; Ogawa et al., 1992; Murphy & Hoffman, 
2001). In addition, this region is a critical site for both stimulation-produced and 
morphine-induced analgesia (Reynolds, 1969; Behbehani & Fields, 1979; Fardin et al., 
1984a; b; Morgan et al., 1991; Morgan et al., 1992; Zhang et al., 1998). Given that 
morphine produces a greater degree of analgesia in males in comparison to females 
(Cicero et al., 1996a; Craft et al., 1996; Bartok & Craft, 1997; Cicero et al., 1997; Boyer 
et al., 1998; Tershner et al., 2000; Barrett et al., 2001; Cepeda & Carr, 2003; Stoffel et 
al., 2003; Stoffel et al., 2005; Wang & Murphy, 2005) and the PAG-RVM pathway is a 
critical circuit for opioid analgesia, we had initially hypothesized that if this circuit was 
sexually dimorphic, retrograde labeling from the RVM would be more prominent in 
males in comparison to females. Therefore, subsequent experiments were conducted to 
examine the ‘activation’ of this circuit by a persistent noxious stimulus.  
 
Intraplantar injection of the bacterium Complete Freund’s adjuvant is a well-established 
model of persistent inflammatory pain (Millan et al., 1988; Stein et al., 1988a). Twenty-
four hours following injection, edema and hyperalgesia are present in the injected paw. 
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We have previously used this model and reported no sex differences in either the 
degree of edema produced by intraplantar CFA, or in the withdrawal latencies following 
application of a noxious thermal stimulus (Loyd et al., 2005; Wang & Murphy, 2005).  
Hyperalgesia in animal models of inflammatory pain is closely linked to activation of 
PAG-RVM descending modulatory circuits (Morgan et al., 1991; Williams et al., 1995) 
and involve both facilitation and inhibition of inflammatory pain (Guan et al., 2002; Miki 
et al., 2002; Ren & Dubner, 2002; Guan et al., 2003). In the present study, persistent 
inflammatory pain induced extensive Fos expression throughout the rostrocaudal axis of 
the PAG, indicating comparable activation of the PAG in males and females.  
Interestingly, while no differences were noted in either the number or distribution of Fos 
between males and females, persistent inflammatory pain preferentially activated the 
PAG-RVM circuit in males and not females. Thus, while females have almost twice the 
number of PAG-RVM output neurons in comparison to males, this descending 
modulatory circuit is not being ‘engaged’ to the same degree by persistent inflammatory 
pain in both sexes. As activation of the PAG and its descending outputs to the RVM 
inhibits dorsal horn neuronal responses to acute noxious stimuli (Carstens et al., 1979; 
Gray & Dostrovsky, 1983; Aimone et al., 1987; Jones & Gebhart, 1988; Waters & Lumb, 
1997; Budai & Fields, 1998), the results of the present study may account for reported 
sex differences in nociceptive thresholds (Berkley, 1997; Fillingim, 2000; Fillingim & 
Ness, 2000; Barrett et al., 2002).   
 
The adaptive significance of a sexually dimorphic PAG-RVM circuit is not clear. As 
mentioned above, the PAG is involved in a variety of physiological functions, and in 
females, this region is essential for the display of lordosis, the primary motor component 
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of female reproductive behavior (McCarthy et al., 1991a; Ogawa et al., 1991).  
Electrolytic lesions of the PAG, or direct administration of GABA antagonists, 
significantly attenuate lordosis, while stimulation of this region facilitates it (Sakuma & 
Pfaff, 1979a; b; 1980; McCarthy et al., 1991a; Kondo et al., 1993). In addition, 
stimulation of the PAG has been shown to provide excitatory drive over RVM pre-
motoneurons that innervate the axial muscles necessary for the display of lordosis 
(Cottingham et al., 1987; 1988). Together, this suggests that in females, PAG outputs to 
the RVM may be specialized for the modulation of somatosensory information essential 
for the appropriate display of lordosis (Rose, 1975; Robbins et al., 1990; Robbins et al., 
1992), and specifically, may serve to increase somatosensory thresholds during 
reproductive behavior (Crowley et al., 1976; Whipple & Komisaruk, 1985; Komisaruk & 
Whipple, 1986). In support, the PAG receives extensive projections from the 
lumbosacral spinal cord (Vanderhorst et al., 1996; Mouton et al., 2005), and spino-PAG 
afferents terminate preferentially in PAG regions containing dense retrograde labeling 
from the RVM (Murphy, unpublished observations). Therefore, activation of the 
lumbosacral spinal cord by peripheral afferents during mounting by a male may function 
to activate the PAG-RVM inhibitory pathway, thereby increasing sensory thresholds and 
allowing for appropriate postural adjustments necessary for successful intromission by 
the male.  
 
Sexually Dimorphic Effect of Opiates on the PAG-RVM Circuit 
Systemic morphine administration significantly attenuated CFA-induced Fos in males, 
but not females. These results are consistent with previous studies reporting significant 
sex differences in the antihyperalgesic effects of systemic morphine in persistent pain 
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models (Cook & Nickerson, 2005; Wang & Murphy, 2005). Interestingly, while morphine 
clearly suppressed CFA-induced Fos in males, the effect of morphine on Fos 
expression in PAG-RVM neurons was highly variable. Indeed, depending on the PAG 
region and rostrocaudal level, administration of morphine either increased, decreased, 
or had no effect on the percentage of PAG-RVM neurons expressing Fos (%FG/Fos) in 
comparison to saline-treated animals. Similarly, analysis of the percentage of Fos 
present in FG neurons (%Fos/FG) following morphine or saline treatment provided no 
additional clear insight. Two primary mechanisms have been proposed to account for 
morphines’ action in the PAG. First, morphine has been shown to hyperpolarize 
GABAergic interneurons that are presynaptic to PAG-RVM output neurons; this 
hyperpolarization results in the disinhibition of PAG output neurons to the RVM resulting 
in a net excitatory effect (Behbehani & Fields, 1979; Yaksh & Tyce, 1979; Cheng et al., 
1986; Moreau & Fields, 1986; Chieng & Christie, 1994a; Commons et al., 2000a; 
Tortorici & Morgan, 2002). In the present study, this mechanism of morphine action 
would be reflected as a decrease in Fos expression in intrinsic (presumably GABAergic) 
neurons.  The removal of tonic GABAergic inhibition would result in the net activation of 
PAG-RVM neurons, thereby inducing Fos and increasing the percentage of Fos/FG 
neurons in morphine treated animals in comparison to saline.  
 
Morphine has also been shown to directly inhibit PAG-RVM neurons (Osborne et al., 
1996a). Anatomical studies by Commons et al. (2002) and Wang and Wessendorf 
(Wang & Wessendorf, 2002) estimated that between 27-50% of PAG neurons 
retrogradely labeled from the RVM contain MOR; these dual labeled cells were localized 
primarily within the caudal lateral/ventrolateral PAG. In the present study, a direct 
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inhibitory mechanism of morphine action would be reflected as a decrease in the 
percentage of FG+Fos labeled cells following opioid administration.    
 
A precise mechanism of morphine action (presynaptic versus direct) cannot be 
discerned in the present study, and the results suggest that both mechanisms 
contributed to the suppression of persistent pain induced Fos in the PAG of males. The 
variability noted in the action of morphine on PAG-RVM neurons is not easily 
attributable to level and region-dependent differences in PAG mu opioid receptor 
expression. Mu opioid receptors are localized throughout the rostral-caudal axis of PAG, 
with low to moderate levels of expression noted in the rostral two-thirds of PAG 
(Bregma –6.72 to –8.00) (Duncan and Murphy, 2005).  The highest level of MOR 
expression is within the caudal ventrolateral PAG (Bregma –8.30 to -8.80), and in the 
present study, the effects of morphine on Fos expression in PAG-RVM neurons were 
quite variable at this level.   
 
It is important to consider that while lesions of the PAG or intra-PAG naloxone 
significantly attenuate the effects of systemic morphine, they do not block it completely. 
This suggests the involvement of additional loci, including both central (Jensen & 
Yaksh, 1986; Heinricher et al., 1994) and peripheral (Stein et al., 1988b) sites of 
morphine action.  Thus, in addition to a direct action within the PAG, morphine would 
also reduce incoming noxious input to the spinal cord at the primary afferent synapse, 
which would ultimately reduce noxious stimulus-induced Fos in PAG. 
 
There was no effect of morphine on CFA-induced Fos in females. These results concur 
with our recent data indicating that the ED50 for either systemic (Loyd et al., 2005) or 
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intra-PAG (Loyd et al., 2005) morphine is approximately two times higher in females 
than males in a model of persistent inflammatory pain. Similar findings for intra-PAG 
morphine administration have been reported in studies utilizing acute pain models 
(Rossi et al., 1994; Krzanowska & Bodnar, 1999; 2000).   
 
Interestingly, recent studies report that systemic morphine simultaneously activates both 
pain inhibitory as well as pain facilitatory systems (Vanderah et al., 2001a; Vanderah et 
al., 2001b). Specifically, in rats, sub-analgesic doses of morphine (0.002-0.2 mg/kg) 
result in a hyperalgesic response, and this effect is significantly more pronounced in 
females than males (Holtman & Wala, 2005). While the mechanism(s) and neural 
substrates underlying morphine-induced hyperalgesia are unknown, it is interesting to 
speculate that in females, a low dose of morphine may concurrently activate both pain 
facilitatory and inhibitory circuits within the PAG, thereby resulting in no change in CFA-
induced Fos. Further studies are obviously warranted.  
 
Unfortunately, to date, all studies examining the antinociceptive mechanisms of 
morphine action in the PAG have been conducted exclusively in males; therefore, it is 
not known whether morphine administration has the same physiological effect on PAG 
neurons in females. The PAG contains a large population of estrogen receptors (ERα) 
(Murphy & Hoffman, 1999; Murphy & Hoffman, 2001), and in both males and females, 
approximately 20-25% of PAG-RVM neurons contain ERα (Loyd & Murphy, 2004a). 
Estrogen binding to its receptor within PAG-RVM neurons may be involved in ligand-
dependent transcriptional events, thereby influencing the expression of various 
neurotransmitters and/or membrane properties (Zakon & Dunlap, 1999). Alternatively, 
as the gene encoding Fos contains an estrogen response element (Loose-Mitchell et 
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al., 1988; Wang et al., 2003), changes in cycle status may have potentially influenced 
the effect of morphine on CFA-induced Fos in females, particularly if the animals were 
in similar stages of estrous. In the present study, the phase of the estrous cycle was not 
determined. However, if cycle status differentially affected Fos expression, then the 
degree of variability in CFA-induced Fos should be greater in females in comparison to 
males; however, this was not observed in the present study.   
 
Alternatively, the mu opioid receptor is a member of the inhibitory G protein-coupled 
receptor superfamily, and in hypothalamic slices, estrogen has been shown to rapidly 
uncouple the mu receptor from G protein-gated inwardly rectifying potassium channels 
resulting in a reduced hyperpolarization by MOR agonists (Kelly et al., 2003; Malyala et 
al., 2005). Estrogen has also been shown to result in MOR internalization, thereby 
limiting the amount of receptor available for exogenous ligand binding (Eckersell et al., 
1998a). Lastly, we have recently reported significant sex differences in mu opioid 
receptor protein levels within the caudal lateral/ventrolateral PAG, with intact males 
have 11% higher levels of MOR protein in comparison to diestrus females (Duncan & 
Murphy, 2005). Together, these studies may provide several direct mechanisms for the 
reduced potency of mu agonists noted in females.  
 
2.6 CHAPTER SUMMARY 
 
There are now well-established sex differences in the analgesic effects of morphine; 
however, the CNS mechanisms underlying the sexually dimorphic actions of morphine 
are unclear. The PAG, and its descending projections to the RVM and dorsal horn of the 
spinal cord, constitute an essential neural circuit for opioid-based analgesia. The results 
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of the present study demonstrate for the first time that the PAG-RVM pathway is 
sexually dimorphic in its anatomical organization and in its activation during persistent 
inflammatory pain. The actions of morphine on PAG neurons are also sexually 
dimorphic. Together, these results suggest that the PAG-RVM pathway may provide an 
anatomical basis for observed sex differences in morphine analgesia. 
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Figure 2.1.  Representative examples of FG injection localization in the RVM of a male 
(top) and female (bottom) rat. Scale bar: 200µm. 
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Figure 2.2.  Distribution of cells retrogradely labeled from the rostral ventromedial 
medulla in males and females at six rostrocaudal levels of the periaqueductal gray.  
Each black circle represents one FG-immunoreactive cell.  Bar graphs show the mean 
number (+ S.E.M.) of FG-immunoreactive cells for the dorsomedial and 
lateral/ventrolateral regions of PAG. 
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Figure 2.2 continued 
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Figure 2.3. Photomicrographs of cortical retrograde labeling following tracer injection 
into the RVM in the male (A) and female (B) rat (Bregma –1.0). Scale bar: 200µm. Bar 
graph (C) shows the mean number (+ S.E.M.) of retrogradely labeled cells in the cortex 
of males and females. Labeling was localized to pyramidal cells in layer 5. Dorsal 
counts include primarily motor cortex, while ventral counts are primarily somatosensory 
cortex.   
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Figure 2.4.  Distribution of CFA induced Fos within the periaqueductal gray of males 
and females across six rostrocaudal levels.  Each black circle represents one Fos+ cell. 
No sex differences were noted in either the distribution or number of Fos+ cells for 
males and females.  
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Figure 2.5. Distribution of PAG-RVM output neurons that expressed CFA-induced Fos 
for males and females across six rostrocaudal levels of the PAG.  Each black circle 
represents one double-labeled (FG+Fos) cell.  Bar graphs display the mean number of 
FG/Fos cells (+ S.E.M.) for each level and region.  
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Figure 2.5 continued 
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Figure 2.6.  Color photomicrograph showing a low (A) and high (B) power example of 
single and double labeled Fos and FG labeled cells in the PAG of a male rat.  Scale bar 
= 100 µm in panel A; scale bar = 50 µm in panel B.  
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Figure 2.7.  Percentage of PAG-RVM neurons that were activated by persistent 
inflammatory pain (FG+Fos) in males (left) and females (right) throughout the 
rostrocaudal axis of PAG. 
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Figure 2.8.  Percentage of Fos+ PAG neurons that were retrogradely labeled from the 
RVM (Fos+FG) in males (left) and females (right) throughout the rostrocaudal axis of 
PAG. 
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Figure 2.9. Distribution of CFA-induced Fos (black dots) following saline (black) or 
morphine (white) administration in males (left) and females (right) along the 
rostrocaudal axis of PAG.  Each black circle represents one Fos+ cell.  Bar graphs show 
mean number of Fos+ cells (+ S.E.M.) for each treatment group broken down 
separately for the dorsomedial and lateral/ventrolateral PAG. 
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Figure 2.9 continued 
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Figure 2.10.  Percentage of PAG-RVM neurons expressing CFA-induced Fos 
(%FG/Fos) following saline (black bars) or morphine (4.5 mg/kg; s.c.; white bars) in 
male (left) and female (right) rats for six rostrocaudal levels of PAG.  
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Figure 2.11.  Percentage of CFA-induced Fos positive neurons that were retrogradely 
labeled from the RVM (%Fos/FG) following saline (black bars) or morphine (4.5 mg/kg; 
s.c.; white bars) in male (left) and female (right) rats for six rostrocaudal levels of PAG.  
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3.1  ABSTRACT 
 
The midbrain periaqueductal gray (PAG) and its descending projections to the rostral 
ventromedial medulla (RVM) provide an essential neural circuit for opioid-produced 
antinociception.  Recent anatomical studies have reported that the projections from the 
PAG to the RVM are sexually dimorphic and that systemic administration of morphine 
significantly suppresses pain-induced activation of the PAG in male but not female rats. 
Given that morphine antinociception is produced in part by disinhibition of PAG output 
neurons, it is hypothesized that a differential activation of PAG output neurons mediates 
the sexually dimorphic actions of morphine.  The present study examined systemic 
morphine-induced activation of PAG-RVM neurons in the absence of pain.  The 
retrograde tracer fluorogold (FG) was injected into the RVM to label PAG-RVM output 
neurons.  Activation of PAG neurons was determined by quantifying the number of Fos-
positive neurons one hour following systemic morphine administration (4.5 mg/kg).  
Morphine produced comparable activation of the PAG in both male and female rats, 
with no significant differences in either the quantitative or qualitative distribution of Fos.  
While microinjection of FG into the RVM labeled significantly more PAG output neurons 
in female rats than male rats, very few of these neurons (20%) were activated by 
systemic morphine administration in comparison to males (50%). The absolute number 
of PAG-RVM neurons activated by morphine was also greater in males.  These data 
demonstrate widespread disinhibition of PAG neurons following morphine 
administration.  The greater morphine-induced activation of PAG output neurons in male 
compared to female rats is consistent with the greater morphine-induced antinociception 
observed in males.  
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3.2 INTRODUCTION 
 
Morphine and other mu-opioid receptor agonists are the most effective pharmacological 
treatment for the alleviation of persistent pain. However, morphine does not produce the 
same degree of analgesia in males and females.  In the majority of studies reported to 
date, morphine produced a greater antinociceptive response in males compared to 
females (Bodnar et al., 1988a; Craft, 2003b; a; Cook & Nickerson, 2005; Wang et al., 
2006).  Sex differences in morphine analgesia have been reported in studies employing 
orofacial (Okamoto et al., 2005), somatic (Bartok & Craft, 1997; Cicero et al., 1997; 
Boyer et al., 1998; Kest et al., 1999; Barrett et al., 2001) or visceral (Ji et al., 2006; in 
press) pain models. To date, the mechanism(s) whereby morphine produces a 
differential degree of analgesia is unclear.  
 
The midbrain periaqueductal gray (PAG), and its descending projections to the rostral 
ventromedial medulla (RVM) and spinal cord, comprises an essential neural circuit for 
both endogenous and exogenous opioid-mediated analgesia (Basbaum et al., 1978; 
Basbaum & Fields, 1978; Basbaum & Fields, 1984).  The PAG contains a high density 
of mu opioid receptors (Commons et al., 1999; Commons et al., 2000b; Wang & 
Wessendorf, 2002) and microinjection of opioid antagonists into the PAG significantly 
attenuates systemic morphine-produced analgesia (Zambotti et al., 1982; Randich et 
al., 1992; Lane et al., 2005; Bernal et al., 2007).  Similarly, microinjection of the mu 
opioid selective neurotoxin dermorphin-saporin (Porreca et al., 2001; Burgess et al., 
2002; Vera-Portocarrero et al., 2006a; Vera-Portocarrero et al., 2006b) into the PAG 
significantly attenuates systemic morphine analgesia (Loyd & Murphy, 2007a). 
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Together, these studies indicate that the PAG is a primary neural structure for opioid-
mediated analgesia. 
 
Recent studies have reported sex differences in both the anatomical and physiological 
organization of the PAG-RVM pathway. These sex differences may provide the 
biological bases for the observed sexually dimorphic actions of morphine. For example, 
recent anatomical studies have shown that females have a significantly greater number 
of PAG neurons retrogradely labeled from the RVM in comparison to males. 
Interestingly, persistent inflammatory pain only activates this pathway in males. 
Similarly, systemic morphine administration decreases noxious stimulus-induced 
activation of the PAG in male but not female rats (Loyd & Murphy, 2006).  Together, 
these studies suggest a sexually dimorphic action of morphine within the PAG.  This 
suggestion is further supported by studies showing that microinjection of morphine into 
the PAG produces greater antinociception in male in comparison to female rats 
(Krzanowska & Bodnar, 1999; Bernal et al., 2007; Wang et al., submitted).  
 
Electrophysiological studies have reported that morphine, as well as other opioid 
agonists, inhibit and excite different populations of PAG neurons. In vitro recordings 
have shown that opioids disinhibit PAG-RVM output neurons by presynaptically 
inhibiting tonically active GABAergic neurons (Behbehani et al., 1990a; Behbehani et 
al., 1990b; Chieng & Christie, 1994a; Stiller et al., 1995). This GABA-mediated 
disinhibition results in the activation of PAG-RVM neurons. However, other studies have 
shown that opioids directly inhibit a subset of PAG-RVM projection neurons (Chieng & 
Christie, 1994a; Osborne et al., 1996b), and mu opioid receptors have been localized 
on approximately 27-50% of PAG neurons retrogradely labeled from the RVM 
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(Commons et al., 2000b; Wang & Wessendorf, 2002). If GABA disinhibition is the 
primary mechanism for morphine action in the PAG, then administration of morphine 
should preferentially induce Fos in PAG-RVM output neurons.  By contrast, if morphine 
antinociception is primarily mediated via direct inhibition of PAG-RVM output neurons, 
then systemic administration of morphine should not induce Fos in these neurons as 
Fos induction requires membrane depolarization (Greenberg et al., 1986a; Greenberg 
et al., 1986b; Bartel et al., 1989). 
 
The present studies were conducted to determine whether morphine administration 
preferentially activates PAG-RVM output neurons using retrograde tract tracing in 
combination with Fos immunocytochemistry. Morphine-induced Fos in PAG-RVM output 
neurons was compared in male and females rats to determine if there were qualitative 
or quantitative sex differences in activation of this pathway in the absence of persistent 
pain. If sex differences in the PAG-RVM circuit provide the basis for the sexually 
dimorphic actions of morphine, then activation of this pathway should be greater in male 
compared to female rats when given the same dose of morphine. 
 
3.3 METHODS 
 
Subjects 
Adult male and weight-matched (250-350g) cycling female Sprague-Dawley rats (Zivic-
Miller; Pittsburg, PA) were used. Rats were housed in same-sex pairs in separate 
rooms on a 12:12 hour light: dark cycle (lights on at 7:00A.M.).  Access to food and water 
was ad libitum throughout the experiment except during surgery.  Vaginal lavages were 
taken daily to determine if the female rats were cycling normally and to keep daily 
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records on the stages of their cycle in respect to the experimental testing.  These 
studies were performed in compliance with the Institutional Animal Care and Use 
Committee at Georgia State University.     
 
Retrograde Tracer Injections 
Six male and six female rats were deeply anesthetized with ketamine/xylazine (50 
mg/kg / 10mg/kg; s.c.) and placed in a stereotaxic frame. The position of the skull was 
adjusted so that bregma and lambda were at the same dorsal-ventral plane.  Glass 
micropipettes (10-20 µM) filled with the retrograde tracer Fluorogold (FG; 2% soln. w/v 
in saline; Fluorochrome LLC; Denver, CO) were lowered into the RVM using the 
following coordinates (in mm): AP: -2.0 Lambda; ML: 0.0; DV: -8.5.  FG was 
iontophoresed (50/50 duty cycle, 7.5 µA current) into the RVM for 25 minutes to 
facilitate neuronal uptake.  The current was then turned off, and the pipettes remained 
in place for an additional 5 minutes to reduce backflow of tracer along the pipette track.  
Only males and females that had comparable injection sites were used for data 
collection.  Following tracer injections, wounds were sutured closed, the antibiotic 
Neosporin was applied to the wound, and the animals were placed in clean cages to 
recover under a heat lamp.   Upon complete recovery from the anesthetic, animals were 
returned to their original housing facilities. 
 
Morphine Administration 
All animals were given a subcutaneous injection of either morphine sulfate (4.5 mg/kg, 
s.c.; NIDA; Bethesda, MD) or sterile saline as a control. All injections were performed 
between the hours of 12:00P.M. and 2:00P.M.  Morphine sulfate was prepared fresh in a 
saline vehicle within one hour prior to injection.   
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Perfusion fixation 
One hour after morphine administration, animals were given a lethal dose of Nembutal 
(160 mg/kg; i.p.).  The animals were transcardially perfused with 150-200 ml of 0.9% 
sodium chloride containing 2% sodium nitrite as a vasodilator, to remove blood from the 
brain.  Immediately following removal of blood, 300 ml of 4% paraformaldehyde in 0.1M 
phosphate buffer containing 2.5% acrolein (Polyscience; Niles, IL) was perfused 
through the brain as a fixative.  A final rinse with 150-200 ml of the sodium 
chloride/sodium nitrate solution was perfused through the brain to remove any residual 
acrolein.  Immediately following perfusion, the brains were carefully removed, placed in 
a 30% sucrose solution and stored at 40C for at least one week prior to sectioning.  To 
section the brain, the dura and pia mater were carefully removed and the brains were 
cut into six series of 25 µm coronal sections with a Leica 2000R freezing microtome and 
stored free-floating in cryoprotectant-antifreeze solution (Watson et al., 1986b) at –20oC 
until immunocytochemical processing. 
 
Immunocytochemistry 
A 1:6 series through the rostrocaudal axis of each brain was processed for FG and/or 
Fos immunoreactivity as previously described (Murphy & Hoffman, 2001).  Briefly, 
sections were rinsed extensively in potassium phosphate-buffered saline (KPBS) to 
remove cryoprotectant solution immediately followed by a 20-minute incubation in 1% 
sodium borohydride to remove excess aldehydes.  The tissue was then incubated in 
primary antibody solution(s) previously described (Loyd & Murphy, 2006): rabbit anti-
Fos (Oncogene; Cambridge, MA, lot no. 4194; 1:50,000) and/or rabbit anti-FG 
(Chemicon; Billerica, MA, lot no. 25060005; 1:10,000) in KPBS containing 1.0% Triton-X 
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for one hour at room temperature followed by 48 hours at 4°C. After rinsing out the 
primary antibody with KPBS, the tissue was incubated for one hour in biotinylated goat 
anti-rabbit IgG (Jackson Immunoresearch; West Grove, PA, 1:200), rinsed with KPBS, 
followed by a one hour incubation in an avidin-biotin peroxidase complex (1:10; ABC 
Elite Kit, Vector Labs).  After rinsing in KPBS and sodium acetate (0.175 M; pH 6.5), 
Fos was visualized as a black reaction product using nickel sulfate intensified 3,3’-
diaminobenzidine solution containing 0.08% hydrogen peroxide in sodium acetate 
buffer.  FG was visualized as a brown reaction product using 3,3’-diaminobenzidine 
containing 0.08% hydrogen peroxide in Trizma buffer (pH 7.2).  After 15-30 minutes, 
three rinses in sodium acetate buffer terminated the reaction.  Sections were then 
mounted out of saline onto gelatin-subbed slides, air-dried overnight, dehydrated in a 
series of graded alcohols, cleared in xylene, and cover-slipped using Permount. 
 
Data Analysis and Presentation 
The number of PAG-RVM output neurons (FG+), the number of activated intrinsic PAG 
neurons (Fos+), and the number of activated PAG-RVM output neurons (Fos+FG) was 
determined across six rostrocaudal levels of PAG (Bregma -6.72, -7.04, -7.74, -8.00, -
8.30, -8.80). The experimenter was blind to the experimental condition. Neurons were 
counted in two PAG subdivisions: dorsomedial and lateral/ventrolateral; these 
subdivisions are clearly distinguishable based on the distribution of retrograde labeling 
from the RVM (van Bockstaele et al., 1991; Bandler & Shipley, 1994b). The 
lateral/ventrolateral region was counted unilaterally as there are no differences in the 
number of FG+ cells for the left versus right side of PAG (Loyd & Murphy, 2006). There 
are no cytoarchitectural or anatomical boundaries between the lateral and ventrolateral 
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regions; therefore, these regions were counted together to avoid experimenter bias. The 
tissue was sectioned at 25µm so that 125µm separated each analyzed level of the PAG 
thus avoiding any bias of counting the same cell twice.  Additionally, previous data have 
shown that there are no sex differences in the mean area (mm2) of PAG between 
weight-matched male and female Sprague-Dawley rats (Loyd & Murphy, 2006).  
 
Data are expressed as the mean + standard error of the mean (SEM) from which 
percentages were calculated. A four-way analysis of variance (ANOVA) was used to 
test for significant main effects of sex (male, female), PAG subdivision (dorsomedial, 
lateral/ventrolateral), PAG level (Bregma –6.72 through -8.80) and treatment (morphine, 
saline). P<0.05 was considered significant for all analyses. For data presentation, a 
representative animal from each experimental group was selected and the distribution 
of FG and Fos within the PAG were plotted using a Nikon Drawing Tube attached to a 
Nikon Optiphot microscope. Plots were then scanned onto the computer and adjusted to 
figure format using Adobe Illustrator 10.  Photomicrographs were generated using a 
Synsys digital camera attached to a Nikon Eclipse E800 microscope.  Images were 
captured with IP Spectrum software, adjusted to figure format by adjusting brightness 
and contrast levels using Adobe Photoshop 7.0.  
 
3.4 RESULTS  
 
Systemic Morphine-Induced Activation of the PAG 
The objective of the present experiment was to examine if morphine activation of the 
PAG is quantitatively and/or qualitatively different in male and female rats.  Animals 
were given a systemic injection of either morphine (4.5 mg/kg, s.c.; n=6/sex) or sterile 
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saline (n=5 males and n=6 females) and perfused one hour later.  The distribution and 
number of neurons expressing Fos were determined across six rostrocaudal levels of 
the PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -8.80) and within the dorsomedial 
and lateral/ventrolateral regions.   
 
In animals treated with systemic morphine, Fos+ cells were primarily distributed 
throughout the dorsomedial, lateral and ventrolateral regions of the PAG with very little 
Fos in the dorsolateral or ventromedial regions (see Figure 3.1).  The quantity and 
distribution of Fos labeled neurons was relatively consistent across the rostrocaudal 
axis of the PAG (Bregma –6.72 to –8.80 mm) and was almost two-fold greater in 
morphine treated animals in comparison to saline control [F(1,252) = 106.7, p < 0.0001].  
In animals treated with morphine, the mean number of Fos+ cells in the rostral PAG was 
77.5 + 13.4 in comparison to 25 + 8 in saline treated animals.  Caudally (Bregma -8.30), 
the mean number of Fos+ cells in morphine treated animals was 78 + 3 versus 33 + 7 
for saline control. Morphine administration induced comparable Fos expression in the 
PAG in both male and female rats [F (1,252) = 1.60, p > 0.05]. For example, at rostral 
levels of PAG (Bregma -7.04), the mean number of Fos+ cells was 73 + 16 for males, in 
comparison to 77 + 13 for females.  More caudally (Bregma -8.30), the mean number of 
Fos+ cells was 78.3 + 14 in males in comparison to 81 + 12 in females.  
 
Sexually Dimorphic Activation of the PAG-RVM Circuit by Morphine 
The results from the first set of experiments demonstrate that acute morphine 
administration induces greater activation of the PAG compared to acute saline 
administration, and that this activation is comparable in male and female rats.  The 
objectives of the next experiment were to determine (1) whether morphine preferentially 
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activates PAG-RVM output neurons, and (2) if this activation is sexually dimorphic. 
Animals received Fluorogold injections into the RVM; ten days later they were injected 
with either systemic morphine (4.5 mg/kg; n=5 per sex) or sterile saline (n=5 males and 
n=6 females) and perfused one hour later.  
 
Figure 3.2 shows an example of a typical iontophoretic injection of FG into the RVM of a 
male (top) and female (bottom).  All injections were located on the midline and dorsal to 
the pyramidal tract, at the level of the caudal pole of the facial nucleus (lambda –
2.0mm).  Injections outside of the RVM were not included for analysis. Injection of FG 
into the RVM produced dense retrograde labeling across the rostrocaudal axis of the 
PAG in both male and female rats.  As reported previously (Loyd & Murphy, 2006), 
there were significantly more retrogradely labeled neurons across all rostrocaudal levels 
of the PAG in female as compared to male rats [F (1,216) = 48.2, p < 0.0001].  Acute 
systemic administration of morphine induced Fos labeling in a subset of PAG output 
neurons in both male and female rats. The number of activated PAG output neurons 
was consistently higher in the PAG of male compared to female rats (Figure 3). For 
example, at rostral levels of PAG (Bregma -6.72), the mean number of double-labeled 
cells in the lateral/ventrolateral subdivision of the PAG was 18 + 4 for males, in 
comparison to 6 + 1 for females.  More caudally (Bregma -8.30), the mean number of 
double-labeled cells in the lateral/ventrolateral subdivision of the PAG was 42 + 11 in 
males, in comparison to 20 + 3 in females.  This activation of output neurons was 
significantly greater in male compared to female rats whether analyzed as number of 
double labeled neurons [F(1,192) = 43.3, p < 0.0001] (Figure 3.3), percent of FG 
labeled neurons expressing Fos [F(1,192) = 223.2, p < 0.0001] or percent Fos that was 
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expressed in FG neurons [F(1,192) = 65.379, p < 0.0001] (Figure 3.4).  The greater 
mean number of Fos-positive PAG-RVM neurons in male rats is particularly noteworthy 
given that the total number of projecting neurons is greater in female rats. The greater 
number of double labeled neurons in male rats is evident in both dorsomedial and 
lateral/ventrolateral regions across all rostrocaudal levels of the PAG (Figure 3.3).  
 
The number of double-labeled cells also varied across PAG levels with caudal regions 
showing greater label in the lateral/ventrolateral compared to dorsomedial subdivision 
and rostral regions showing comparable labeling in the two subdivisions. An ANOVA on 
the number of Fos+ neurons revealed a significant main effect of levels-by-subdivision 
interaction [F(5,252) = 2.97, p < 0.05]; no other interactions reached significance (p > 
0.05). 
 
3.5 DISCUSSION 
 
It is becoming increasingly evident that morphine produces a greater degree of 
analgesia in males in comparison to females. To date, the mechanisms underlying sex 
differences in morphine analgesia remain unknown. The PAG and its descending 
projections to the RVM provide the primary circuit for opioid-produced analgesia, and 
sex differences in the activation of this circuit by morphine would be predicted to 
contribute to the reported sex differences in morphine analgesia. The results of our 
studies demonstrate that systemic morphine administration induces extensive Fos 
expression within the PAG of male and female rats. Interestingly, while no sex 
differences were noted in the overall number or distribution of morphine-induced Fos, 
morphine preferentially activated the PAG-RVM circuit in males. Indeed, at most rostral-
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caudal levels of PAG, the percentage of PAG-RVM neurons expressing morphine 
induced Fos was two-fold higher in males in comparison to females.  
 
In the present study, the observed morphine-induced Fos may be due to direct actions 
of morphine at the mu opioid receptor (MOR) or alternatively, due to secondary effects 
associated with morphine administration, including changes in blood pressure, 
respiration and cardiac output. These autonomic changes have been shown previously 
to induce Fos expression within the PAG of the rat (Murphy et al., 1995a). However, as 
pharmacological or neurotoxic blockade of MOR in the PAG significantly attenuates the 
analgesic effects of systemic morphine, this suggests that the Fos observed in the 
present study was primarily due to direct actions of morphine in the PAG.  In support of 
this, Fos expression was primarily localized within the dorsomedial and 
lateral/ventrolateral PAG; these regions contain high levels of mu opioid receptor 
(Commons et al., 2000b; Wang & Wessendorf, 2002; Wang et al., submitted). 
Interestingly, mu opioid receptors are virtually absent in the dorsolateral PAG; similarly, 
this region contained very little, if any, morphine-induced Fos.  
 
The PAG-RVM Circuit is Preferentially Activated in Male Rats 
Fluorogold injection into the RVM produced dense retrograde labeling within the 
dorsomedial, lateral and ventrolateral divisions of the PAG, consistent with previous 
anatomical studies in the rat (Beitz et al., 1983; van Bockstaele et al., 1991; Rizvi et al., 
1996). Interestingly, while the number of PAG neurons retrogradely labeled from the 
RVM is almost two-fold higher in females in comparison to males, very few of these 
PAG-RVM cells were activated following morphine administration (FG/Fos; overall 
between 14-25% of FG+ cells). Similarly, although morphine induced comparable levels 
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of Fos within the PAG of males and females, the percentage of Fos present in FG+ cells 
(Fos/FG) was only between 14-25%.  By contrast, in males, the percentage of FG+ cells 
co-expressing Fos ranged between 48-77%, while the percentage of Fos+ cells labeled 
with FG was between 34-54%. The results of the present study indicating that between 
48-77% of PAG-RVM neurons in males express morphine-induced Fos, suggesting that 
administration of morphine results primarily in the net excitation of PAG-RVM neurons, 
most likely through removal of tonic GABA inhibition (Moreau & Fields, 1986; Behbehani 
et al., 1990b; Vaughan & Christie, 1997; Commons et al., 2000b). Direct inhibition of 
PAG-RVM neurons by morphine may also contribute to morphine analgesia and cannot 
be ruled out in the present study. 
 
Interestingly, while females had extensive Fos present in the PAG, very little Fos was 
present in PAG output neurons. As activation of the PAG-RVM pathway is essential for 
morphine-induced analgesia, these results provide a likely mechanism for sex 
differences in morphine analgesia. It is not clear why females had such extensive Fos 
expression overall in the PAG, but very little in RVM projection neurons. Unfortunately, 
to date, no in vitro recordings have been conducted from female PAG slices so the 
effects of morphine on the physiological properties of PAG neurons can only be inferred 
from male data. Clearly, this needs to be addressed in the future. One possibility is that 
in females, morphine activates a pain facilitation network. A PAG-RVM pain facilitatory 
system has been shown to contribute to hyperalgesia produced by opiate withdrawal 
(Bederson et al., 1990), chronic inflammation (Terayama et al., 2000; Guan et al., 
2002), and morphine tolerance (Vanderah et al., 2001b). Interestingly, morphine-
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induced hyperalgesia is significantly more pronounced in females in comparison to 
males (Holtman & Wala, 2005).   
 
Alternatively, there may be a sex difference in the organization or function of the 
GABAergic system inhibiting the PAG cells involved in modulating nociceptive 
transmission.  Intra-PAG administered GABA antagonists block pain behaviors (Budai 
and Fields, 1998; Moreau and Fields, 1986) and lead to depolarization, increased firing 
frequency, and increased excitatory post-synaptic potentials in PAG neurons responsive 
to GABA (Behbehani et al., 1990b).  Intra-PAG GABA agonists (Moreau and Fields, 
1986) and mu opioid receptor antagonists (Budai and Fields, 1998) reverse the 
analgesic effects of the GABA antagonists and of morphine.  While the ventrolateral 
PAG contains a high density of mu opioid receptors, very few of the neurons that project 
to the RVM are directly inhibited by opioid agonists (Osborne et al., 1996). In the 
present study, males had greater activation of the PAG-RVM pathway by systemic 
morphine, indicating that morphine is acting through local GABA neurons, whereas 
females potentially have a different organization or function of this GABAergic system. 
The present study used gonadally intact, cycling females and a number of studies have 
suggested that gonadal steroids may influence morphine potency. For example, 
treatment of female rat pups with androgen on the day of birth results in a leftward shift 
of the morphine dose response curve (Krzanowska & Bodnar, 1999; Cicero et al., 2002; 
Cataldo et al., 2005). In adulthood, ovariectomy increases morphine potency in female 
rats and this effect is blocked by exogenous estradiol replacement (Negus & Mello, 
1999; Stoffel et al., 2005; Ji et al., in press). Similarly, in males, castration decreases 
and testosterone replacement restores morphine potency (Stoffel et al., 2005). The rat 
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PAG contains a dense population of estrogen (ERα) and androgen (AR) receptor 
containing neurons (Murphy & Hoffman, 1999; Murphy & Hoffman, 2001; Marson & 
Murphy, 2006). These receptors are localized in similar regions of the PAG as the mu 
opioid receptor and in our preliminary studies, we noted that a large proportion of PAG-
RVM neurons also contain ERα (Loyd & Murphy, 2004). 
 
In hypothalamic slices, estrogen has been shown to rapidly uncouple the mu opioid 
receptor from G protein-gated inwardly rectifying potassium channels resulting in a 
reduced hyperpolarization by MOR agonists (Kelly et al., 2003).  Estrogen-mediated 
hyperpolarization of PAG-RVM neurons would provide a direct mechanism whereby 
morphine failed to elicit Fos in PAG-RVM neurons. Alternatively, as the gene encoding 
Fos contains an estrogen response element (Loose-Mitchell et al., 1988; Wang et al., 
2003), changes in cycle status may have potentially influenced the ability of morphine to 
induce Fos in PAG-RVM neurons in females. Lastly, estradiol has also been shown to 
induce MOR internalization (Eckersell et al., 1998b; Sinchak & Micevych, 2001; 
Micevych et al., 2003; Mills et al., 2004); this would limit the amount of receptor 
available for ligand binding and would thereby potentially decrease morphine’s ability to 
induce Fos in PAG-RVM neurons. Future studies are necessary to further test these 
potential mechanisms.  
 
3.6 CHAPTER SUMMARY 
 
The results of the present study indicate that morphine preferentially activates the PAG-
RVM pathway in males.  These results concur with our previous study demonstrating 
that persistent inflammatory pain selectively activates the PAG-RVM pathway in males, 
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but not females. In that study, we also demonstrated that morphine preferentially 
suppressed persistent pain induced Fos in males, but not females. Unfortunately, the 
effects of morphine on persistent pain induced Fos in PAG-RVM output neurons was 
quite variable, and it was unknown whether the effects we were observing were due to 
morphine acting directly on PAG-RVM neurons and/or if morphine was decreasing pain-
induced drive to the PAG.  In the present study, morphine was given in the absence of 
pain and was shown to preferentially activate the PAG-RVM circuit in males. Indeed, at 
most rostral-caudal levels of the PAG, the percentage of PAG-RVM neurons expressing 
morphine-induced Fos was two-fold higher in males in comparison to females. As the 
PAG-RVM circuit is essential for morphine analgesia, sex differences in the activation of 
this pathway may provide the biological bases for the sexually dimorphic actions of 
morphine.  
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Figure 3.1. Distribution of morphine-induced Fos in male and female rats at six 
rostrocaudal levels of the PAG.  Each black circle represents one Fos-immunoreactive 
cell.  Bar graphs compare the mean number (+ S.E.M.) of Fos-immunoreactive cells in 
male and female rats 1 hr after administration of morphine or saline. Morphine 
administration induced a significant increase in the number of Fos labeled neurons 
compared to saline. This increase was comparable in male and female rats. 
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Figure 3.1 Continued 
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Figure 3.2. Representative examples of FG injection localization in the RVM of a male 
(top) and female (bottom) rat. All injections were along the midline and in the bottom 
third of the medulla. Gi, gigantocellularis; 7, facial nucleus; py, pyramidal tract; 4V, 
fourth ventricle. 
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Figure 3.3. Distribution of PAG-RVM output neurons that expressed morphine-induced 
Fos in male and female rats across six rostrocaudal levels of the PAG.  Each black 
circle represents one double-labeled (Fos+FG) cell.  Bar graphs display the mean 
number of Fos+FG cells (+ S.E.M.) for each level of the dorsomedial and 
lateral/ventrolateral regions of the PAG. Overall, Fos labeling was greater in FG+ cells 
in male versus female rats in PAG. 
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Figure 3.3 continued 
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Figure 3.4. Photomicrograph showing morphine-induced Fos in FG+ cells for males (A, 
10X; B, 20X) and females (C, 10X; D, 20X). Note that while females have a greater 
number of FG+ cells than males, very few of these cells expressed morphine-induced 
Fos (indicated with red arrows).  No sex differences were noted in the total number of 
Fos+ cells.  
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Figure 3.5. Percentage of morphine-induced Fos+ PAG neurons that were retrogradely 
labeled from the RVM (Fos+FG) in male (left) and female (right) rats in the dorsomedial 
and lateral/ventrolateral regions of the PAG at six representative levels. The proportion 
of Fos positive neurons projecting to the RVM was greater in male than female rats 
across all PAG regions. 
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4.1  ABSTRACT 
 
The midbrain periaqueductal gray (PAG) and its descending projections to the rostral 
ventromedial medulla (RVM) provide an essential neural circuit for the antinociceptive 
effects of opiates and has been implicated in the development of tolerance to morphine. 
Systemic morphine activates a greater proportion of PAG-RVM neurons in male versus 
female rats and induces tolerance to a greater degree in males. The present studies 
tested the hypothesis that if the PAG-RVM pathway is essential for the development of 
tolerance, then (1) morphine activation of the PAG-RVM pathway should decline as 
tolerance develops, and (2) sex differences in the development of tolerance to morphine 
should be reflected as a greater decline in the activation of this pathway in males. 
These hypotheses were tested in male and female rats using behavioral testing (hot 
plate) and immunohistochemistry to map the activation of the PAG-RVM pathway 
following repeated morphine administration (5 mg/kg; s.c.). In males, morphine potency 
decreased from 3.0 to 6.3 mg/kg indicating tolerance, and this was paralleled by a 
steady decline in the percentage of PAG-RVM output neurons activated by morphine. In 
contrast, in females the shift in morphine potency was significantly attenuated (D50 6 to 
8.3 mg/kg) and no significant difference in the activity of PAG-RVM output neurons was 
noted. These results demonstrate that the greater development of tolerance to 
morphine administration in male rats corresponds with a significant reduction in the 
activation of the PAG-RVM circuit and suggest a central role for the PAG in the 
development of tolerance to morphine. 
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4.2  INTRODUCTION 
 
It is estimated that as many as one in five adults currently experience chronic pain.  Of 
that population, 41% are receiving treatment with opioid-based narcotics (Breivik et al., 
2006).  While morphine and other opioid-based narcotics are the most effective 
treatment for pain, opiates do not provide adequate pain relief for many people. The sex 
of the patient and the development of tolerance to morphine’s analgesic effects are two 
particularly important factors that limit the effectiveness of opiates.  Men tend to 
experience greater analgesia following opiate administration compared to women 
(Cepeda & Carr, 2003; Miller & Ernst, 2004), a difference that has been reported for a 
wide range of species using both somatic and visceral pain models (Craft, 2003a; Ji et 
al., 2006; Loyd & Murphy, 2006; Wang et al., 2006; Loyd et al., 2007).   
 
Recent findings suggest that the midbrain periaqueductal gray (PAG) and its 
descending projections to the rostral ventromedial medulla (RVM) contribute to the 
sexually dimorphic actions of morphine. Microinjection of morphine directly into the PAG 
produces greater antinociception in male compared to female rats (Krzanowska & 
Bodnar, 1999; Wang et al., submitted) and blocking PAG opioid receptors reduces 
morphine antinociception to a greater extent in female rats (Bernal et al., 2007). 
Furthermore, both the anatomy and physiology of the PAG-RVM pathway is sexually 
dimorphic, with males having a significantly greater percentage of PAG-RVM neurons 
activated by either inflammatory pain (Loyd & Murphy, 2006) or systemic morphine 
(Loyd et al., 2007). 
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Tolerance is known to occur with repeated or continuous administration of morphine into 
the ventrolateral PAG of male rats (Jacquet & Lajtha, 1976; Siuciak & Advokat, 1987; 
Tortorici et al., 1999; Tortorici & Morgan, 2002, Tortorici, 1999 #2314; Lane et al., 2005; 
Morgan et al., 2006). In addition, blocking opioid binding in the ventrolateral PAG 
attenuates tolerance to systemically administered morphine (Lane et al., 2005). 
Tolerance appears to be mediated by a reduction in mu opioid receptor signaling 
efficacy in PAG neurons (Bagley et al., 2005), an effect that is reversed when mu opioid 
receptor coupling is enhanced via upregulated cyclase activity (Hack et al., 2003). 
These findings suggest that the PAG contributes to the decrease in antinociception that 
occurs with the development of tolerance. 
 
Given that morphine activates a greater percentage of PAG-RVM output neurons in 
male compared to female rats (Loyd et al., 2007), our working hypothesis is that if the 
PAG-RVM pathway is essential for the development of tolerance to morphine, then (1) 
activation of the PAG-RVM pathway should decline as tolerance to repeated injections 
of systemic morphine develops, and (2) given that males show greater antinociception 
and greater tolerance (Craft et al., 1999; Barrett et al., 2001), these sex differences 
should be reflected as a greater decline in the activation of the PAG-RVM pathway in 
male compared to female rats. These hypotheses were tested using behavioral 
assessment of nociception in combination with immunohistochemistry to map the 
activation of the PAG-RVM pathway over the time course of the development of 
tolerance to repeated administration of morphine.  
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4.2 METHODS 
 
Experimental Subjects 
Thirty-five adult male and thirty-seven weight-matched (250-350g) cycling female 
Sprague-Dawley rats were used in these experiments (behavior subjects from Harlan, 
Indianapolis, IN and anatomy subjects from Zivic-Miller; Pittsburg, PA). Rats were 
housed in same-sex pairs on a 12:12 hour light:dark cycle.  Access to food and water 
was ad libitum throughout the experiment except during surgery and testing. These 
studies were performed in compliance with the Institutional Animal Care and Use 
Committees at Georgia State University and at Washington State University. All efforts 
were made to minimize any possible suffering by the animal, and to reduce the number 
of animals used. 
 
Vaginal Cytology  
Vaginal lavages were performed daily to confirm that the female rats were cycling 
normally and to keep daily records on the stages of their cycle in respect to 
experimental testing.  Stage of estrous was determined for two weeks prior to testing 
and during the three days of morphine or saline injections.  Proestrus was identified as 
a predominance of nucleated epithelial cells and estrus was identified as a 
predominance of cornified epithelial cells.  Diestrus 1 was differentiated from Diestrus 2 
by the presence of leukocytes.  Rats that appeared between phases were noted as 
being in the more advanced stage. 
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Behavioral Assessment of Tolerance to Repeated Morphine Administration 
Thirteen male and fourteen female rats were handled daily for five days prior to initiation 
of drug administration. Morphine sulfate (5 mg/kg; s.c., provided by the National Institute 
on Drug Abuse, Bethesda, MD) was prepared in a 0.9% saline vehicle and administered 
systemically twice a day for three consecutive days to male (n=7) and female (n=7) rats. 
The 5 mg/kg dose was chosen based on our previous studies demonstrating this to be 
the 50% effective dose (ED50) for systemic morphine in male rats (Morgan et al., 
2006b; Wang et al., 2006; Loyd et al., 2007). Control groups consisting of six male and 
seven female rats received daily injections of saline (1 ml/kg, s.c.). Tolerance was 
assessed on Day 4 by injecting cumulative doses of morphine every 20 minutes 
resulting in quarter log doses of 1.8, 3.2, 5.6, 10.0, and 18.0 mg/kg.  Nociception was 
assessed using the hot-plate test 15 minutes after each injection by an experimenter 
blind to the pretreatment condition.  The hot plate test measures the latency to lick the 
hindpaw when the rat is placed on a 52.5oC plate.  If the animal did not respond within 
50 seconds, it was removed from the plate and given a score of 50 seconds.  The mean 
latency at each dose was calculated for male and female rats pretreated with morphine 
or saline.  
 
Behavioral Data Analysis and Presentation 
The half-maximal antinociceptive effect (D50; Tallarida, 2000) and 95% confidence 
intervals (CI) were calculated from dose-response curves generated using GraphPad 
software. The lower limit for calculating D50 values was the mean baseline score, and 
the upper limit was the mean hot plate latency following administration of the highest 
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morphine dose. Changes in D50 between groups were assessed using ANOVA 
(GraphPad). 
 
Anatomical Assessment of Tolerance to Repeated Morphine Administration  
Retrograde Tracer Injections 
Twenty-two male and twenty-four female rats were deeply anesthetized with 
ketamine/xylazine (50 mg/kg / 10mg/kg; s.c.).  When a surgical plane of anesthesia was 
reached, the animal was placed in a stereotaxic frame with bregma and lambda at the 
same dorsal-ventral plane.  A glass micropipette (10-20 µM) filled with the retrograde 
tracer Fluorogold (FG; 2% soln. w/v in saline; Fluorochrome LLC; Denver, CO) was 
lowered into the RVM using the following coordinates (in mm): AP: -2.0 Lambda; ML: 
0.0; DV: -8.5).  FG was iontophoresed (50/50 duty cycle, 7 seconds on/7 seconds off, 
7.5 µA current) into the RVM for 25 minutes to facilitate neuronal uptake.  The current 
was then turned off and the pipette remained in place for an additional 5 minutes prior to 
removal to minimize backflow of the tracer along the pipette track. Following the tracer 
injection, wounds were sutured closed, the antibiotic Neosporin was applied to the 
wound, and the animal was placed in a clean cage to recover under a heat lamp. Upon 
complete recovery from the anesthetic, the rat was returned to its original housing 
facility. 
      
Morphine Administration 
Ten days following tracer injection, animals were administered morphine or saline for 
three consecutive days.  Morphine sulfate (5 mg/kg, s.c.) was prepared fresh in a 0.9% 
saline vehicle within one hour prior to administration. Animals were divided into two 
experimental groups: (1) eight male and eight female rats received one daily injection of 
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morphine sulfate for three consecutive days and (2) five male and five female rats 
received two daily injections of morphine sulfate for three consecutive days. Injections 
were administered between the hours of 10:00A.M. and 4:00P.M. with multiple daily 
injections separated by six hours.  Two control groups were used: (3) the morphine 
naïve group consisted of five male and six female rats injected with saline twice daily for 
three consecutive days (no morphine injections) and (4) the acute morphine group 
consisted of four male and five female rats injected with saline twice daily for 2.5 
consecutive days followed by a final injection of morphine (see Table 4.1). 
 
Perfusion fixation 
All animals were given a lethal dose of Nembutal (160 mg/kg; i.p.) one hour following 
the last injection of morphine or saline. This time point was chosen based on previous 
studies showing that expression of c-fos mRNA peaks within 30-60 minutes after 
increased neuronal activity, while the Fos protein is detectable after 60 minutes (Sharp 
et al., 1991; Murphy et al., 1995; Rizvi et al., 1996; Zimmer et al., 1997). Additionally, 
our previous studies show that Fos is expressed in a strong, consistent pattern in the 
PAG one hour following systemic morphine administration (Loyd and Murphy, 2006; 
Loyd et al., 2007). The animals were transcardially perfused with 200-250 ml of 0.9% 
sodium chloride containing 2% sodium nitrite as a vasodilator to remove blood from the 
brain. Immediately following removal of blood, 300 ml of 4% paraformaldehyde in 0.1M 
phosphate buffer containing 2.5% acrolein (Polyscience; Niles, IL) was perfused 
through the brain as a fixative. A final rinse with 200-250 ml of the sodium 
chloride/sodium nitrate solution was perfused through the brain to remove any residual 
acrolein. Immediately following perfusion, the brains were carefully removed, placed in a 
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30% sucrose solution and stored at 4oC for at least one week prior to sectioning. 
Sucrose solutions were changed daily to optimize saturation of sucrose into the tissue. 
To section the brain, the dura and pia matter were carefully removed and the brains 
were cut into six series of 25 µm coronal sections with a Leica 2000R freezing 
microtome and stored free-floating in cryoprotectant-antifreeze solution (Watson et al., 
1986b) at –20oC until immunocytochemical processing. 
  
Immunocytochemistry 
A 1:6 series through the rostrocaudal axis of each brain was processed for FG and Fos 
immunoreactivity as previously described (Murphy & Hoffman, 2001). Briefly, sections 
were rinsed extensively in potassium phosphate-buffered saline (KPBS) to remove 
cryoprotectant solution immediately followed by a 20-minute incubation in 1% sodium 
borohydride to remove excess aldehydes.  The tissue was then incubated in primary 
antibody solution rabbit anti-Fos (Oncogene; Cambridge, MA, lot no. 4194; 1:50,000) in 
KPBS containing 1.0% Triton-X for one hour at room temperature followed by 48 hours 
at 4°C. After rinsing out the primary antibody with KPBS, the tissue was incubated for 
one hour in biotinylated goat anti-rabbit IgG (Jackson Immunoresearch; West Grove, 
PA, 1:200), rinsed with KPBS, followed by a one hour incubation in avidin-biotin 
peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and 
sodium acetate (0.175 M; pH 6.5), Fos was visualized as a black reaction product using 
nickel sulfate intensified 3,3’-diaminobenzidine solution containing 0.08% hydrogen 
peroxide in sodium acetate buffer. After rinsing, sections were placed in primary 
antibody solution rabbit anti-FG (Chemicon; Billerica, MA, lot no. 25060005; 1:10,000) in 
KPBS containing 1.0% Triton-X for one hour at room temperature followed by 48 hours 
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at 4°C. FG was visualized as a brown reaction product using 3,3’-diaminobenzidine 
containing 0.08% hydrogen peroxide in Trizma buffer (pH 7.2). After 15-30 minutes, 
three rinses in sodium acetate buffer terminated the reaction. Sections were then 
mounted out of saline onto gelatin-subbed slides, air-dried overnight, dehydrated in a 
series of graded alcohols, cleared in xylene, and cover-slipped using Permount. 
  
Anatomical Data Analysis and Presentation 
Data were analyzed across six representative levels through the rostrocaudal axis of the 
PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -8.80). As there was no significant effect 
of level in all analyses conducted, data are presented as rostral (Bregma -6.72, -7.04, -
7.74) versus caudal (Bregma -8.00, -8.30, -8.80) PAG. The number of PAG-RVM output 
neurons (FG+), the total number of activated PAG neurons (Fos+), and the number of 
activated PAG-RVM output neurons (Fos+FG) were quantified by an experimenter 
blinded to the experimental condition. Cell counts were conducted unilaterally as there 
are no differences in the number of FG+ cells for the left versus right side of PAG (Loyd 
& Murphy, 2006). The tissue was sectioned at 25 µm so that 125 µm separates each 
analyzed level of the PAG thus eliminating any possible bias from counting the same 
cell twice.  Additionally, previous data have shown that there are no sex differences in 
total area (mm2) of the PAG between weight-matched male and female Sprague-
Dawley rats (Loyd & Murphy, 2006).  
 
Data are expressed as the mean + standard error of the mean from which percentages 
were calculated. As females have a greater number of PAG-RVM output neurons (Loyd 
and Murphy, 2006), data are presented as the percentage of Fos that was colocalized in 
PAG-RVM output neurons (%Fos in FG+ cells). A three-way analysis of variance 
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(ANOVA) was used to test for significant main effects of sex (male, female), PAG level 
(Bregma –6.72 through -8.80) and treatment (two experimental groups of morphine 
administration and two control groups). A one-way ANOVA was used for post-hoc 
analysis to test for significant main effects of treatment and the Fishers PLSD was used 
to determine significant interactions between treatment groups when there was a 
significant main effect independent of sex. P<.05 was considered significant for all 
analyses.  
 
Photomicrographs were generated using a Synsys digital camera attached to a Nikon 
Eclipse E800 microscope.  Images were captured with IP Spectrum software, adjusted 
to figure format by adjusting brightness and contrast levels using Adobe Photoshop 7.0.  
 
4.4 RESULTS 
 
Experiment 1: Behavioral Assessment of Tolerance to Repeated Morphine 
Administration 
The objective of the present experiment was to compare the development of tolerance 
to morphine in male and female rats. Following three days of morphine or saline 
injections, administration of cumulative doses of morphine on Day 4 produced a dose-
dependent increase in hot-plate latency in all groups tested (Figure 4.1). The 
antinociceptive potency of morphine was greatest in male rats pretreated with saline on 
days 1-3 (D50 = 3.0 mg/kg). In contrast, the D50 for female rats pretreated with saline 
was 6.1 mg/kg, a 2.0 fold difference when compared to males. Consistent with the 
development of tolerance, male rats pretreated with morphine showed a significant 
rightward shift in the morphine dose-response curve compared to male rats pretreated 
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with saline ([F(1,74) = 20.04, p<.001]; Figure 4.1A).  Specifically, the D50 increased from 
3.0 mg/kg (CI = 2.2 – 3.7) to 6.3 mg/kg (CI = 5.1 – 7.6) in rats pretreated with morphine, 
a 2.1 fold shift in the D50. Female rats showed significantly less tolerance than male 
rats. In females, pretreatment with morphine on days 1-3 resulted in a small rightward 
shift [F(1,115) = 5.63; p<.05] in the dose-response curve from 6.1 mg/kg (CI = 5.2 – 7.0) 
to 8.0 mg/kg (CI = 6.6 – 9.4; Figure 4.1B), a 1.3 fold increase. 
 
Experiment 2a: Anatomical Assessment of the PAG During Tolerance to Repeated 
Morphine Administration 
The next series of experiments were conducted to determine if the activation of the 
PAG-RVM pathway decreases during the development of tolerance to repeated 
systemic morphine administration in male and female rats. Across all groups (Table 
4.1), systemic morphine administration induced extensive Fos expression throughout 
the rostrocaudal axis of the PAG. Fos was present in both FG+ and non-FG+ PAG 
neurons. No significant main effect of sex [F(1,208)= .764, n.s.] or PAG level [F(5,208)= 
.0454, n.s.] was noted in the mean number of morphine-induced Fos-positive neurons in 
the PAG. However, there was a significant main effect of treatment [F(3,208)= 8.733, 
p<.05] and a significant sex-by-treatment interaction [F(3,208)= 10.617, p<.05]. Male 
rats treated with saline had significantly less Fos expression compared to all other 
treatment groups in the caudal PAG (Figure 4.2, p<.05). In females, administration of 
one dose of morphine resulted in significantly less Fos expression in comparison to the 
other treatment groups (Figure 4.2, p<.05). Total Fos expression was comparable 
between the two repeated morphine administration groups and, in females, as 
compared to the morphine naïve group. 
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Experiment 2b: Anatomical Assessment of Tolerance to Morphine in the PAG-RVM 
Circuit 
Figure 4.3 shows an example of a typical iontophoretic injection of retrograde tracer 
Fluorogold (FG) into the RVM of a male (top) and female (bottom) rat.  All injections 
were located on the midline and dorsal to the pyramidal tract, at the level of the caudal 
pole of the facial nucleus (lambda –2.0mm).  Injections outside of the RVM were not 
included for analysis. Injection of FG into the RVM produced dense retrograde labeling 
throughout the rostrocaudal axis of the PAG, with females having a significantly greater 
amount of labeling compared to males [F(1,208)=59.610, p<.05] (data not shown; Loyd 
et al, 2006, Loyd et al., 2007).  
 
Administration of one dose of morphine following three days of saline injections resulted 
in extensive Fos expression in PAG-RVM output neurons across all rostrocaudal levels 
of the PAG (Figure 4.4).  An analysis of the %Fos in FG+ (PAG-RVM output neurons) 
cells revealed a significant main effect of sex [F(1,208)= 41.194, p<.05], treatment 
[F(3,208)= 43.607, p<.05] and a significant sex by treatment interaction [F(3,208)= 
19.440, p<.05]. There was no significant main effect of PAG level [F(5,208)= .1883, n.s.] 
indicating that these results were consistent across the rostrocaudal axis of the PAG. 
The %Fos in FG+ neurons decreased as a function of morphine treatment in males only 
[F(2,71)= 26.546, p<.05]. Overall, the average %Fos in FG+ neurons decreased from 
52±5% in males receiving one injection of morphine to 14±6% in males following the 
sixth injection of morphine. In females, the %Fos in FG+ cells was low across all 
rostrocaudal levels of the PAG and no significant effect of treatment was observed 
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[F(2,83)= 1.919, n.s.]. Together, these results parallel our behavioral data indicating 
greater tolerance to morphine in male rats. 
 
4.5  DISCUSSION 
 
In the present study, behavioral and neuroanatomical techniques were used to examine 
the role of the PAG-RVM circuit in the development of tolerance to systemic morphine in 
male and female rats. The results demonstrate that repeated administration of systemic 
morphine induces tolerance in male to a much greater extent than in female rats. In 
parallel, repeated morphine administration significantly reduces the activation of PAG-
RVM neurons by morphine in males but not females. The half maximal antinociceptive 
effect of a single injection of morphine was two times greater for female compared to 
male rats and is consistent with previous research (Cicero et al., 1997; Cook & 
Nickerson, 2005; Ji et al., 2006; Wang et al., 2006). This sex difference in morphine 
potency is reflected in the greater activation of PAG-RVM output neurons in males 
following morphine administration reported here and previously (Loyd et al., 2007). In 
addition, the greater tolerance to morphine in male compared to female rats also is 
consistent with previous research (Barrett et al., 2001; Bernal et al., 2007). Our data 
show that two injections of morphine per day for three consecutive days was sufficient 
to reduce morphine potency by 2.1 times in male rats. However, in females, the half 
maximal effective dose of morphine only increased from 6.1 to 8.0 mg/kg. Thus, not 
only do female rats show less antinociception in response to morphine, but they also 
show much less tolerance to morphine. 
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Our data indicate that the PAG and its projections to the RVM likely contribute to the 
observed behavioral differences between male and female rats. Both the number of 
Fos+ neurons in the PAG and the number of Fos+ neurons in the PAG that were 
retrogradely labeled from the RVM following a single dose of morphine was greater in 
male compared to female rats. Although there was no significant main effect of sex in 
the number of Fos+ neurons in the PAG observed following repeated morphine 
administration, there was a progressive decrease in the %Fos in FG+ cells following 
three or six repeated injections of morphine in male rats. This decrease in activation of 
PAG-RVM output neurons in male rats led to a decrease in the %Fos in FG+ cells so 
that male rats were comparable to female rats. Moreover, the slight tolerance observed 
in females is consistent with a lack of change in the %Fos in FG+ cells following one, 
three, or six repeated injections of morphine. These data correspond very closely with 
the behavioral data showing that morphine antinociception is greater in male compared 
to female rats and tolerance causes a reduction in morphine potency so that tolerant 
male rats experience comparable analgesia to less tolerant female rats. These results 
demonstrate that the development of tolerance to morphine is associated with a 
reduction in the activation of the PAG-RVM circuit in male rats and provide additional 
data demonstrating a central role for the PAG in tolerance to morphine.   
 
Tolerance develops with repeated microinjections of morphine directly into the 
ventrolateral PAG (Morgan et al., 2006a; Tortorici et al., 1999) and is associated with a 
reduction in mu opioid receptor signaling in the PAG (Bagley et al., 2005). Importantly, 
blocking opioid binding in the PAG attenuates the development of tolerance to systemic 
morphine administration (Lane et al., 2005). While the PAG does not project directly to 
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the spinal cord, it projects heavily to the RVM which in turn projects to the spinal cord 
(Beitz, 1982b; Beitz et al., 1983). RVM on-cells and off-cells that are normally inhibited 
and activated by morphine, respectively, show normal responses to nociceptive reflexes 
during the induction of tolerance following repeated intra-PAG administration of 
morphine (Lane et al., 2004).  Given that tolerance develops to a greater degree when 
morphine is administered directly into the PAG compared to administration into the RVM 
(Morgan et al., 2005) and that there is a corresponding progressive decrease in the 
activation of PAG-RVM neurons, these data together indicate that a key mechanism for 
tolerance resides within the PAG.  
 
Previous data have shown that one systemic injection of morphine induces extensive 
Fos expression in the PAG that is comparable in male and female rats (Loyd et al., 
2007). Similarly, in the present study, total Fos expression in the PAG following 
morphine administration over three days was not sexually dimorphic.  However, unlike 
our previous study, acute morphine administration following three days of saline 
injections in males did not induce significantly greater Fos labeling compared to saline-
treated rats and female rats showed a significant decline in Fos labeling. This difference 
in Fos induction by morphine in these two studies suggests that the multiple injections 
of saline over three days in the present study induce Fos expression that is independent 
of morphine. The significant decline in Fos labeling in the PAG following one dose of 
morphine in female rats indicates that there is a sexually dimorphic effect of multiple 
injections of saline on the type of stimuli inducing activation in the PAG; further studies 
are warranted to examine this result. 
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Given that Fos expression in the PAG can be induced by a wide range of stimuli 
including fear and anxiety (Kim et al., 1993), changes in respiration (Zhang et al., 
1990b; Harper et al., 1996), vocalization (Davis et al., 1993; Zhang et al., 1994), blood 
pressure (Carrive, 1991, Murphy, 1995 #1312; Murphy et al., 1995a), and in fight or 
flight responses (Bandler et al., 1985; Bandler & Carrive, 1988b; Depaulis et al., 1992), 
it is not surprising that repeated daily injections of saline induced Fos in PAG neurons. 
In contrast, PAG neurons retrogradely labeled with FG from the RVM were more likely 
to express Fos following morphine administration than in saline treated rats. Moreover, 
this increase in Fos expression was greater in male compared to female rats. The 
greater Fos expression in FG+ cells correlates with the greater morphine 
antinociception produced in male compared to female rats. The limited Fos expression 
in the PAG-RVM output neurons of female rats is consistent with the low antinociceptive 
potency of morphine in these animals. Likewise, the lack of change in Fos expression 
with repeated morphine administration is consistent with the limited antinociceptive 
tolerance to repeated intra-PAG microinjections of morphine in female rats.  
 
It was recently reported that males have a higher density of mu opioid receptor (MOR) 
immunoreactivity in the PAG (Duncan & Murphy, 2005), which may provide a 
mechanism for sex differences in the development of tolerance to morphine. 
Furthermore, cells that express both MOR and GABA are common in the PAG (Williams 
& Beitz, 1990; Kalyuzhny & Wessendorf, 1998) suggesting that morphine directly 
modulates the GABAergic neurons that tonically inhibit PAG-RVM neurons (Behbehani 
& Fields, 1979; Chieng & Christie, 1994b; Vaughan & Christie, 1997; Commons et al., 
2000b; Tortorici & Morgan, 2002). Administration of GABA agonists hyperpolarizes 
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PAG-RVM neurons (Osborne et al., 1996b) and microinjection of GABA antagonists into 
the PAG results in a net increase in membrane depolarization, firing frequency, 
frequency of EPSPs (Behbehani et al., 1990b) and antinociception (Morgan et al., 
2005). A potential mechanism of action is that morphine is hyperpolarizing GABA 
interneurons in the PAG. As tolerance develops, these GABAergic cells are no longer 
inhibited by morphine resulting in a progressive increase in tonic inhibition on PAG-RVM 
neurons and thus a corresponding decrease in the antinociceptive effects of morphine. 
The decrease in Fos expression in PAG neurons projecting to the RVM is consistent 
with this model and indicates that tolerance is caused by a change in morphine-
sensitive GABAergic neurons. 
 
The PAG also contains a high density of estrogen (ERα) receptors (Murphy & Hoffman, 
1999; Murphy & Hoffman, 2001; Marson & Murphy, 2006) and approximately 25% of 
PAG-RVM neurons contain ERα (Loyd and Murphy, unpublished observations). 
Estrogen has been shown to uncouple MOR from G protein-gated inwardly rectifying 
potassium channels, thus reducing morphine hyperpolarization of PAG-RVM neurons 
(Kelly et al., 2003).  In the present study, circulating estrogen acting at ERα receptors 
may be uncoupling MOR in the PAG of female rats, resulting in an overall reduction in 
the activity of these cells and the analgesic effects. Interestingly, it has been shown that 
the excitability of neurons in the PAG is variable across the estrous cycle of the rat, 
such that during estrus and late diestrus, GABA receptor antagonists greatly increase 
PAG output neuronal firing rates, suggesting a decrease in GABAergic tone (Brack & 
Lovick, 2007).  
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Cycling females were used in these studies; all rats continued to cycle normally during 
the three consecutive days of morphine or saline administration. The activation of PAG 
neurons in females tended to be more variable compared to males and stage of estrous 
may potentially affect morphine potency and tolerance. Unfortunately, in the present 
study we were unable to statistically analyze the effect of cycle on morphine potency 
due to limitations in the number of animals per stage of estrous. Upon looking for trends 
in the data, there appears to be an effect of cycle on the activation of the PAG following 
repeated administration of morphine. Female rats in diestrus 2 had on average two 
times more Fos expression in the PAG following six repeated doses of morphine (n=3) 
compared to rats in estrus (n=2; data not shown). In addition, rats in diestrus 2 (n=3) 
that received three repeated doses of morphine had on average two times more 
activated FG+ (%Fos in FG+) cells as compared to rats in estrus (n=2) and in diestrus 1 
(n=3; data not shown). No other trends were observed, however, further studies are 
clearly warranted to examine the potential effect of estrous cycle on tolerance. 
 
4.6 CHAPTER SUMMARY 
 
In summary, the results of the present study indicate that tolerance to repeated 
systemic injections of morphine occurs to a greater extent in male compared to female 
rats.  As tolerance develops, there is a corresponding steady decline in the activation of 
the PAG-RVM pathway in male rats. Activation of this pathway by morphine in female 
rats is not significant, and it does not significantly decline following repeated 
administration of morphine. Together, these data provide additional data demonstrating 
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a central role for the PAG in the development of tolerance to repeated administration of 
morphine. 
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Table 4.1: Dosing schedule for experimental and control groups 
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Figure 4.1. Comparison of tolerance to the antinociceptive effects of morphine in male 
(A) and female (B) rats. Rats were pretreated with morphine (5mg/kg) or saline twice a 
day for 3 days. Morphine dose-response curves for antinociception on the hot plate 
(HP) test were generated on Day 4 using a cumulative dosing paradigm. Both 
antinociceptive potency and tolerance to morphine were greater in male compared to 
female rats. 
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Figure 4.2. Mean number of Fos-positive cells in male and female rats injected with 
either morphine (5mg/kg) or saline once or twice daily for three days for the rostral (A; 
Bregma    -6.72, -7.04, -7.74) and caudal (B; Bregma -8.00, -8.30, -8.80) PAG. The # 
indicates a significant main effect of treatment (morphine and saline) and the * indicates 
a significant main effect of sex. Saline: morphine naïve; 1 Dose: saline pretreatment 
followed by one dose of morphine; 3 Doses: one dose of morphine per day; 6 Doses: 
two doses of morphine per day.  
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Figure 4.3. Color photomicrograph of representative examples of FG injection sites at 
the RVM of a male (top) and female (bottom) rat. Injection sites were limited to 
localization within the bottom third of the medulla along the midline between the facial 
nuclei and dorsal to the pyramidal tract. Gi: gigantocellularis; py: pyramidal tract; 4V: 
fourth ventricle; 7: facial nucleus. 
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Figure 4.4. Percentage of Fos-positive neurons that were retrogradely labeled from the 
RVM (%Fos in FG+ cells) in male (solid bars) and female (open bars) rats injected with 
either morphine or saline once or twice daily for three days for the rostral (A; Bregma -
6.72, -7.04, -7.74) and caudal (B; Bregma -8.00, -8.30, -8.80) PAG. A decrease in 
labeling is evident with an increase in the number of morphine injections for male rats. 
The # indicates a significant effect of treatment and the * indicates a significant effect of 
sex. Saline: morphine naïve; 1 Dose: saline pretreatment followed by one dose of 
morphine; 3 Doses: one dose of morphine per day; 6 Doses: two doses of morphine per 
day.  
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5.1 ABSTRACT 
 
The periaqueductal gray (PAG) is involved in many gonadal steroid-sensitive behaviors, 
including responsiveness to pain. The PAG projects to the rostral ventromedial medulla 
(RVM), comprising the primary circuit driving pain inhibition. Morphine administered 
systemically or directly into the PAG produces greater analgesia in male compared to 
female rats, while manipulation of gonadal hormones alters morphine potency in both 
sexes. It is unknown if these alterations are due to steroidal actions on PAG neurons 
projecting to the RVM. The expression of androgen (AR) and estrogen (ERα) receptors 
in the PAG of female rats and within this descending inhibitory pathway in both sexes is 
unknown. The present study used immunohistochemical techniques (1) to map the 
distribution of AR and ERα across the rostrocaudal axis of the PAG; and (2) to 
determine whether AR and/or ERα were colocalized on PAG neurons projecting to the 
RVM in male and female rats. AR and ERα immunoreactive neurons (AR-IR, ERα-IR) 
were densely distributed within the caudal PAG of male rats, with the majority localized 
in the lateral/ventrolateral PAG. Females had significantly fewer AR-IR neurons, while 
the quantity of ERα was comparable between the sexes. In both sexes, approximately 
25-50% of AR-IR neurons and 20-50% of ERα-IR neurons were retrogradely labeled. 
This study provides direct evidence of the expression of steroid receptors in the PAG 
and the descending pathway driving pain inhibition in both male and female rats and 
may provide a mechanism whereby gonadal steroids modulate pain and morphine 
potency. 
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5.2 INTRODUCTION 
 
Anatomical and physiological studies have shown that the midbrain periaqueductal gray 
(PAG) plays a modulatory role in a variety of behaviors including antinociception 
(Reynolds, 1969; Behbehani & Fields, 1979; Heinricher et al., 1987; Behbehani, 1995; 
Budai et al., 1998), reproduction (McCarthy et al., 1991b; Ogawa et al., 1991; Murphy & 
Hoffman, 1998; Daniels et al., 1999), fear and anxiety (Kim et al., 1993), aggression 
(Bandler et al., 1985; Bandler & Carrive, 1988b; Depaulis et al., 1992; Scordalakes & 
Rissman, 2004) and vocalization (Davis et al., 1993; Zhang et al., 1994). While these 
behaviors have been shown to be modulated by gonadal steroids, our knowledge of the 
qualitative and quantitative aspects of gonadal steroid receptors in the PAG is 
incomplete. The PAG has been shown to contain a large number of both androgen 
receptor (AR) and estrogen receptor (ERα) immunoreactive neurons (Murphy & 
Hoffman, 1999; Murphy & Hoffman, 2001), however these studies were conducted 
exclusively in male rats. While the distribution of ERα in the female PAG has been 
reported in a few species, including the cat (VanderHorst et al., 1998), the golden 
hamster (Boers et al., 1999), the guinea pig (Turcotte & Blaustein, 1993) and the rhesus 
monkey (Vanderhorst et al., 2002; VanderHorst et al., 2004), the quantity and 
distribution of AR and ERα in the female rat is currently unknown.  
 
The PAG projects heavily to the rostral ventromedial medulla (RVM), which in turn 
projects to the dorsal horn of the spinal cord. This PAG-RVM-spinal cord circuit is the 
primary neural pathway that elicits the antinociceptive effects of opiates. Previous 
studies have reported sex differences in the anatomical organization of the projections 
from the PAG to the RVM and activation of these neurons by inflammatory pain (Loyd & 
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Murphy, 2006). In addition, there are significant sex differences in the activation of this 
pathway by systemic morphine, both in the presence and absence of inflammatory pain 
(Loyd & Murphy, 2006; Loyd et al., 2007; Loyd et al., 2008). To date, it is not known 
whether ERα and AR are expressed on PAG neurons projecting to the RVM. Numerous 
behavioral studies have shown that sex differences in opioid analgesia are modulated 
by both the organizational and activational effects of gonadal steroids (Kepler et al., 
1989; Islam et al., 1993; Krzanowska & Bodnar, 1999; 2000; Stoffel et al., 2003; 
Cataldo et al., 2005; Stoffel et al., 2005). Male rats castrated at birth experience 
decreased morphine potency in adulthood, while female rats masculinized at birth 
experience greater morphine potency in adulthood whether morphine is administered 
systemically (Cicero et al., 2002) or directly into the PAG (Krzanowska et al., 2002). 
Similarly, both systemic and central administration of morphine is less effective in 
gonadectomized adult males and more effective in ovariectomized adult females 
(Kepler et al., 1989; Ratka & Simpkins, 1991; Krzanowska & Bodnar, 1999; Terner et 
al., 2002; Stoffel et al., 2003; Stoffel et al., 2005; Terner et al., 2005); effects are 
reversed with hormone replacement (Ratka & Simpkins, 1991; Kiefel & Bodnar, 1992); 
Stoffel et al., 2003; (Ji et al., 2007).  
 
While the organizational and activational effects of gonadal steroids are likely to 
contribute to the sexually dimorphic actions of morphine, it is currently unknown whether 
gonadal steroid receptors are expressed on PAG neurons projecting to the RVM. In 
addition, the qualitative and quantitative aspects of AR and ERα expression in the PAG 
of the female rat are not known. The present studies utilized immunohistochemistry to 
map (1) the quantity and distribution of AR and ERα immunoreactive neurons across 
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the rostrocaudal axis of the PAG; and (2) to determine if the PAG neurons projecting to 
the RVM express AR and ERα immunoreactivity. Due to a lack of commercially 
available antibodies at the time these studies were conducted, ERβ was not analyzed in 
this study. This study is the first to report AR and ERα immunoreactivity in the PAG and 
its descending projections to the RVM in both male and female rats.  
 
5.3 METHODS 
 
Subjects 
Six adult male and six weight-matched (250-350g) cycling female Sprague-Dawley rats 
were used in these experiments (Zivic-Miller; Pittsburgh, PA). Rats were housed in 
same-sex pairs on a 12:12 hour light:dark cycle. Access to food and water was ad 
libitum throughout the experiment except during surgery. These studies were performed 
in compliance with the Institutional Animal Care and Use Committee at Georgia State 
University. All efforts were made to reduce the number of animals used in these 
experiments and to minimize any possible suffering by the animal. 
 
Vaginal Cytology  
Vaginal lavages were performed daily beginning two weeks prior to experimental 
manipulations to confirm that the female rats were cycling normally and to keep daily 
records on the stages of their cycle up to the day of sacrifice. Proestrus was identified 
as a predominance of nucleated epithelial cells and estrus was identified as a 
predominance of cornified epithelial cells.  Diestrus 1 was differentiated from Diestrus 2 
by the presence of leukocytes.  Rats that appeared between phases were noted as 
being in the more advanced stage. 
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Retrograde Tracer Injections 
Animals were deeply anesthetized with a cocktail of ketamine/xylazine/acepromazine 
(50 mg/kg / 3.3 mg/kg / 3.3 mg/kg; i.p.; Henry Schein, Melville, NY). When a surgical 
plane of anesthesia was reached each animal was placed in a stereotaxic frame and 
the skull was adjusted so bregma and lambda were at the same dorsal-ventral plane. 
Glass micropipettes (10-20 µM) filled with the retrograde tracer Fluorogold (FG; 2% 
soln. w/v in saline; Fluorochrome LLC; Denver, CO) were lowered into the RVM using 
the following coordinates (in mm): AP: -2.0 Lambda; ML: 0.0; DV: -8.5). FG was 
iontophoresed (50/50 duty cycle, 7.5 µA current) into the RVM for 25 minutes to 
facilitate neuronal uptake. The current was then turned off and the pipettes remained in 
place for an additional 5 minutes prior to removal to minimize backflow of the tracer 
along the pipette track. Following tracer injections, wounds were sutured closed, the 
antibiotic Neosporin was applied to the wound, and the animals were placed in clean 
cages to recover under a heat lamp. Upon complete recovery from the anesthetic, 
animals were returned to their original housing facilities. 
 
Perfusion fixation 
Ten days following surgery, animals were given a lethal dose of Nembutal (160 mg/kg; 
i.p.) and transcardially perfused with 200-250 ml of 0.9% sodium chloride containing 2% 
sodium nitrite as a vasodilator to remove blood from the brain. Immediately following 
removal of blood, 300 ml of 4% paraformaldehyde in 0.1M phosphate buffer containing 
2.5% acrolein (Polyscience; Niles, IL) was perfused through the brain as a fixative. A 
final rinse with 200-250 ml of the sodium chloride/sodium nitrate solution was perfused 
through the brain to remove any residual acrolein. Immediately following perfusion, the 
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brains were carefully removed, placed in a 30% sucrose solution and stored at 4°C for 
at least one week prior to sectioning. Sucrose solutions were changed daily to optimize 
saturation of sucrose into the tissue. To section the brain, the dura and pia mater were 
carefully removed and the brains were cut into six series of 25 µm coronal sections with 
a Leica 2000R freezing microtome and stored free-floating in cryoprotectant-antifreeze 
solution (Watson et al., 1986b) at –20oC until immunocytochemical processing. The 
tissue was sectioned at 25 µm so that 125 µm separates each analyzed level of the 
PAG thus eliminating any possible bias from counting the same cell twice during data 
collection. 
 
Immunocytochemistry 
A 1:6 series through the rostrocaudal axis of each brain was processed for FG 
immunoreactivity and AR (n=5 males; n=6 females) or ERα (n=6 males; n=5 females) 
immunoreactivity as previously described (Murphy & Hoffman, 2001). Briefly, sections 
were rinsed extensively in potassium phosphate-buffered saline (KPBS) to remove 
cryoprotectant solution, immediately followed by a 20-minute incubation in 1% sodium 
borohydride to remove excess aldehydes. The tissue was then incubated in either 
primary antibody solution rabbit anti-AR (Santa Cruz Biotechnology; Santa Cruz, CA, lot 
no. L0407; 1:10,000) or rabbit anti-ERα (Santa Cruz Biotechnology; Santa Cruz, CA, lot 
no. I2607; 1:20,000) in KPBS containing 1.0% Triton-X for one hour at room 
temperature followed by 48 hours at 4°C. The rabbit anti-AR antiserum was prepared 
against a peptide mapping at the N-terminus of AR of human origin 
(MEVQLGLGRVYPRPPSKTYRG) corresponding to amino acids 2-21 (manufacturer’s 
technical information) and specificity has been confirmed (Creutz & Kritzer, 2004). The 
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rabbit anti-ERα antiserum was prepared against a peptide mapping at the C-terminus of 
ERα of mouse origin (HSLQTYYIPPEAEGFPNTI) corresponding to amino acids 580-
559 (manufacturer’s technical information) and specificity has been confirmed (Quesada 
et al., 2007).  
 
After rinsing out the primary antibody with KPBS, the tissue was incubated for one hour 
in biotinylated goat anti-rabbit IgG (Jackson Immunoresearch; West Grove, PA, 1:600), 
rinsed with KPBS, followed by a one hour incubation in an avidin-biotin peroxidase 
complex (1:10; ABC Elite Kit, Vector Labs). After rinsing in KPBS and sodium acetate 
(0.175 M; pH 6.5), AR or ERα immunoreactivity was visualized as a black reaction 
product using nickel sulfate intensified 3,3’-diaminobenzidine solution containing 0.08% 
hydrogen peroxide in sodium acetate buffer. After rinsing, AR or ERα labeled sections 
were then placed in primary antibody solution rabbit anti-FG (Chemicon; Billerica, MA, 
lot no. 25060005; 1:10,000) in KPBS containing 1.0% Triton-X for one hour at room 
temperature followed by 48 hours at 4°C. FG was visualized as a brown reaction 
product using 3,3’-diaminobenzidine containing 0.08% hydrogen peroxide in Trizma 
buffer (pH 7.2). After 15-30 minutes, three rinses in sodium acetate buffer terminated 
the reaction and tissue was given a final rinse in KPBS. Sections were then mounted 
out of saline onto gelatin-subbed slides, air-dried and dehydrated in a series of graded 
alcohols. Tissue-mounted slides were then cleared in xylene and glass cover-slipped 
using Permount. 
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Data Analysis and Presentation 
Data were analyzed across six representative levels through the rostrocaudal axis of the 
PAG (Bregma -6.72, -7.04, -7.74, -8.00, -8.30, -8.80). The number of AR 
immunoreactive neurons (AR-IR), ERα immunoreactive neurons (ERα-IR), and the 
number of AR-IR and ERα-IR neurons that were retrogradely labeled (AR/FG+, 
ERα/FG+) were quantified. The experimenter was blind to the experimental condition. In 
levels where significant differences were found, a second blinded observer confirmed 
results. Cell counts were conducted unilaterally as there are no differences in the 
number of FG+ cells (Loyd & Murphy, 2006) or the number of AR-IR and ERα-IR 
neurons (Murphy & Hoffman, 2001) for the left versus right side of PAG. Additionally, 
previous data have shown that there are no sex differences in total area (mm2) of the 
PAG between weight-matched male and female Sprague-Dawley rats (Loyd & Murphy, 
2006).  
 
Data are reported as the mean + standard error of the mean (SEM) from which 
percentages were calculated and reported as the percentage of receptor that was 
localized in retrogradely labeled cells (%AR/FG+; %ERα/FG+) or as the percentage of 
retrogradely labeled cells that were colocalized with receptor (%FG/AR; %FG/ ERα). A 
three-way analysis of variance (ANOVA) was used to test for significant main effects of 
sex (male, female), PAG level (Bregma –6.72 through -8.80), and PAG subdivision 
(dorsomedial, lateral/ventrolateral). For percentile date, percentages were transformed 
to standard scores. Fishers’s post hoc tests were used to determine specific group 
differences when a main effect or interaction was observed. P<.05 was considered 
significant for all analyses. For data presentation, a representative animal from each 
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experimental group was selected and the distribution of (1) AR-IR neurons, (2) ERα-IR 
neurons, (3) FG+ neurons, (4) AR/FG+ neurons and (5) ERα/FG+ neurons within the 
PAG were plotted using a Nikon Drawing Tube attached to a Nikon Optiphot 
microscope. Plots were then scanned onto the computer and adjusted to figure format 
using Adobe Illustrator 10.  Photomicrographs were generated using a Synsys digital 
camera attached to a Nikon Eclipse E800 microscope.  Images were captured with IP 
Spectrum software and adjusted to figure format by alterations in brightness and 
contrast levels using Adobe Photoshop 7.0.  
 
5.4 RESULTS  
 
Androgen Receptor Distribution in the PAG 
AR-IR neurons were distributed across the rostrocaudal axis of the PAG in both male 
and female rats (Figure 5.1; green circles). AR-IR neurons were confined to the 
dorsomedial and lateral/ventrolateral subdivisions of the PAG, with the dorsolateral 
subdivision of the PAG lacking AR-IR neurons. These results are consistent with 
previous studies showing AR localization in the PAG of male rats (Murphy & Hoffman, 
1999; Murphy & Hoffman, 2001). While the qualitative distribution of AR-IR neurons was 
similar in both males and females, quantitatively males had a significantly greater 
number of AR-IR neurons compared to females [F(1, 54)=22.7, p<.00001) (Figure 5.2; 
green bars) with a significantly greater number of AR-IR neurons localized in the 
lateral/ventrolateral PAG compared to the dorsomedial subdivision [F(1, 108)=22.1, 
p<.0001]. This sex difference was evident across the rostrocaudal axis of the PAG. 
There was no main effect of level of PAG [F(5,54)=1.2; n.s.] and no significant sex by 
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level interaction [F(5,54)=0.3; n.s.], indicating that the number of AR-IR neurons 
remained consistent across the rostrocaudal axis of the PAG of both male and female 
rats.  
 
Estrogen (α) Receptor Distribution in the PAG  
ERα-IR neurons were densely distributed throughout the rostrocaudal axis of the PAG 
in both male and female rats (Figure 5.1; purple circles). Similar to the distribution of 
AR-IR neurons, ERα-IR neurons were confined to the dorsomedial and 
lateral/ventrolateral subdivisions of the PAG, with the majority of ERα-IR neurons 
localized in the lateral/ventrolateral PAG [F(1, 108)=105.8, p<.0001]. Overall, there was 
no sex difference in the number of ERα-IR neurons in the PAG [F(1, 54)=1.2, n.s.] 
(Figure 5.2; purple bars). A significant increase in the number of ERα-IR neurons [F(5, 
54)=9.02, p<.0001] was noted along the rostrocaudal axis of the PAG. All female rats 
were cycling normally during these experiments.  
 
Androgen Receptor Distribution in PAG Neurons Projecting to the RVM 
All iontophoretic injections of the retrograde tracer Fluorogold (FG) into the RVM were 
located on the midline and dorsal to the pyramidal tract, at the level of the caudal pole of 
the facial nucleus (lambda –2.0mm). Analysis was limited to injection sites that occurred 
between the facial nucleus and the olivary complex across approximately 2mm 
rostrocaudally (Bregma -9.30 to -11.60). In our studies using anterograde tracing from 
the PAG to the RVM, we have noted that this region of RVM contains the highest 
density of anterogradely labeled fibers and is remarkably consistent throughout this 
2mm window of RVM (unpublished observations). Injections outside of the RVM were 
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not included for analysis. Only male and female rats with comparable injection sites 
were used for analysis. Injection of FG into the RVM produced dense retrograde 
labeling throughout the rostrocaudal axis of the PAG consistent with our previous 
studies (Loyd et al, 2006, Loyd et al., 2007; Loyd et al., 2008). Females had a 
significantly greater number of PAG cells retrogradely labeled from the RVM compared 
to males [F(1,70)=14.4, p<.0003]. 
 
Figure 5.3 shows an example of AR and FG immunoreactivity within the lateral PAG of 
a representative male (A-B) and female (C-D) rat. AR-IR neurons there were 
retrogradely labeled were densely localized throughout the rostrocaudal axis of the PAG 
in both male and female rats (Figure 5.4; green stars), with males expressing more dual 
labeled cells [F(1,54)=19.5; p<.0001]. The percentage of retrogradely labeled cells that 
expressed AR was comparable between the sexes [F(1,54)=13.51; n.s.] (Figure 5.5, 
%FG/AR), and significantly increased moving caudally through the PAG [F(5,54)=7.29; 
p<.0001]. Since female rats had a greater number of PAG neurons projecting to the 
RVM compared to males, the percentage of AR that was localized in retrogradely 
labeled cells was also determined (Figure 5.5; %AR/FG+) and was found to be 
comparable between the sexes [F(1, 54)=1.4; n.s.].  
 
Estrogen (α) Receptor Distribution in PAG Neurons Projecting to the RVM 
An example of ERα and FG immunoreactivity within the lateral PAG of a representative 
male (A-B) and female (C-D) rat is shown in Figure 5.6. ERα-IR neurons that were 
retrogradely labeled were densely localized throughout the rostrocaudal axis of the PAG 
in both male and female rats (Figure 5.4; purple stars) [F(1,54)=1.1; n.s.], with the 
majority localized in the lateral/ventrolateral subdivision [F(1, 54)=7.5; p<.0001]. Across 
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all levels and regions of the PAG, the percentage of retrogradely labeled cells that 
expressed ERα was comparable between the sexes [F(1,54)=0.176; n.s.] (Figure 5, 
%FG/ERα). Similarly, the percentage of ERα that was localized in retrogradely labeled 
cells was comparable between the sexes [F(1, 54)=0.292; n.s.] (Figure 5.5; 
%ERα/FG+). Additionally, a significantly greater percentage of retrogradely labeled cells 
that expressed ERα were observed in the caudal PAG [F(5,54)=15.1; p<.0001].  
 
5.5  DISCUSSION 
 
The PAG has been implicated in a variety of hormone-sensitive behaviors (Bandler & 
Shipley, 1994b; Keay & Bandler, 2001; 2002); however, gonadal steroid receptor 
expression in the PAG had not been reported in both male and female rats. Here we 
report that the expression of AR is sexually dimorphic along the entire rostrocaudal axis 
of the PAG, with males having a significantly greater number of immunoreactive 
neurons. No sex differences were noted in the qualitative or quantitative aspects of ERα 
expression in the PAG. In the present study, ERβ was not examined due to a lack of a 
reliable antibody at the time these studies were conducted; therefore, the possibility 
remains that the expression of ERβ in the PAG is sexually dimorphic. Similarly, in this 
study we were unable to determine the effects of estrous on ERα expression in the PAG 
due to low number of animals. On the day of sacrifice, ten days following tracer 
injections, all female rats were in either the estrus (n=4) or proestrus (n=2) phase of 
their cycle; no animals were in the diestrus phase.  
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The sex difference in the expression of AR in the PAG may play a role in sex 
differences in pain and analgesia. There are numerous behavioral studies indicating a 
role of gonadal steroids in modulating morphine potency. Gonadectomy reduces 
morphine potency in male rats (Kepler et al., 1989) and increases morphine potency in 
females (Terner et al., 2002; Terner et al., 2005), while hormone replacement reverses 
these effects (Stoffel et al., 2003; Stoffel et al., 2005). Masculinizing female rat pups 
with testosterone increases morphine potency to male-like levels (Cicero et al., 2002). 
In addition, testosterone has been shown to oppose the effects of estradiol on neuronal 
excitability (Edwards et al., 1999) and decrease pain sensitivity in both male and female 
rats (Aloisi et al., 2004). A greater expression of AR in the PAG of males may provide 
an anatomical substrate for the sexually dimorphic modulation of pain by gonadal 
steroids. 
 
The distribution of AR-IR and ERα-IR neurons was remarkably similar; both receptor 
types were preferentially localized within the dorsomedial and lateral/ventrolateral 
subdivisions of the PAG and both increased in density along the rostrocaudal axis of the 
PAG. These results are similar to the distribution of AR-IR and ERα-IR neurons 
previously reported in the PAG of the male rat (Murphy & Hoffman, 1999; Murphy & 
Hoffman, 2001). In addition, the distribution of ERα-IR neurons in the female rat PAG is 
similar to that previously reported in the cat (VanderHorst et al., 1998), the golden 
hamster (Boers et al., 1999), the guinea pig (Turcotte & Blaustein, 1993) and the rhesus 
monkey (Vanderhorst et al., 2002; VanderHorst et al., 2004).  
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Steroid Receptor Colocalization within the Endogenous Descending Pathway Driving 
Pain Inhibition 
The dense projections from the PAG to the RVM provide an essential neural circuit for 
the antinociceptive effects of opiates. Many behavioral studies have reported an effect 
of steroid hormones on morphine potency; however, this study is the first to report the 
expression of AR and ERα within the endogenous descending pathway driving pain 
inhibition. Using immunohistochemical analysis, we report that AR and ERα were 
expressed on PAG neurons projecting to the RVM in both the dorsomedial and 
lateral/ventrolateral subdivisions of the PAG. Male rats had a greater number AR-IR 
neurons that were retrogradely labeled, however, there was so sex difference in either 
the percentage of retrogradely labeled cells that expressed AR or the percentage of AR 
that was located within retrogradely labeled cells.  Similarly, the percentage of ERα that 
was localized in retrogradely labeled cells was comparable between the sexes and was 
significantly greater in the caudal PAG with the majority localized in the 
lateral/ventrolateral subdivision. 
 
Role in Pain and Analgesia 
The present results report a dense colocalization of gonadal steroid receptors on PAG 
neurons projecting to the RVM, which may provide the anatomical substrate for the 
reported sex differences in morphine potency. Between 27-50% of PAG neurons 
projecting to the RVM contain mu opioid receptor (MOR); these MOR+ cells are 
localized primarily within the caudal lateral/ventrolateral PAG (Commons et al., 2000b; 
Wang & Wessendorf, 2002), in the same subdivision of the PAG that we report a dense 
distribution of both steroid hormone receptors. Estradiol has been shown to both 
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uncouple MORs from G protein-gated inwardly rectifying potassium channels causing a 
reduction in hyperpolarization by MOR agonists (Kelly et al., 2003) and induce mu 
opioid receptor (MOR) internalization (Eckersell et al., 1998b).  Furthermore, MOR 
internalization requires the presence of ERα (Micevych et al., 2003) suggesting that 
colocalization of MOR and ERα in the descending inhibitory circuit may provide a 
mechanism through which gonadal hormones differentially affect morphine potency in 
male and female rats. 
 
Although not determined in the present study, it is possible that both AR and ERα are 
colocalized within the same PAG cells, as is the case in other brain areas (Wood & 
Newman, 1995); (Greco et al., 1998). A population of neurons expressing both AR and 
ERα in the PAG may provide a potential mechanism for the diverse effects of gonadal 
steroid hormones. For example, there are numerous reports of sex differences in pain 
sensitivity; however, there is no clear consensus on the direction of the sex difference 
(Mogil et al., 2000; Gaumond et al., 2002; Aloisi et al., 2004; LaCroix-Fralish et al., 
2005). In addition, pain sensitivity varies across the rat estrous cycle (Gintzler, 1980) 
and the human menstrual cycle (Cogan & Spinnato, 1986; Hellstrom & Anderberg, 
2003). Sex differences in circulating gonadal steroids acting via a differential expression 
of AR and ERα within the same PAG neuron may provide a mechanism for the diverse 
effects of gonadal steroids on pain sensitivity.  
 
Other Functional Considerations  
The PAG has also been implicated in the regulation of the autonomic system controlling 
blood pressure, heart rate, and regional blood flow, all of which have shown to be 
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modulated by gonadal hormones (Alper & Schmitz, 1996); (Morgan & Pfaff, 2001). In 
parallel, the PAG initiates defensive and aggressive behaviors, such as the ‘fight or 
flight’ response (Bandler et al., 1985; Bandler & Carrive, 1988b; Depaulis et al., 1992; 
Scordalakes & Rissman, 2004), and evidence suggests that gonadal hormones 
increase these behaviors in both male and female rats (Albert et al., 1990; Albert et al., 
1991; Johansson et al., 2000). Additionally, the PAG has also been implicated in 
initiating sex behavior, in that stimulation of the PAG facilitates lordosis in female rats 
(Sakuma & Pfaff, 1979a; 1979b; McCarthy et al., 1991b), while lesions of the PAG 
suppress this behavior (Sakuma & Pfaff, 1979b; Lonstein & Stern, 1998). Here we 
report that the PAG, an anatomical substrate essential for the integration of sensory 
input and autonomic output, contains a large population of gonadal steroid receptor-
expressing neurons, which appear to be involved in modulating both autonomic and 
sensory responses involved in producing steroid-sensitive behaviors. 
 
5.6  CHAPTER SUMMARY 
 
The present study demonstrates that there are sex differences in the qualitative and 
quantitative aspects of the gonadal steroid receptors in the PAG. These reported 
differences in AR and ERα immunoreactivity in the PAG have an important impact on 
steroid-sensitive behaviors modulated by the PAG, such as reproduction, aggression, 
autonomic regulation, pain and morphine analgesia. We additionally report that the 
primary neural circuit for the antinociceptive effects of opioids expresses steroid 
receptors and may provide a direct mechanism for sex differences in morphine 
analgesia.  
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Figure 5.1. Distribution of cells in the PAG immunoreactive for AR (green circles) and 
ERα (purple circles) in male (left side of plots) and female rats (right side of plots) at six 
rostrocaudal levels (A-F) of the PAG.  
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Figure 5.2. Bar graphs display the mean number (+ S.E.M.) of AR immunoreactive cells 
(green bars) and ERα immunoreactive cells (purple bars) across six rostrocaudal levels 
of the PAG. Cell counts were combined for the dorsomedial and lateral/ventrolateral 
subdivisions of PAG. # denotes a significant sex difference in mean number of steroid 
receptors. 
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Figure 5.3. Color photomicrograph showing a low (A,C) and high (B,D) power example 
of single- and double-labeled AR and FG immunoreactive cells in the lateral PAG 
(bregma -8.00) of a male (A-B) and female rat (C-D). Scale bar = 100 µm for low power 
images; scale bar = 50 µm for high power images. 
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Figure 5.4. Distribution of cells in the PAG retrogradely labeled from the rostral 
ventromedial medulla (black circles) and immunoreactive for AR (green stars) and ERα 
(purple stars) in male (left side of plots) and female rats (right side of plots) at six 
rostrocaudal levels of the PAG.  
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Figure 5.5. Bar graphs display the mean (+ S.E.M.) %AR/FG+, %FG/AR+, %ERα/FG+, 
and %FG/ERα+ immunoreactive neurons for the dorsomedial combined with 
lateral/ventrolateral regions of PAG across six rostrocaudal levels of the PAG. # 
denotes a significant sex difference in %FG/AR+ by level. 
 121 
 
 
 
 
 
 
Figure 5.6. Color photomicrograph showing a low (A,C) and high (B,D) power example 
of single- and double-labeled ERα and FG immunoreactive cells in the lateral PAG 
(bregma -8.00) of a male (A-B) and female rat (C-D). Scale bar = 100 µm for low power 
images; scale bar = 50 µm for high power images. 
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6.1 ABSTRACT 
 
Opioid-based narcotics are the most widely prescribed therapeutic agents for the 
alleviation of persistent pain; however, it is becoming increasingly clear that morphine is 
less potent in women compared to men. Morphine primarily binds to mu opioid 
receptors (MOR), and the periaqueductal gray (PAG) contains a dense population of 
MOR-expressing neurons. Via its descending projections to the rostral ventromedial 
medulla and then the dorsal horn of the spinal cord, the PAG is considered an essential 
neural substrate for opioid-based analgesia. We hypothesized that MOR expression in 
the PAG is sexually dimorphic, and that this receptor expression is both necessary and 
sufficient for eliciting sex differences in morphine potency. Using immunohistochemistry, 
we report that males have a significantly higher expression of MOR in the ventrolateral 
PAG (vlPAG) compared to cycling females, while the lowest level of expression are 
observed during proestrus. Microinjection of morphine directly into the vlPAG produced 
a significantly greater degree of antihyperalgesia to a thermal stimulus during CFA-
induced inflammatory pain in males compared to proestrus and estrus females. 
Selective lesions of MOR-expressing neurons in the vlPAG resulted in a significant 
reduction in morphine antihyperalgesia in males only, and this reduction was positively 
correlated with the level of vlPAG MOR expression. Together, these results indicate that 
MOR-expressing neurons in the vlPAG are sexually dimorphic. Furthermore, these 
neurons are both necessary and sufficient for eliciting sexually dimorphic 
antihyperalgesia following systemic morphine administration, providing a potential 
primary mechanism for sex differences in morphine potency. 
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6.2 INTRODUCTION 
 
In both humans and rodents, morphine produces a significantly greater degree of 
analgesia in males compared to females (Cepeda et al., 2002; Cepeda & Carr, 2003; 
Miller & Ernst, 2004). Sex differences in morphine analgesia have been demonstrated in 
studies employing either acute or persistent orofacial (Okamoto et al., 2005), visceral (Ji 
et al., 2006; 2007) and somatic (Bartok & Craft, 1997; Cicero et al., 1997; Boyer et al., 
1998; Kest et al., 1999; Barrett et al., 2001; Cook & Nickerson, 2005; Wang et al., 2006) 
pain models, with ED50 values two times higher in females compared to males (Wang et 
al., 2006; Ji et al., 2007). Importantly, sex-based differences in opiate sensitivity are not 
due to the pharmacokinetics of morphine as no sex difference has been reported in 
serum or brain levels of morphine; and elimination and metabolic rates are comparable 
between sexes (Cicero et al., 1996b; Craft et al., 1996; Cicero et al., 1997; Sarton et al., 
2000). Rather, sex related differences in morphine analgesia are likely due to 
dissimilarities in opiate receptor density, binding and localization, as well as sex 
differences in the anatomy and physiology of opiate-responsive neural circuits (Loyd & 
Murphy, 2006; Loyd et al., 2007; Loyd et al., 2008). 
 
The midbrain periaqueductal gray (PAG) and its descending projections to the rostral 
ventromedial medulla (RVM), constitutes an essential neural circuit for opioid-based 
antinociception (Basbaum et al., 1976; 1978; Fields & Basbaum, 1978; Basbaum & 
Fields, 1979; Behbehani & Fields, 1979; Shah & Dostrovsky, 1980; Abols & Basbaum, 
1981; Beitz, 1985; Beitz & Shepard, 1985). Administration of mu opioid receptor (MOR) 
agonists into the PAG produces potent analgesia that is blocked by central or systemic 
administration of the opioid antagonist naloxone (Satoh et al., 1983; Jensen & Yaksh, 
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1986; Bodnar et al., 1988b). Similarly, direct administration of MOR antagonists into the 
PAG blocks the antinociceptive effects of systemic morphine (Wilcox et al., 1979; Ma & 
Han, 1991; Zhang et al., 1998) indicating that the PAG is an essential loci for 
exogenous opioid-mediated analgesia.  
 
The ventrolateral PAG (vlPAG) contains a high density of MOR (Mansour et al., 1986; 
Mansour et al., 1987; Kalyuzhny et al., 1996; Gutstein et al., 1998; Commons et al., 
1999; Commons et al., 2000b; Wang & Wessendorf, 2002) and approximately 27-50% 
of PAG neurons projecting to the RVM express MOR (Commons et al., 2000b; Wang & 
Wessendorf, 2002). Unfortunately, previous studies examining the distribution of MOR 
within the PAG-RVM circuit were conducted exclusively in males. One mechanism that 
may contribute to sex-based differences in morphine potency are sex differences in 
MOR expression in the vlPAG. The present studies tested the hypothesis that sex 
differences in MOR expression within the vlPAG provide a primary mechanism 
underlying the sexually dimorphic effects of morphine across three experimental 
designs: (1) immunocytochemical localization of MOR in the vlPAG; (2) microinjection of 
morphine directly into the vlPAG and (3) site-specific lesions of MOR-expressing 
neuronal populations in the vlPAG. 
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6.3 METHODS 
 
Experimental Subjects  
Adult weight-matched (250-350g) intact male and cycling female Sprague-Dawley rats 
were used in these experiments (Zivic-Miller; Pittsburg, PA). Rats were housed in same-
sex pairs on a 12:12 hour light:dark cycle. Access to food and water was ad libitum 
throughout the experiment except during surgery. These studies were performed in 
compliance with the Institutional Animal Care and Use Committee at Georgia State 
University. All efforts were made to reduce the number of animals used in these 
experiments and to minimize any possible suffering by the animal. 
 
Vaginal Cytology 
Vaginal lavages were performed daily beginning two weeks prior to testing to confirm 
that all female rats were cycling normally and to keep daily records on the stages of 
their cycle in respect to experimental testing. Proestrus was identified as a 
predominance of nucleated epithelial cells and estrus was identified as a predominance 
of cornified epithelial cells.  Diestrus 1 was differentiated from Diestrus 2 by the 
presence of leukocytes. However, as there were no significant differences noted in 
either the anatomy or behavior of diestrus 1 and diestrus 2 animals, these data are 
pooled (diestrus). Rats that appeared between phases were noted as being in the more 
advanced stage. 
 
Intra-PAG Cannulae Implantation 
Intact males (n=30) and cycling females (n=34) were deeply anesthetized with a cocktail 
of ketamine/xylazine/acepromazine (50 mg/kg / 3.3mg/kg / 3.3 mg.kg; i.p.; Henry Shein, 
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Melville, NY). Guide cannulae (22 gauge; 5.0 mm; Plastics One, Roanoke, VA) were 
lowered bilaterally into the ventrolateral PAG using the following coordinates (in mm): 
AP: +0.75 Lambda; ML: 0.60; DV: -3.5. Cannula skull screws and dental acrylic were 
applied to secure placement. Cannulae were flushed daily with 0.5 µl saline over a 60 
second period to acclimate the animals to the injection procedure and maintain cannula 
patency. 
 
Lesions of Mu Opioid Receptor-Expressing PAG Neurons 
Intact males (n=11) and cycling females (n=11) were deeply anesthetized with a cocktail 
of ketamine/xylazine/acepromazine (50 mg/kg / 3.3mg/kg / 3.3 mg.kg; i.p.; Henry Shein, 
Melville, NY). Dermorphin-saporin (DermSAP; MOR agonist-saporin cytotoxin 
conjugate; Advanced Targeting Systems, San Diego, CA) or blank-saporin (BlankSAP; 
nonsense peptide-saporin cytotoxin control conjugate; Advanced Targeting Systems, 
San Diego, CA) were freshly diluted from stock (DermSap 0.91µg/µl, 46.9µM; BlankSAP 
1.5µg/µl, 46.9µM; 32kDa) and stored on ice during experimental procedures. DermSAP 
(n=6 males; n=6 females) or BlankSAP (n=5 males; n=5 females) was injected into the 
ventrolateral PAG (coordinates in mm): AP: +0.75 Lambda; ML: 0.60; DV: -3.5) using a 
1µl Hamilton syringe. DermSAP (3 pmol/400nl; 7.5µM) or BlankSAP (3pmol/400nl; 
7.5µM) was microinjected over 30 seconds. This procedure was repeated on the 
contralateral side. Saporin has been previously shown to have no effect in the absence 
of conjugation (Porreca et al., 2001; Burgess et al., 2002; Vera-Portocarrero et al., 
2006b). In addition, dermorphin has been shown to have a high binding affinity selective 
for the MOR (Ki value of 0.7mM) and that conjugation to saporin does not significantly 
alter its binding affinity (Ki value of 0.1nM; Porreca et al., 2001). This technique has 
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been previously been shown to result in a significant attenuation of MOR expression in 
the RVM (Porreca et al., 2001) and the spinal cord (Kline & Wiley, 2008). Loss of mu 
opioid receptor containing neurons was confirmed in the present study using both 
immunohistochemistry and autoradiography. Cell necrosis due to the injection 
procedure was determined using immunocytochemistry for neuronal nuclei. 
 
Inflammatory Hyperalgesia. Persistent inflammatory pain was induced by injection of 
complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis; Sigma; 200 µl), 
suspended in an oil/saline (1:1) emulsion, into the plantar surface of the right hindpaw. 
Paw diameters were determined using calibrated calipers applied midpoint across the 
dorsal to plantar surface of both hindpaws before and after induction of inflammation.  
 
Inflammatory Hyperalgesia 
Persistent inflammatory pain was induced by injection of complete Freund’s adjuvant 
(CFA; Mycobacterium tuberculosis; Sigma; 200 µl), suspended in an oil/saline (1:1) 
emulsion, into the plantar surface of the right hindpaw. Animals were under brief Isoflo 
(isofluorane, USP) anesthesia during the plantar injections. Paw diameters determined 
using calibrated calipers applied midpoint across the dorsal to plantar surface of both 
hindpaws before baseline testing and after induction of inflammation.  
 
Behavioral Testing  
Paw withdrawal latencies to a noxious thermal stimulus were determined using the Paw 
Thermal Stimulator (Univ. California San Diego) as previously described (Hargreaves et 
al., 1988; Wang et al., 2006). Briefly, for this test, the rat is placed in a clear Plexiglas 
box resting on an elevated glass plate maintained at 30oC.  Following a one-hour 
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acclimation, a radiant beam of light is positioned under the hindpaw and the time for the 
rat to remove the paw from the thermal stimulus is electronically recorded as the paw 
withdrawal latency (PWL). The intensity of the beam was set to produce basal PWL’s of 
6-8 seconds. A maximal PWL of 20 seconds was used to prevent excessive tissue 
damage due to repeated application of a noxious thermal stimulus.   
 
Perfusion fixation  
Following experimental manipulations, animals were given a lethal dose of Nembutal 
(160 mg/kg; i.p.) and transcardially perfused with 200-250 ml of 0.9% sodium chloride 
containing 2% sodium nitrite as a vasodilator to remove blood from the brain. 
Immediately following removal of blood, 300 ml of 4% paraformaldehyde in 0.1M 
phosphate buffer containing 2.5% acrolein (Polyscience; Niles, IL) was perfused 
through the brain as a fixative. A final rinse with 200-250 ml of the sodium 
chloride/sodium nitrate solution was perfused through the brain to remove any residual 
acrolein. Brains were placed in a 30% sucrose solution and stored at 4°C.  
 
Immunohistochemistry 
Perfusion fixed brains were sectioned into 25 µm coronal sections with a Leica 2000R 
freezing microtome and stored free-floating in cryoprotectant-antifreeze solution 
(Watson et al., 1986b) at –20oC. A 1:6 series through the rostrocaudal axis of each 
brain was processed for mu opioid receptor-1 (MOR1) or neuronal nuclei (NeuN) 
immunoreactivity using standard immunhistochemical techniques as previously 
described (Murphy & Hoffman, 2001). Briefly, sections were rinsed extensively in 
potassium phosphate-buffered saline (KPBS) immediately followed by a 20-minute 
incubation in 1% sodium borohydride. The tissue was then incubated in primary 
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antibody solution rabbit anti-MOR1 (donated by Robert Elde, Ph.D. at the University of 
Minnesota; 1:70,000) or rabbit anti-MOR1 (Abcam, Cambridge, MA; 1,50,000; lot 
317653) or mouse anti-NeuN (Chemicon, Temecula, CA; 1,50,000; lot 23112968) in 
KPBS containing 1.0% Triton-X for one hour at room temperature followed by 48 hours 
at 4°C. Both MOR1 antibodies were prepared against the synthetic peptide 
(NHQLENLEAETAPLP) corresponding to amino acids 384-398 of rat MOR1 (Arvidsson 
et al., 1995; Starowicz et al., 2007). After rinsing with KPBS, the tissue was incubated 
for one hour in biotinylated goat anti-rabbit IgG or anti-mouse (Jackson 
Immunoresearch; West Grove, PA, 1:600), rinsed with KPBS and incubated for one 
hour in an avidin-biotin peroxidase complex (1:10; ABC Elite Kit, Vector Labs). After 
rinsing in KPBS and sodium acetate (0.175 M; pH 6.5), MOR1 or NeuN 
immunoreactivity was visualized as a black reaction product using nickel sulfate 
intensified 3,3’-diaminobenzidine solution containing 0.08% hydrogen peroxide in 
sodium acetate buffer. After 15-30 minutes, tissue was rinsed in sodium acetate buffer 
followed by KPBS. Sections were then mounted out of saline onto gelatin-subbed 
slides, air-dried and dehydrated in a series of graded alcohols. Tissue-mounted slides 
were then cleared in xylene and glass cover-slipped using Permount.  
 
Receptor Autoradiography 
Dermorphin-saporin (n=4 males; n=4 females) and blank-saporin (n=4 males; n=4 
females) treated animals were rapidly decapitated. Brains were removed rapidly, flash 
frozen in 2-Methylbutane and stored at -80oC. Fresh frozen tissue was cut in a 1:4 
series of 20 µm coronal sections at -20 oC with a Leica CM3050S cryostat, immediately 
mounted onto glass slides and stored at -80oC. Slides were dried and fixed in 4% 
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paraformaldehyde followed by rinses in 50mM Tris buffer (pH 7.4) containing 100nM 
NaCl. Slides were then placed in a tracer buffer containing tritiated DAMGO (1 nM; 
Amersham, Pittsburg, PA) for 60 minutes followed by a series of rinses in 50mM Tris 
buffer (pH 7.4) containing MgCl2. Tissue was allowed to try and placed on 
autoradiographic film for 5 weeks at which point films were developed with a FujiFilm 
BAS 5000 (Valhalla, NY).   
 
Densitometry 
For immunohistochemistry data, 12-bit grayscale images were captured using a 
QImaging Retiga EXi CCD camera (Surrey, BC, Canada) and IPLab Image Analysis 
Software (BD Biosciences, Rockville, MD). The vlPAG was bilaterally sampled (35mm2 
at 10X magnification) between Bregma -7.04 to -8.30 (Paxinos & Watson, 1997) three 
times per section (6-8 sections per brain) and the average grayscale pixel value was 
recorded. Measures were corrected for non-specific immunoreactivity background by 
subtraction of measures taken from areas of equal size lacking specific 
immunoreactivity adjacent to the vlPAG in the same section. For autoradiography data, 
color images were captured and the brightness/contrast was adjusted using Fujifilm 
Multigauge software (Vallhala, NY). The injection site area in the vlPAG (Bregma -7.04 
to -8.30) was sampled three times per section (6-8 sections per brain), averaged and 
the photo-stimulated luminescence per mm2 (PSL/mm2) was recorded. Measures were 
corrected for non-specific binding by subtraction of measures taken from a same 
section area adjacent to the vlPAG of equal size. 
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Statistical Analysis  
For behavioral data analysis, data are expressed as either raw PWL's or percent 
maximal possible effect (%MPE), defined as [(PWL – CFA baseline)/(Maximal PWL – 
CFA baseline)]*100 (Jensen & Yaksh, 1986). PWL data were analyzed for significant 
main effects of sex and estrous cycle using ANOVA. Percentile data was transformed 
into standard scores. Unpaired t-tests were used to determine significant differences in 
baseline data. As no significant differences in %MPE were noted for the 30, 45 and 60 
minute time points, these values were averaged for derivation of ED50, defined as the 
dose of morphine that produced 50% of the maximum possible increase in PWL, with 
the Prism software program and analyzed for significant reductions in values ANOVA. 
P<.05 was considered statistically significant. Fisher’s post hoc tests were used to 
determine specific group differences when a main effect or interaction was observed.  
 
Specific Experiments 
     Experiment 1.  Do sex or estrous cycle influence MOR expression in the vlPAG?  
Male and female rats with an established four-day estrous cycle were perfused 
transcardially with fixative on the morning a specific stage of estrous (diestrus 1, n=12; 
diestrus 2, n=12; proestrus, n=12; estrus, n=12). Males (n=12) and ovariectomized 
females (n=12) were sacrificed at the same time. Tissue sections were processed 
immunohistochemically for MOR1 immunoreactivity (Dr. Elde’s antibody; (Arvidsson et 
al., 1995; Kalyuzhny et al., 1996; Kalyuzhny & Wessendorf, 1997; 1998; Wang & 
Wessendorf, 1999; Kalyuzhny et al., 2000; Wang & Wessendorf, 2002) and 
densitometry values were recorded across vlPAG.  
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     Experiment 2.  Do sex and estrous-induced changes in PAG MOR expression 
influence the antihyperalgesic effects of morphine administered into the vlPAG?     
Intact male and cycling female rats were implanted with cannulae directed at the 
ventrolateral PAG. One week later, baseline PWLs and paw diameters were determined 
followed by induction of CFA-induced inflammation. Twenty-four hours later, PWL and 
paw diameters were re-determined to ensure the presence of hyperalgesia. Saline or 
morphine sulfate prepared fresh on the day of experiment (obtained from the National 
Institute on Drug Abuse, Rockville, MD) was injected into the PAG using a syringe pump 
attached to a 33-gauge injector (7 mm; Plastics One, Roanoke, VA). Separate groups of 
animals received morphine (1.75, 2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 18.0 µg) or saline in a 
total volume of 0.5 µl over 60 seconds. PWLs for the inflamed paw were determined at 
15, 30, 45, 60, 90 and 120 min post injection to assess morphine antihyperalgesia. At 
the end of the experiment, Chicago Sky Blue dye (Sigma; St. Louis, MO) was injected 
through the guide cannulae for injection site verification. Analysis was limited to those 
animals with injections into the caudal vlPAG (Bregma -7.04 to -8.30).  
     Experiment 3. Do lesions of MOR-expressing neurons in the vlPAG attenuate the 
antihyperalgesic effects of morphine? Following determination of baseline PWLs, 
animals were administered either DermSAP or BlankSAP bilaterally into the vlPAG. 
Twenty-eight days later, PWLs were determined (baseline pre-inflamed PWL). CFA was 
then injected intraplantar to induce persistent inflammatory pain. Twenty-four hours 
later, PWLs’ were determined to ensure that DermSAP had no effect on baseline 
hyperalgesia. Animals then received cumulative doses of morphine every 20 minutes 
(1.8, 3.2, 5.6, 8.0, 10.0,18.0 mg/kg; (Loyd et al., 2008); PWLs were determined 5 min 
 134 
post-administration. At the end of the experiment, animals were perfused and lesion 
sites verified immunohistochemically with antibodies directed against MOR1 and NeuN. 
An additional group of animals received either DermSAP or BlankSAP were decapitated 
28 days later and receptor autoradiography was performed to examine the effectiveness 
of MOR lesioning. 
 
6.4  RESULTS  
 
Sex differences in mu opioid receptor expression in the ventrolateral PAG   
Expression of mu opioid receptor protein in the PAG of intact male and cycling female 
rats was examined immunohistochemically. Within the rostral PAG, MOR 
immunoreactivity was localized primarily within the dorsomedial subdivision of the PAG 
and was comparable between the sexes. Moving caudally, MOR immunoreactivity 
shifted and was densely localized within the vlPAG, primarily at the level of the dorsal 
raphe (Bregma -7.04 to -8.30). Overall, females had significantly less MOR 
immunoreactivity in the caudal vlPAG compared to males [F(2,33)=2.064; p=.1430] 
(Figure 6.1A-B). As shown in Figure 6.1C, MOR expression fluctuated across the 
estrous cycle, with significantly reduced MOR immunoreactivity noted in proestrus 
versus diestrus females (p=.0528) and intact males (p=.0068).  
 
Intra-vlPAG morphine produces greater antihyperalgesia in males 
We have previously reported that morphine produces a significantly greater degree of 
antihyperalgesia in male versus female rats (Wang et al., 2006; Ji et al., 2007). We next 
tested whether sex and estrous-induced differences in PAG MOR expression drive our 
observed sex differences in morphine antihyperalgesia. Intra-PAG cannulae were 
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localized within the caudal vlPAG at the level of the dorsal raphe (Bregma -7.04 to -
8.30). Figure 6.2 shows a representative photomicrograph of the intra-vlPAG injection 
site in a male (A) and female (B) rat. Overall, microinjection of morphine directly into the 
vlPAG resulted in greater antihyperalgesia in male compared to female rats 
[F(1,21)=188.78; p<.0001], with a significant dose by sex interaction [F(1,21)=21.81; 
p=.0001]. In male rats, intra-vlPAG morphine resulted in a dose-dependent 
antihyperalgesia with the administration of 10µg resulting in 100%MPE at 30, 45 and 60 
minutes post-injection (Figure 6.3A). Remarkably, in females, administration of this dose 
resulted in PWLs that were not significantly different than saline controls. As there were 
no significant differences in the %MPE observed for the 30, 45 and 60-minute time 
points, these data are collapsed and presented for all doses (Figure 6.3B). As noted in 
Figure 6.3B, in males, intra-vlPAG morphine (1.75-10µg) resulted in a dose-dependent 
antihyperalgesic response, with 10µg resulting in 100%MPE. By contrast, administration 
of these doses in females did not alter PWLs significantly compared to saline. Indeed, 
no significant differences in the effects of morphine versus saline were noted until the 
12.5µg dose in females, and even at this dose, the %MPE was only approximately 30%. 
Interestingly, increasing the dose of morphine from 15µg to 18µg did not result in any 
significant increase in %MPE in females (approximately 55% to 40%). A small group of 
females were administered 20µg, however this dose was lethal in most of the animals 
so additional testing at this dose was terminated. Similarly, administration of the 12.5µg 
and 15µg doses were lethal to all males so testing at this dose was terminated. 
 
As there was no significant difference in the %MPE between the 12, 15 and 18µg/0.5µl 
doses of morphine in females, these data were collapsed and examined for a main 
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effect of estrus on morphine anithyperalgesia. There was a significant main effect of 
estrous stage [F(2,17)=15.35; p=.0002]; such that proestrus (p=.0001) and estrus 
(p=.0005) females had significantly lower levels of morphine antihyperalgesia (20-
25%MPE), while diestrus females had the greatest levels of morphine antihyperalgesia 
(70%MPE; Figure 6.3C). Our observed sex differences in intra-vlPAG morphine 
antihyperalgesia are not due to sex or estrous differences in baseline pain sensitivity 
[F(3,60)=1.027; p=.3870] (Figure 6.4A) or in CFA-induced hyperalgesia [F(3,60)=1.244; 
p=.3017 (Figure 6.4B) and there was no difference in the degree of edema produced by 
intraplantar CFA [F(3,60)=1.842; p=.1492] (Figure 6.4C). 
 
Lesions of MOR-expressing neurons in the vlPAG attenuate morphine antihyperalgesia 
in males only 
To test the role of vlPAG MOR in driving sex differences in morphine analgesia, we 
injected DermSAP into the vlPAG to site-specifically lesion MOR-expressing neurons. 
Lesions that were used for analysis were limited to localization within the vlPAG 
between Bregma -7.04 to -8.30 (Figure 6.5). The effectiveness of the lesions were 
confirmed in three ways: (1) a significant reduction in MOR immunoreactivity (Figure 
6.6A-B), (2) a reduction in neuronal nuclei without complete cell necrosis (Figure 6.6C-
D), and a significant reduction in tritiated DAMGO binding (Figure 6.6E-F). DermSAP 
treatment significantly reduced MOR expression [F(1,19)=8.951; p=.0075] and MOR 
agonist binding [F(1,12)=115.468; p<.0001] in the vlPAG compared to BlankSAP 
controls. There was no evidence of cell necrosis due to the injection procedure in any of 
the animals used for analysis, similar to previous reports (Porreca et al., 2001). 
Lesioning MOR-expressing neurons in the vlPAG had no effect on baseline pain 
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sensitivity to either a thermal [F(1,13)=.193; p=.6677] (Figure 6.7A) or mechanical 
[F(1,15)=2.833; p=.1130] (Figure 6.7B) noxious stimulus in either sex. Following twenty-
four hours of CFA-induced inflammation, there was no effect of lesions on thermal 
[F(1,16)=.283; p=.6018] (Figure 6.7A) or mechanical [F(1,16)=.147; p=.7064] (Figure 
6.7B) hyperalgesia in either sexes.  
 
Following twenty-four hours of CFA-induced inflammation, the antihyperalgesic effects 
of morphine were assessed using a cumulative dosing paradigm. BlankSAP control 
male and female rats showed normal levels of morphine antihyperalgesia to cumulative 
doses of morphine (Figure 6.8), with a mean average ED50 value of 4.07mg/kg in males 
versus 10.39mg/kg in females. There was a significant main effect of treatment 
[F(3,130)=4.750; p<.0001], such that DermSAP treated males displayed a significant 
rightward shift in ED50 from 4.07mg/kg in controls to 12.55mg/kg; no significant change 
in ED50 was noted in females (10.39mg/kg to 9.21mg/kg). 
 
Positive correlation between morphine antihyperalgesia and vlPAG MOR expression 
levels in males only 
DermSAP treatment resulted in a differential loss of MOR protein across the caudal 
vlPAG with levels ranging from abnormally low to normal or high levels. To further 
examine the effect of lesioning vlPAG MOR on morphine antihyperalgesia, DermSAP 
and BlankSAP animals were pooled and grouped into the following three categories 
based on the extent of lesions: (1) abnormally low level of MOR immunoreactivity 
(densitometry value 49.80 to 91.82; n=3 males, n=4 females), (2) moderate reduction of 
MOR immunoreactivity (93.57 to 121.78; n=3 males, n=4 females) and (3) normal or 
high levels of MOR immunoreactivity (126.48 to 181.33; n=4 males, n=3 females). 
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Normal density of MOR expression was over two-fold higher than that of abnormal 
levels of expression (Figure 6.9A; R2=.787). In males, there was a positive correlation 
between the density of vlPAG MOR-expressing neurons and the level of morphine 
antihyperalgesia (Figure 6.9B). Reducing the expression of MOR in the vlPAG caused a 
significant reduction in ED50 in males: ED50 3.46 in males with a high expression (group 
3; CI=1.7-6.9) to ED50 11.85 (group 1; CI=7.04-13.9) in males with abnormally low levels 
of expression. There was no significant difference observed in females with a low 
density (ED50 9.46; CI=7.8-11.6) versus a normal ‘high’ density (ED50= 8.77; CI=7.5-
10.3) of MOR in the vlPAG (Figure 6.9C).  
 
6.5  DISCUSSION 
Many factors limit the efficacy of opiates, including tolerance (Christie et al., 1987; 
Morgan et al., 2003; Bagley et al., 2005; Lane et al., 2005; Loyd et al., 2008), 
dependence (Ingram et al., 1998; Williams et al., 2001; Hack et al., 2003), negative side 
effects (Cepeda & Carr, 2003; Cepeda et al., 2003; Fillingim et al., 2005; Panchal et al., 
2007) and more recently, ‘gender’ or ‘sex’ (Wang et al., 2006). It is now well known that 
morphine is not as potent in females compared to males; however, the mechanism 
driving this phenomenon is unknown. The present experiments tested the hypothesis 
that the expression of MOR in the vlPAG is sexually dimorphic and responsible for the 
observed sex difference in morphine potency. Here we report that (1) males have 
significantly higher levels of MOR protein in the vlPAG compared to females; (2) intra-
vlPAG administration of morphine produces significantly greater antihyperalgesia in 
males; (3) lesions of MOR-expressing PAG neurons attenuate systemic morphine 
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antihyperalgesia in males only; and (4) the degree of systemic morphine-produced 
antihyperalgesia is positively correlated with the density of MOR immunoreactivity in the 
vlPAG. 
 
Sex Differences in Mu Opioid Receptor Expression in the ventrolateral PAG 
In male rats, studies utilizing both autoradiography and immunohistochemistry have 
previously reported that the PAG contains a high density of MOR (Mansour et al., 1986; 
Mansour et al., 1987; Arvidsson et al., 1995; Kalyuzhny et al., 1996; Gutstein et al., 
1998; Commons et al., 1999; Commons et al., 2000b; Wang & Wessendorf, 2002). In 
the present study, the highest density of MOR immunoreactivity was observed in the 
caudal vlPAG, similar to previous reports (Kalyuzhny et al., 1996; Commons et al., 
2000b). Overall, females rats had significantly less MOR immunoreactivity in the vlPAG, 
with the greatest difference observed in proestrus females with approximately one-third 
less labeling compared to males. Interestingly, females in diestrus, the stage where 
estrogen and progesterone are the lowest, had comparable levels of MOR 
immunoreactivity compared to males. These results are consistent with a recent study 
that reported two fold lower MOR protein expression in the female rat midbrain 
compared to males (Kren et al., 2008). These findings may indicate that steroid 
hormones play a role in MOR expression in the region of the PAG that is essential for 
antinociception.  
  
Intra-vlPAG Morphine Produces Greater Antihyperalgesia in Males Compared to 
Estrous and Proestrus Females 
The antinociceptive effects of morphine are mediated primarily by the MOR, which is 
expressed in several supraspinal sites including the habenula, striatum, hippocampus, 
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locus coeruleus, the nucleus raphe magnus and the periaqueductal gray (Arvidsson et 
al., 1995). Given that (1) up to 50% of PAG-RVM projection neurons contain MOR 
(Commons et al., 2000b; Wang & Wessendorf, 2002) and (2) female rats have reduced 
levels of MOR in the vlPAG, we hypothesized that the PAG was sufficient for sex 
differences in morphine antihyperalgesia. Microinjection of morphine directly into the 
vlPAG produced a significantly greater degree of analgesia in males compared to 
females at all doses tested. Indeed, intra-vlPAG morphine at 10µg resulted in 
100%MPE in males; while in females this dose had no antihyperalgesic effect at all until 
the highest doses tested. These results indicate that females require twice the amount 
of morphine, when administered into the vlPAG, as males to produce comparable levels 
of antihyperalgesia. These results are consistent with our previous studies using 
systemic morphine in which female ED50 values were two fold higher in male rats (Ji et 
al., 2006; Wang et al., 2006).  
 
In the present study, we observed an effect of estrous on morphine antihyperalgesia in 
females. Specifically, morphine antihyperalgesia was reduced during proestrus and 
estrous, in comparison to diestrus and is consistent with previous studies examining the 
influence of estrous on morphine antihyperalgesia (Kepler et al., 1989; Islam et al., 
1993; Krzanowska & Bodnar, 1999; Krzanowska et al., 2002). In particular, increased 
levels of morphine antihyperalgesia are observed during diestrus when estrogen and 
progesterone are lowest. In fact, morphine antihyperalgesia during diestrus was not 
significantly different than males. These results parallel our finding of reduced MOR 
protein levels during proestrus compared to diestrus, and provide further support for our 
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finding that the amount of available MOR is positively correlated with the degree of 
antihyperalgesia produced by morphine.  
 
Between 20-50% of PAG-RVM neurons retrogradely labeled from the RVM contain 
receptors for the steroid hormones estrogen and androgen (Loyd & Murphy, 2008b), 
while 27-50% express MOR (Commons et al., 2000b; Wang & Wessendorf, 2002); 
therefore it is likely that a proportion of PAG-RVM projection neurons express both 
receptor types. There are several mechanisms whereby changes in gonadal steroid 
levels could influence MOR expression and ultimately, morphine antihyperalgesia. First, 
several studies have reported that increased levels of estradiol result in MOR 
internalization (Eckersell et al., 1998b; Micevych et al., 2003), thereby reducing 
available opioid binding sites. Secondly, studies by Kelly et al. (2003) have shown that 
administration of estradiol results in the rapid uncoupling of MOR from G protein-gated 
inwardly rectifying potassium channels (Kelly et al., 2003) thus resulting in a reduction in 
morphine’s ability to hyperpolarize PAG-RVM neurons. Obviously, further research on 
the mechanism whereby estradiol alters MOR expression is warranted. 
  
Mu Opioid-Expressing Neurons in the Ventrolateral PAG are Necessary for Sex 
Differences in Morphine Antihyperalgesia 
As microinjection of morphine into the vlPAG resulted in greater antihyperalgesia in 
males, we next lesioned MOR-expressing vlPAG neurons to test their necessity in 
driving sex differences in morphine antihyperalgesia. Using site-specific lesioning 
techniques, we found that reducing the density of MOR in the caudal vlPAG significantly 
attenuated morphine antihyperalgesia to systemic morphine in male but not female rats. 
The ED50 in males shifted from 4.07mg/kg in controls to 12.55mg/kg in males, while no 
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shift was noted in the ED50 in females. These data provide evidence that MOR 
expression in the PAG is necessary for the antihyperalgesic effects of systemic 
morphine, but only in males. Interestingly, removal of MOR in the PAG of females had 
no impact on morphine-induced antihyperalgesia; however, at high doses of systemic 
administration, morphine still produces analgesia. This suggests that in females, the 
PAG is not the primary anatomical substrate for the antihyperalgesic effects of 
morphine. Both the RVM (Porreca et al., 2001; Burgess et al., 2002) and in the dorsal 
horn of the spinal cord (Kline & Wiley, 2008) have been shown to also contribute to 
morphine antihyperalgesia and perhaps these sites are more critical in females. In 
support, we have recently reported no differences in MOR expression within the 
lumbosacral spinal cord and similarly, no differences in ED50 values for morphine when 
administered intrathecally (Ji et al., 2006).  
 
Administration of DermSAP resulted in a range of MOR immunoreactivity within the 
caudal vlPAG. Interestingly, we found that the density of vlPAG MOR immunoreactivity 
was positively correlated with morphine antihyperalgesia in male, but not female rats. 
Males with normal levels of MOR immunoreactivity in the vlPAG had significantly lower 
ED50 values compared to males with two-fold less MOR immunoreactivity. These results 
further indicate that MOR-expressing neurons in the PAG are essential for morphine 
antihyperalgesia in male but not female rats. 
 
Our observed sex difference in the actions of morphine is not to due sex differences in 
pain sensitivity or hyperalgesia. Interestingly, removal of vlPAG MOR with DermSAP 
had no effect on baseline pain sensitivity or inflammatory hyperalgesia to either a 
painful thermal or mechanical stimulus, indicating that removal of vlPAG MOR does not 
 143 
affect endogenous pain modulation. Thus, while vlPAG MOR obviously contributes to 
the exogenous effects of morphine, its reduction does not alter the endogenous system. 
Previous studies have reported that DermSAP lesions of MOR-expressing neurons in 
the RVM (Porreca et al., 2001; Burgess et al., 2002) and dorsal horn neurons (Kline & 
Wiley, 2008) attenuate hyperalgesia in male rats. Together, these data indicate that the 
RVM and the dorsal horn of the spinal cord, but not the PAG, are essential for driving 
descending facilitation (Terayama et al., 2000; Ren & Dubner, 2002; Dubner & Ren, 
2004). 
 
Importantly, our results indicate that morphine is a remarkably ineffective opiate for the 
alleviation of persistent pain in females. Sex differences in morphine potency are well 
known in animal research, and have also been widely reported in humans (Kest et al., 
2000; Sarton et al., 2000; Zacny, 2001; Cepeda et al., 2002; Cepeda & Carr, 2003; 
Miller & Ernst, 2004). Interestingly, sex is not the only factor that has been shown to 
affect the efficacy and potency of various pharmacological agents. Indeed, recent 
studies have reported an influence of age (Smith & Gray, 2001; Aubrun & Marmion, 
2007; Gagliese et al., 2008) and ethnicity (Kaiko et al., 1983), and further argue for the 
inclusion of a wide range of study subjects in pain management research. In addition, 
despite the rapidly mounting evidence of limitations of opiates in treating persistent pain, 
opioid-based drugs remain the primary pharmacological tool for pain management. 
Clearly additional research with the inclusion of female subjects needs to be devoted to 
determining a more potent treatment for persistent pain in women. 
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6.6 CHAPTER SUMMARY 
Overall, we report that there are sex differences in the expression of MOR in the vlPAG 
of the rat, with males having nearly 50% higher levels of MOR immunoreactivity as 
compared to proestrus females. Similarly, administration of morphine into the vlPAG 
produces significantly greater antihyperalgesia in males compared to females, which 
suggests that sex differences in PAG MOR may provide a primary mechanism for the 
sexually dimorphic effects of morphine. Furthermore, lesioning MOR-expressing 
neurons in the vlPAG attenuated morphine antihyperalgesia in males only, providing 
further evidence that MOR in the vlPAG is a primary anatomical substrate for the 
analgesic effects of morphine. Together, these results indicate that sex differences in 
MOR in the vlPAG provide a necessary and sufficient neural mechanism for eliciting sex 
differences in morphine antihyperalgesia.  
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Figure 6.1. A-B. Photomicrograph depicting mu opioid receptor immunoreactivity in the 
caudal ventrolateral PAG (Bregma -8.00). C. Mean densitometry value of mu opioid 
receptor immunoreactivity in male (closed) and proestrus, estrus and diestrus females 
(open) averaged across the caudal PAG (Bregma -7.04 to -8.30). *denotes a significant 
effect. 
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Figure 6.2. Microphotograph of an example of an intra-PAG cannulation site for 
morphine microinjection in the caudal ventrolateral PAG (Bregma -8.00) of a 
representative male (A) and female (B) rat. 
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Figure 6.3. A. Percent maximal possible effect (MPE) of intra-PAG morphine 
administration of 5 and 10µg/µl in males (closed symbols) and 5, 10 and 18µg/µl in 
female (open symbols) rats. B. Percent maximal possible effect of intra-PAG morphine 
administration averaged across the time points 30, 60 and 90 minutes in male (black 
bars) and female (white bars) rats. C. Percent maximal possible effect of intra-PAG 
morphine administration in proestrus, estrus and diestrus females (open bars) 
compared to intact male (closed bars) rats. *denotes a significant effect. 
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Figure 6.4. A. Mean paw withdrawal latency (PWL) in seconds to a thermal stimulus in 
proestrus, estrus and diestrus females (open bars) compared to male (closed bars) rats. 
B. Mean paw withdrawal latency in seconds to a thermal stimulus following 24 hours of 
CFA-induced inflammation in proestrus, estrus and diestrus females (white bars) 
compared to male (black bars) rats.  C. Percent change in paw diameter following 24 
hours of CFA-induced inflammation. 
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Figure 6.5. Illustration depicting localization of DermSAP (closed symbols) versus 
BlankSAP (open symbols) injection sites within the caudal ventrolateral PAG (Bregma -
7.04 to -8.30) of male (triangle) versus female (circle) rats. 
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Figure 6.6. A-B. Photomicrograph depicting mu opioid receptor density in the vlPAG 
(Bregma -8.00) following BlankSAP (A) versus DermSAP (B) treatment. C-D. 
Photomicrograph depicting NeuN density in the vlPAG (Bregma -8.00) following 
BlankSAP (C) versus DermSAP (D) treatment. E-F. Photomicrograph depicting tritiated 
DAMGO binding in the vlPAG (Bregma -8.00) following BlankSAP (E) versus DermSAP 
(F) treatment.  
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Figure 6.7. Paw withdrawal latencies (PWL) to a thermal (A) or mechanical (B) painful 
stimulus prior to surgical manipulation (Pre-Lesion), following DermSAP or BlankSAP 
treatment (Pre-Inflamed), and following 24 hours of CFA-induced hyperalgesia 
(Inflamed) in male (closed bars) versus female (open bars) rats.  
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Figure 6.8. Percent maximal possible effect (MPE) of cumulative doses of systemic 
morphine in inflamed male (triangle) and female (circle) rats following DermSAP (closed 
symbols) or BlankSAP (open symbols). 
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Figure 6.9. A. Degree of positive correlation of densitometry value versus grouping of 
individuals based on mu opioid receptor density in the ventrolateral PAG following 
DermSAP or BlankSAP treatment. B-C. Percent maximal possible effect of cumulative 
doses of systemic morphine (0, 1.8, 3.2, 5.6, 8, 10, 18mg/kg) in inflamed male (B) and 
female (C) rats expressing low (1), moderate (2) and high (3) mu opioid receptor 
density.
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7.1  SEXUALLY DIMORPHIC ORGANIZATION OF THE DESCENDING PAIN 
INHIBITORY PATHWAY 
 
We used neuroanatomical tract tracing techniques to examine whether there were 
qualitative and/or quantitative differences in the projections from the PAG to the RVM in 
both males and female rats.  Consistent with previous anatomical studies (Beitz, 1982c; 
Beitz et al., 1983; van Bockstaele et al., 1991), we reported that the dorsomedial, lateral 
and ventrolateral PAG heavily project to the RVM in both male and female rats (Loyd & 
Murphy, 2006). Interestingly, while no qualitative sex differences were noted in the 
overall distribution of PAG-RVM output neurons, females had significantly more PAG-
RVM projection neurons across the rostrocaudal axis of the PAG compared to males 
(Loyd et al., 2007; Loyd et al., 2008; Figure 7.1a-c). The average number of 
retrogradely labeled cells across the rostrocaudal extent of the PAG was greater by a 
third in female compared to male rats (Figure 7.2a). The most prominent sex difference 
in retrograde labeling was observed within the lateral and ventrolateral regions of the 
PAG, an area known to contain a dense distribution of mu opioid receptors (Kalyuzhny 
et al., 1996; Wang & Wessendorf, 2002).  
 
7.2 SEXUALLY DIMORPHIC PHYSIOLOGY OF THE DESCENDING PAIN 
INHIBITORY PATHWAY  
 
Sexually Dimorphic Response of the PAG-RVM Pathway to Inflammatory Pain 
Inflammatory pain results in the activation of descending modulatory circuits (Morgan et 
al., 1991; Williams et al., 1995) and contributes to both hyperalgesia and antinociception 
(Guan et al., 2002; Miki et al., 2002; Ren & Dubner, 2002; Guan et al., 2003). We found 
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that the persistent inflammatory pain induced by injection of CFA into the hindpaw 
caused extensive activation of PAG neurons as measured by Fos labeling. This 
activation was comparable in males and female rats (Loyd & Murphy, 2006). Although 
females have almost twice the number of PAG-RVM output neurons in comparison to 
males, very few of these cells in female rats expressed inflammation-induced Fos, 
suggesting that this circuit is preferentially activated in males (Figure 7.2b). Indeed we 
found that, overall, persistent inflammatory pain activated approximately 43% of PAG-
RVM neurons in the dorsomedial, lateral and ventrolateral PAG of males, but only half 
as many PAG-RVM output neurons were activated by inflammatory pain in females. 
Together, these data suggest that this descending modulatory circuit is not being 
engaged to the same degree by persistent inflammatory pain in males and females. 
Given that activation of the PAG and its descending outputs to the RVM results primarily 
in the inhibition of dorsal horn neuronal responses to acute noxious stimuli (Carstens et 
al., 1979; Gray & Dostrovsky, 1983; Aimone et al., 1987; Jones & Gebhart, 1988; 
Waters & Lumb, 1997; Budai & Fields, 1998), reports of sex differences in the activation 
of the PAG-RVM pathway may account for reported sex differences in responses to 
acute noxious stimuli (Berkley, 1997; Fillingim, 2000; Fillingim & Ness, 2000; Barrett et 
al., 2002).  
 
Our findings that (1) persistent pain results in comparable activation of the PAG in both 
sexes (Loyd & Murphy, 2006) and, (2) there are no sex differences in either baseline 
nociceptive threshold or inflammatory pain induced hyperalgesia (Wang et al., 2006) 
suggests the possibility that females utilize a distinct pathway other than the PAG-RVM 
for endogenous pain modulation. We have recently begun exploring this possibility 
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using combinatorial anterograde and retrograde tract-tracing in combination with 
persistent pain-induced Fos labeling. The results of these studies suggest that there are 
indeed sex differences in both the efferent and afferent projections of the PAG. 
Specifically, the amygdala, ventromedial hypothalamus and periventricular nucleus 
project more heavily to the PAG in females than males. In contrast, the medial preoptic 
area, parabrachial nucleus, and locus coeruleus project more heavily to the PAG in 
males than females (Loyd & Murphy, 2007b). In addition, our data indicate that the 
projections to the parabrachial nucleus, locus coerulus, and the A5/A7 noraderanergic 
cell group appear to be greater in males (Loyd and Murphy, unpublished observations). 
Obviously, further research on the anatomy and physiology of pain modulatory circuits 
in females is warranted. 
 
Sex Differences in the Activation of the Descending Inhibitory Pathway by Morphine 
Until recently, all studies examining the mechanisms of morphine action in the PAG 
were conducted exclusively in males; therefore it was unknown whether morphine 
administration has the same physiological effect on PAG neurons in females. 
Electrophysiological studies of PAG neurons are limited because they examine the 
response of a single neuron (Basbaum & Fields, 1979; Behbehani & Fields, 1979; Shah 
& Dostrovsky, 1980; Behbehani, 1981; Behbehani et al., 1981; Behbehani, 1982; 
Chieng & Christie, 1994b; a; Osborne et al., 1996b; Vaughan & Christie, 1997; Vaughan 
et al., 1997) whereas we have shown that an important difference between males and 
females is the number of neurons projecting from the PAG to the RVM (Loyd & Murphy, 
2006). Moreover, electrophysiological studies have focused on the activity of PAG 
neurons from males exclusively. We have addressed this problem by using tract-tracing 
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techniques and Fos labeling to measure the activity of populations of PAG-RVM 
neurons in the PAG of males and females. Systemic morphine administration 
attenuates the persistent pain induced Fos expression within the PAG of male but not 
female rats (Loyd & Murphy, 2006). This selective inhibition of Fos is consistent with our 
data showing that the ED50 for systemic morphine is approximately two times higher in 
females compared to males in a model of persistent inflammatory pain (Wang et al., 
2006).  
 
In addition to the inhibition of PAG activation caused by persistent pain, morphine 
activates a subset of PAG neurons that produce antinociception. Morphine activates 
these PAG neurons by inhibiting tonically active GABAergic neurons (Vaughan et al., 
1997). We found that morphine administration induced an approximately two-fold 
greater activation of PAG neurons compared to saline administration (Loyd et al., 2007). 
Interestingly, no sex difference was observed in the activation of PAG neurons by 
morphine (Figure 7.3a-c, black circles), suggesting that in the absence of pain, 
morphine is equipotent in its ability to depolarize PAG neurons. However, when the 
analysis was limited to PAG neurons projecting to the RVM, the number of neurons 
activated by morphine was consistently and significantly higher in males compared to 
females (Figure 7.3a-c, red stars) (Loyd et al., 2007). Indeed, approximately half of 
PAG-RVM neurons in males were activated by morphine, whereas only 20% were 
activated in females (Figure 7.2c). Together, these results suggest that morphine results 
primarily in the net excitation of PAG-RVM neurons, most likely through removal of tonic 
GABA inhibition (Moreau & Fields, 1986; Behbehani et al., 1990b; Vaughan & Christie, 
1997; Commons et al., 2000b). The finding that very few PAG-RVM neurons were 
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activated by morphine in females suggests that morphine may be engaging alternative 
pathways that do not involve the RVM, thereby limiting the effectiveness of morphine as 
a pain modulator. 
 
Given that more PAG neurons project to the RVM in female compared to male rats, it is 
possible that pain modulation in females is less dependent on opioids. If this is the case, 
then direct activation of PAG output neurons should produce greater antinociception in 
females, not males. Microinjection of the GABA antagonist bicuculline into the PAG 
produces antinociception (Moreau & Fields, 1986; Morgan et al., 2003) by disinhibiting 
output neurons. Surprisingly, even though females have more output neurons, the 
antinociceptive effect of microinjecting bicuculline into the PAG is greater in males 
(Michael M. Morgan personal communication).  
 
Sex Differences in the Development of Tolerance to Repeated Morphine Administration 
Repeated or continuous administration of morphine into the ventrolateral PAG of male 
rats has been shown to result in the development of tolerance (Jacquet & Lajtha, 1976; 
Siuciak & Advokat, 1987; Tortorici et al., 1999; Tortorici & Morgan, 2002; Lane et al., 
2005; Morgan et al., 2006). In addition, blocking opioid binding sites in the ventrolateral 
PAG attenuates the development of tolerance to systemically administered morphine 
(Lane et al., 2005). Tolerance appears to be mediated by a reduction in mu opioid 
receptor signaling efficacy in PAG neurons (Bagley et al., 2005), an effect that is 
reversed when mu opioid receptor coupling is enhanced via upregulated adenylate 
cyclase activity (Hack et al., 2003). If the PAG-RVM pathway is essential for the 
development of tolerance, then activation of the PAG-RVM pathway by morphine should 
decline as tolerance develops, and changes in the activation of this pathway would 
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correlate with sex differences in the development of tolerance to morphine. These 
hypotheses were tested in male and female rats using behavioral testing (hot plate) and 
immunohistochemistry to map the activation of the PAG-RVM pathway following 
repeated morphine administration. 
 
Morphine was administered once or twice a day for three days in rats that received 
retrograde tracer injections into the RVM to examine potential changes in the activation 
of PAG-RVM neurons during the development of tolerance. Repeated administration of 
systemic morphine induced tolerance in males to a significantly greater extent than in 
females (Loyd et al., 2008), consistent with previous research (Barrett et al., 2001; 
Bernal et al., 2007). Indeed, the half maximal antinociceptive effect of a single injection 
of morphine following repeated administration of morphine was two times greater for 
female compared to male rats (Cicero et al., 1997; Cook & Nickerson, 2005; Ji et al., 
2006; Wang et al., 2006). In parallel, the activation of PAG-RVM neurons was 
significantly attenuated following repeated morphine administration in males but not 
females (Loyd et al., 2008). While there was no sex difference in the activation of the 
PAG following three doses or six doses of morphine over three days (Figure 7.3d-f, 
black circles), the activation of the PAG-RVM projection neurons steadily declined in 
males only (Figure 7.3g-i, red stars). Activation of the PAG-RVM pathway by morphine 
in female rats was minimal, and therefore did not decline significantly following repeated 
administration of morphine (Figure 7.4). Together, these data provide further support for 
a central role of the PAG in the development of tolerance to repeated administration of 
morphine. 
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7.3 GONADAL STEROID RECEPTOR EXPRESSION IN THE DESCENDING 
INHIBITORY PATHWAY  
 
The anatomical substrate(s) whereby gonadal steroids influence pain and analgesia are 
unknown. Both androgen (AR) and estrogen receptors (ERα) have been localized in the 
PAG in the male rat (Murphy & Hoffman, 1999; Murphy & Hoffman, 2001). Although it is 
not known if these receptors are present in the female rat, they have been localized in 
other species including the female cat (VanderHorst et al., 1998), golden hamster 
(Boers et al., 1999), guinea pig (Turcotte & Blaustein, 1993) and the rhesus monkey 
(Vanderhorst et al., 2002; VanderHorst et al., 2004). However, the anatomical 
distribution of both receptor types in the PAG neurons projecting to the RVM was not 
reported. 
 
We have combined neuroanatomical tract-tracing techniques and steroid receptor 
immunohistochemistry to characterized the expression of AR and ERα in the PAG-RVM 
pathway of male and female rats (Loyd & Murphy, 2008a). In these studies, we found 
that males had a significantly greater number of AR immunoreactive neurons localized 
within the dorsomedial, lateral and ventrolateral PAG compared to females. 
Interestingly, both the qualitative and quantitative expression of ERα in the PAG was 
comparable between the sexes (Figure 7.1d-f). Both receptor types were preferentially 
localized within the dorsomedial, lateral and ventrolateral subdivisions of the PAG and 
increased in density along the rostrocaudal axis of the PAG with the highest expression 
localized within the caudal PAG (Figure 7.1g-i). In addition, 30-37% of PAG-RVM output 
neurons expressed AR or ERα (Figure 7.2d) with the highest density of co-labeling in 
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the lateral/ventrolateral region of PAG. ERa and AR colocalization in PAG neurons 
projecting to the RVM was comparable between the sexes (Loyd & Murphy, 2008a). 
The high density of steroid receptors localized on PAG-RVM output neurons may 
provide the biological basis for the observed sex differences in morphine analgesia. 
Although there was no sex difference in the distribution of gonadal steroid receptors in 
the PAG, only 27-50% of PAG-RVM neurons contain mu opioid receptor (MOR) (Wang 
& Wessendorf, 2002). Given that morphine activates more of these neurons in male 
compared to female rats, the interaction between morphine and sex hormones is likely 
greater in the PAG of male compared to female rats.  
 
There are several mechanisms whereby gonadal steroids may modulate opioid-
sensitive PAG-RVM output neurons, thereby resulting in a dimorphic response to 
morphine. First, estradiol has been shown to uncouple the mu opioid receptor from G 
protein-gated inwardly rectifying potassium channels (Kelly et al., 2003) resulting in an 
attenuation of morphine-induced hyperpolarization. Second, estradiol has also been 
shown to induce MOR internalization (Eckersell et al., 1998b), thereby reducing 
available opioid binding sites on the cell membrane. Interestingly, ERα is required for 
estradiol-induced MOR internalization (Micevych et al., 2003) supporting the hypothesis 
that colocalization of MOR and ERα in the PAG-RVM output neurons provides a unique 
mechanism through which estrogens may differentially affect morphine potency in male 
and female rats. 
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7.4 MU OPIOID RECEPTORS IN THE VENTROLATERAL PAG ARE ESSENTIAL 
FOR SEX DIFFERENCES IN MORPHINE ANALGESIA 
 
It is now well known that sex-based differences in opiate sensitivity are not due to the 
pharmacokinetics of morphine (Cicero et al., 1996b; Craft et al., 1996; Cicero et al., 
1997; Sarton et al., 2000). Rather, sex related differences in morphine analgesia are 
likely due to dissimilarities in opiate receptor density, binding and localization, as well as 
sexually dimorphic opiate-responsive neural circuits. The vlPAG contains a high density 
of MOR (Mansour et al., 1986; Mansour et al., 1987; Kalyuzhny et al., 1996; Gutstein et 
al., 1998; Commons et al., 1999; Commons et al., 2000b; Wang & Wessendorf, 2002) 
with 27-50% of PAG neurons projecting to the RVM expressing MOR (Commons et al., 
2000b; Wang & Wessendorf, 2002); these studies were conducted in males only. One 
mechanism that may contribute to sex differences in morphine potency is a sexual 
dimorphic MOR expression in the vlPAG, which may also depend on stage of estrous. 
Indeed, vlPAG MOR expression was sexually dimorphic with proestrous females having 
significantly lower levels of PAG vlMOR compared to intact male rats (Figure 7.5A). This 
sex difference appears to be sufficient for sex differences in morphine potency, as 
delivering morphine directly into the vlPAG produced greater morphine antihyperalgesia 
in males (Figure 7.5B). Importantly, vlPAG MOR receptor expression was necessary for 
sex differences in morphine potency, as removal of vlPAG MOR attenuates 
antihyperalgesia in males only (Figure 7.5C) in a density-dependent fashion 
(Figure7.5D).  
 
Together, these data indicate that the MOR in vlPAG is sexually dimorphic so that 
administration of morphine directly into the vlPAG results in sex difference in morphine 
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antihyperalgesia, similar to our results with systemic morphine administration. These 
MOR-expressing neurons in the PAG are necessary for sex differences in morphine 
analgesia, and are essential for morphine analgesia in males, but not female rats.  
 
Overall, while females have more PAG-RVM projection neurons compared to males, 
these neurons are not engaged by morphine to produce an analgesic effect. It appears 
that MOR protein is expressed in lower amounts in females and/or MOR receptors are 
downregulated or uncoupled by estradiol as evidenced by a reduction in MOR in the 
vlPAG during proestrus and a high expression of steroid receptors in the PAG-RVM 
pathway. Alternatively, females may be utilizing a separate, unrecognized endogenous 
system for the descending inhibition of pain at which exogenous opiates are not acting 
as females and male have comparable pain thresholds before and following the 
induction of inflammation. 
 
7.5 FINAL REMARKS 
 
Research spanning four decades has shown that the PAG, and its descending 
projections to the RVM and dorsal horn of the spinal cord, constitute an essential neural 
circuit for opioid-based analgesia. During the last half of that period, numerous rodent 
and human studies have established sex differences in the analgesic effects of 
morphine; however, the neural mechanisms underlying the sexually dimorphic actions 
of morphine remain poorly understood. It is now clear that the anatomical and 
physiological characteristics of the PAG and its descending projections to the RVM are 
sexually dimorphic, with clear biological consequences in terms of morphine action 
(Figure 7.6). Our studies, as well as those of others, have clearly shown that morphine 
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is not the drug of choice for persistent pain modulation in females. Clearly, future 
research efforts need to be devoted toward the identification of effective pain 
therapeutics in women. 
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Figure 7.1. (A-C) Distribution of cells retrogradely labeled from the rostral ventromedial 
medulla in males (left) and females (right) at three representative rostrocaudal levels of 
the periaqueductal gray. Each black circle represents one FG+ cell. (D-F) Distribution of 
cells retrogradely labeled from the rostral ventromedial medulla that were 
immunoreactive for AR (green circles) or ERα (purple circles). (G-I) Distribution of cells 
retrogradely labeled from the rostral ventromedial medulla that were immunoreactive for 
AR (green stars) or ERα (purple stars). 
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Figure 7.2. A. Average of the mean number of periaqueductal cells retrogradely labeled 
from the rostral ventromedial medulla across the rostrocaudal axis in males (left) and 
females (right). B. Percentage of Fos-positive neurons that were retrogradely labeled 
from the RVM in males (left) and females (right) following twenty-four hours of 
inflammation. C. Average of the percentage of androgen (left) and estrogen (right) 
receptor-expressing periaqueductal cells retrogradely labeled from the rostral 
ventromedial medulla. D. Percentage of Fos-positive neurons that were retrogradely 
labeled from the RVM in males (left) and females (right) following twenty-four hours of 
inflammation and one hour of morphine (5mg/kg). 
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Figure 7.3. Distribution of periaqueductal cells expressing Fos (black circles) and 
periaqueductal cells retrogradely labeled from the rostral ventromedial medulla 
expressing Fos (red stars) following: (A-C) one 5mg/kg dose of morphine; (D-F) one 
5mg/kg dose of morphine per day for three consecutive days (G-I) or two 5mg/kg doses 
of morphine per day for three consecutive days in males (left) and females (right) at 
three representative rostrocaudal levels of the periaqueductal gray.   
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Figure 7.4. Percentage of Fos-positive neurons that were retrogradely labeled from the 
RVM (%Fos in FG+ cells) in male (solid bars) and female (open bars) rats injected with 
either morphine or saline once or twice daily for three days for the rostral (A; Bregma -
6.72, -7.04, -7.74) and caudal (B; Bregma -8.00, -8.30, -8.80) PAG. A decrease in 
labeling is evident with an increase in the number of morphine injections for male rats. 
The # indicates a significant effect of treatment and the * indicates a significant effect of 
sex. Saline: morphine naïve; 1 Dose: saline pretreatment followed by one dose of 
morphine; 3 Doses: one dose of morphine per day; 6 Doses: two doses of morphine per 
day. 
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Figure 7.5. A. Mean densitometry values of mu opioid receptor in the caudal 
ventrolateral PAG. * denotes significant difference of main effect. B. %MPE averaged 
over time points 30, 60 and 90 minutes following intra-PAG morphine in males (black) 
compared to females (white). C. %MPE following cumulative doses of morphine in 
DermSAP (closed) and BlankSAP (open) treated male (triangle) and female (circle) rats. 
D.  %MPE following cumulative doses of morphine in male rats only grouped according 
to density of mu opioid receptor.
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Figure 7.6. Proposed model of factors contributing to sex differences in morphine 
potency. Sex differences in the PAG-RVM projections, mu opioid receptors, and 
gonadal steroid receptors in the PAG (panel 1) are involved modulating the activation of 
the PAG-RVM circuit (panel 2) to a differential degree in males and females to produce 
sex differences in morphine potency (panel 3). 
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